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Background: Antibiotics are still prescribed to most patients attending primary care with acute sore
throat, despite evidence that there is modest beneﬁt overall from antibiotics. Targeting antibiotics using
either clinical scoring methods or rapid antigen detection tests (RADTs) could help. However, there is
debate about which groups of streptococci are important (particularly Lanceﬁeld groups C and G), and
uncertainty about the variables that most clearly predict the presence of streptococci.
Objective: This study aimed to compare clinical scores or RADTs with delayed antibiotic prescribing.
Design: The study comprised a RADT in vitro study; two diagnostic cohorts to develop streptococcal scores
(score 1; score 2); and, ﬁnally, an open pragmatic randomised controlled trial with nested qualitative and
cost-effectiveness studies.
Setting: The setting was UK primary care general practices.
Participants: Participants were patients aged ≥ 3 years with acute sore throat.
Interventions: An internet program randomised patients to targeted antibiotic use according to
(1) delayed antibiotics (control group), (2) clinical score or (3) RADT used according to clinical score.
Main outcome measures: The main outcome measures were self-reported antibiotic use and symptom
duration and severity on seven-point Likert scales (primary outcome: mean sore throat/difﬁculty swallowing
score in the ﬁrst 2–4 days).
Results: The IMI TestPack Plus Strep A (Inverness Medical, Bedford, UK) was sensitive, speciﬁc and
easy to use. Lanceﬁeld group A/C/G streptococci were found in 40% of cohort 2 and 34% of cohort 1.
A ﬁve-point score predicting the presence of A/C/G streptococci [FeverPAIN: Fever; Purulence; Attend
rapidly (≤ 3 days); severe Inﬂammation; and No cough or coryza] had moderate predictive value
(bootstrapped estimates of area under receiver operating characteristic curve: 0.73 cohort 1, 0.71vii
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ABSTRACT
viiicohort 2) and identiﬁed a substantial number of participants at low risk of streptococcal infection.
In total, 38% of cohort 1 and 36% of cohort 2 scored ≤ 1 for FeverPAIN, associated with streptococcal
percentages of 13% and 18%, respectively. In an adaptive trial design, the preliminary score (score 1;
n = 1129) was replaced by FeverPAIN (n = 631). For score 1, there were no signiﬁcant differences between
groups. For FeverPAIN, symptom severity was documented in 80% of patients, and was lower in the
clinical score group than in the delayed prescribing group (–0.33; 95% conﬁdence interval –0.64
to –0.02; p = 0.039; equivalent to one in three rating sore throat a slight rather than moderately bad
problem), and a similar reduction was observed for the RADT group (–0.30; –0.61 to 0.00; p = 0.053).
Moderately bad or worse symptoms resolved signiﬁcantly faster (30%) in the clinical score group (hazard
ratio 1.30; 1.03 to 1.63) but not the RADT group (1.11; 0.88 to 1.40). In the delayed group, 75/164
(46%) used antibiotics, and 29% fewer used antibiotics in the clinical score group (risk ratio 0.71; 0.50 to
0.95; p = 0.018) and 27% fewer in the RADT group (0.73; 0.52 to 0.98; p = 0.033). No signiﬁcant
differences in complications or reconsultations were found. The clinical score group dominated both other
groups for both the cost/quality-adjusted life-years and cost/change in symptom severity analyses, being
both less costly and more effective, and cost-effectiveness acceptability curves indicated the clinical score
to be the most likely to be cost-effective from an NHS perspective. Patients were positive about RADTs.
Health professionals’ concerns about test validity, the time the test took and medicalising self-limiting
illness lessened after using the tests. For both RADTs and clinical scores, there were tensions with
established clinical experience.
Conclusions: Targeting antibiotics using a clinical score (FeverPAIN) efﬁciently improves symptoms and
reduces antibiotic use. RADTs used in combination with FeverPAIN provide no clear advantages over
FeverPAIN alone, and RADTs are unlikely to be incorporated into practice until health professionals’
concerns are met and they have experience of using them. Clinical scores also face barriers related to
clinicians’ perceptions of their utility in the face of experience. This study has demonstrated the limitation
of using one data set to develop a clinical score. FeverPAIN, derived from two data sets, appears to be
valid and its use improves outcomes, but diagnostic studies to conﬁrm the validity of FeverPAIN in other
data sets and settings are needed. Experienced clinicians need to identify barriers to the use of clinical
scoring methods. Implementation studies that address perceived barriers in the use of FeverPAIN
are needed.
Trial registration: Current Controlled Trials ISRCTN32027234.
Source of funding: This project was funded by the NIHR Health Technology Assessment programme and
will be published in full in Health Technology Assessment; Vol. 18, No. 6. See the NIHR Journals Library
website for further project information.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6Plain English summaryGeneral background
The overuse of antibiotics in general practices, mostly for illnesses such as sore throat, chest infections and
ear infections, is potentially a big problem for us all for several reasons. First, antibiotic overuse increases
the risk of antibiotic resistance, whereby bacteria become resistant to antibiotics and are no longer killed
by antibiotics. This could potentially lead to serious infections as a result of ‘superbugs’ becoming
untreatable both now and for future generations. Antibiotics commonly cause side effects such as allergic
reactions, diarrhoea and skin rashes. Using them also increases people’s belief in them – because they
think it is the antibiotics that helped them get better, when in fact they would have got better in the same
time anyway. This leads people to think that they need to come back the next time they get an infection –
so it ‘medicalises’ illnesses, uses NHS resources and also exposes patients to unnecessary antibiotics.Background – the context for sore throats
Antibiotics are still prescribed for most patients with a sore throat attending their general practitioner (GP)
or nurse in primary care. This is despite the best available evidence, which suggests there is a modest
beneﬁt overall from antibiotics. One approach to tackle this is to target antibiotics better, using a simple
‘clinical score’ – whereby doctors or nurses prescribe according to particular symptoms and examination
ﬁndings. Another approach is to use rapid antigen detection tests (RADTs), which are very commonly used
in many countries. To use a RADT, a swab is taken from the throat, and the RADT gives a quick answer as
to whether the most important bacteria are present or not. The particular type of bacteria that RADTs pick
up is a common type of streptococcus bacteria – called Lanceﬁeld group A haemolytic streptococcus
(GABHS). This bacterium can cause both a sore throat and more serious illnesses.
However, there are problems with using either a clinical score or a RADT:
l There is debate about which RADT should be used and how.
l It is unclear whether other bacteria (other than GABHS) are important, particularly streptococci from
other groups – Lanceﬁeld groups C and G. RADTs will not pick up these other bacteria.
l For a clinical score, it is not clear which symptoms and examination ﬁndings most clearly tell us
whether bacteria are present.
l There have also been very few good studies that compare RADTs with clinical scores, or with other
approaches, such as delayed antibiotic prescribing. Delayed prescribing is where the patient is advised
to use an antibiotic after several days if symptoms are not starting to settle.
The PRImary care Streptococcal Management (PRISM) study was made up of several substudies that
tackled these issues:Laboratory study
If rapid antigen tests are to be used for patients in everyday practice, they have to be accurate, easy to
use, inexpensive and potentially widely available. Several such tests are available, and in the ﬁrst study ﬁve
RADTs were tested in the laboratory with different types and concentrations of bacteria. One of the best
of these was the IMI test, which was both one of the most accurate and found to be relatively easy to use.xix
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xxClinical study – developing a clinical score
Two large groups of patients (606 in the ﬁrst group, 517 in the second) came to see the doctor or nurse
with a sore throat and agreed to take part. Their symptoms and signs were documented and a throat
swab was sent to the laboratory to see if bacteria were present. The results showed that patients who had
Lanceﬁeld groups C or G bacteria had the same kind of illness as those with group A strains. It was also
possible to develop a useful clinical score to help pick up the main types of bacteria (A, C or G) based on a
simple count of ﬁve items. The ﬁve items make up the acronym FeverPAIN:
l Fever during the last 24 hours
l Pus (white spots) on the tonsils
l coming quickly to see the doctor within 3 days (Attend rapidly)
l very Inﬂamed tonsils
l and No cough or runny nose.Trial of clinical scores and rapid antigen detection tests
The trial compared three ways of managing sore throat among 1760 patients who came to see
their doctor:
1. Delayed antibiotic prescribing group (the control group).
2. Clinical score group: the score was worked out and antibiotics were advised for high scores. No
antibiotics were advised for low scores, and delayed antibiotics for those in the middle. The ﬁrst clinical
score that was developed (score 1; n = 1129) was replaced by a more valid score (FeverPAIN; n = 631)
as the trial went on.
3. RADT group: the clinical score was also worked out. For low and middle scores, the plan was similar to
that used in the clinical score group. A RADT was used for those with high scores, and, if the result was
positive, antibiotics were advised and, if the result was negative, no antibiotics were given.
The study found that using the clinical score (FeverPAIN) improved control of symptoms, and both the
clinical score and the RADT reduced antibiotic use. Moderately bad or worse symptoms resolved
signiﬁcantly faster (30% faster) in the clinical score group but not in the RADT group (11% faster).Health economic analysis
If RADTs were to be used more widely, it would be important to show that using them is a cost-effective
use of time and money for the health service. The study showed that using RADTs was probably more
expensive and less cost-effective than using the clinical score.Qualitative study
Face-to-face and telephone interviews were done with 51 people – GPs, nurse practitioners and patients
from general practices across Hampshire, Oxfordshire and the West Midlands. Patients and nurses were
very positive about using clinical scores and RADTs. Doctors had a number of concerns about both RADTs
and clinical scores that would need to be addressed before widespread implementation would
work – particularly related to the perceived usefulness of clinical scores in the face of clinical experience
and intuition.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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There are RADTs that are not expensive, easy to use and are potentially widely available for use in primary
care. Although they will detect GABHS, RADTs are not designed to detect other strains such as Lanceﬁeld
C or G strains. Lanceﬁeld C or G strains commonly cause streptococcal sore throats, and patients have a
similar illness to those who have A strains. A ﬁve-item score (acronym FeverPAIN) to predict streptococcal
infection is likely to be valid but further validation is preferable. When antibiotics are targeted using a
clinical score (FeverPAIN), this improves control of symptoms, reduces antibiotic use and is very
cost-effective. Using a RADT in addition to using the clinical score provides no clear beneﬁts for patients
over using the clinical score alone. RADT use is also more costly, probably less cost-effective and faces
several barriers from clinicians. To implement the use of clinical scores more widely in everyday practice will
require addressing the issues doctors have.xxi
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The overuse of antibiotics in primary care not only increases the risk of antibiotic resistance but exposes
patients to side effects, and medicalises what are mostly self-limiting illnesses. Antibiotics are still
prescribed for most patients attending primary care with acute sore throat, despite evidence from
systematic reviews that there is modest beneﬁt overall from antibiotics. Approaches to targeting antibiotics
could facilitate more appropriate use of antibiotics, either targeting antibiotics using clinical scoring
methods or using rapid antigen detection tests (RADTs). RADTs are very commonly used in many countries
and are designed to detect the major bacterial pathogen Lanceﬁeld group A beta-haemolytic
streptococcus (GABHS). However, there is debate about the importance of other major groups of
streptococci (particularly Lanceﬁeld groups C and G). Furthermore, there is uncertainty about the variables
that most clearly predict the presence of streptococci, and about the most appropriate RADTs to use in
primary care. There is also very little robust trial evidence comparing management alternatives.Objectives
1. In vitro study: to assess in vitro validity and ease of use of several commercially available RADTs to
detect GABHS and to explore the impact of using commercially available swabs instead of the swabs
provided with the kits.
2. Clinical diagnostic study: to assess the incidence and clinical variables associated with streptococcal
infections and develop a clinical score to help target antibiotic use.
3. Randomised controlled trial: to compare the targeting of antibiotics using a clinical score, or,
alternatively, using a clinical score combined with a RADT, with empirical delayed antibiotic prescribing.
4. Qualitative study: to explore patients’ and health-care professionals’ (HCP) views of clinical scores
and RADTs.
5. Cost-effectiveness analysis: to assess resource use and the health-related quality of life associated with
clinical scores and RADTs and to show whether these can represent an efﬁcient use of NHS resources.Methods
1. In vitro study: different concentrations and strains of GABHS and non-GABHS were assessed with
OSOM® Ultra Strep A (Bio-Stat Limited, Stockport, UK), QuickVue® Dipstick Strep A test (TK Diagnostic,
Oxford, UK), Streptatest® (DECTRA PHARM, Strasbourg, France), Clearview® Exact (Inverness Medical
Professional Diagnostics, Bedford, UK) and IMI TestPack® Plus Strep A (Inverness Medical, Bedford, UK).
Each kit was rated for ease of use. Test kit swabs were also compared with commercially
available swabs.
2. Clinical diagnostic study: the variables signiﬁcantly associated with the presence of pathogenic
streptococci from throat swabs were assessed among patients aged ≥ 5 years presenting with acute
sore throat in two cohorts of patients. Logistic regression was used to identify signiﬁcant variables to
incorporate in clinical prediction rules, and bootstrapping was used to estimate the area under the
receiver operating characteristic (ROC) curve. Patients were recruited for a second cohort (cohort 2,
n = 517) consecutively after the ﬁrst (cohort 1, n = 606) from similar practices.
3. Randomised controlled trial: 1760 patients aged ≥ 3 years with acute sore throat were individually
randomised using a web-based program to one of three structured approaches targeting antibiotic use
according to (1) delayed antibiotic prescribing (control), (2) clinical score or (3) RADT use determined by
a clinical score. The main outcomes were symptom severity, symptom duration and antibiotic usexxiii
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xxiv(all of which were documented in > 80% of participants). The trial was not initially designed as an
adaptive trial, but revision of the trial design and modiﬁcation of the intervention were needed once it
became clear that the ﬁrst clinical score that was developed was not likely to be valid. The adaptive
design was implemented once the change in design had been agreed with the funder.
4. Qualitative study: Semi-structured face-to-face and telephone interviews were conducted with general
practitioners (GPs) and nurse practitioners (NPs) from general practices across Hampshire, Oxfordshire
and the West Midlands.
5. Cost-effectiveness analysis: A cost–utility study [cost/quality-adjusted life-year (QALY)] and a
cost-effectiveness study (cost/change in symptom severity) were carried out as part of the randomised
controlled trial. Resource use data were obtained from GP case notes and from study clinicians. QALYs
were estimated by means of EQ5D scores obtained from the 14-day diary.Results
1. In vitro study: The IMI test was the easiest to use. Sensitivity increased with higher streptococcal
concentration: at high concentrations sensitivity ranged from 62% [Clearview; 95% conﬁdence interval
(CI) 51% to 72%] to 95% (OSOM and IMI; 95% CI 88% to 98%). All tests were speciﬁc (100%). Most
kits performed well independent of what swab was used, but Clearview was much more sensitive with
polyester swabs than the kit swabs and rayon swabs.
2. Clinical diagnostic study: A, C or G beta-haemolytic streptococci were found in 40% of participants in
cohort 2 and 34% in cohort 1. There was variation in the items that were signiﬁcant in multivariate
analysis in both cohorts. The clinical features predicting the presence of these streptococci in
multivariate analysis in both cohorts were as follows: short prior duration of illness (attend rapidly in
≤ 3 days; multivariate-adjusted odds ratio 1.92 cohort 1, 1.67 cohort 2); fever in the last 24 hours
(1.69, 2.40); and doctor’s assessment of severity (severely inﬂamed pharynx/tonsils) (2.28, 2.29).
Absence of coryza or cough and purulent tonsils were also signiﬁcant predictive variables in univariate
analysis in both cohorts and in multivariate analysis in at least one cohort. A ﬁve-item score based on
Fever, Purulence, Attend rapidly (≤ 3 days), severe Inﬂammation and No cough or coryza (acronym
FeverPAIN) had moderate predictive value (bootstrapped estimates of area under ROC curve 0.73
cohort 1, 0.71 cohort 2) and performed well in identifying a substantial number of participants at low
risk of streptococcal infection (38% in cohort 1 and 36% in cohort 2 scored ≤ 1, associated with
streptococcal percentages of 13% and 18%, respectively). A Centor score of ≤ 1 identiﬁed 23% and
26% of participants with streptococcal percentages 10% and 28%, respectively.
3. Randomised controlled trial: A preliminary score to predict streptococcal infection (score 1; n = 1129)
was replaced by a more valid score (FeverPAIN, n = 631) in an adaptive trial design. There were no
signiﬁcant differences between groups for score 1, and it performed signiﬁcantly less well than
FeverPAIN for the key outcomes. For FeverPAIN, symptom severity was documented in 80% of patients
[delayed 168/207 (81%); clinical score 168/211 (80%); RADT 166/213 (78%)]. Severity was lower in
the clinical score group than in the delayed prescribing group (–0.33; 95% CI –0.64 to –0.02;
p = 0.039; equivalent to one in three rating sore throat a slight rather than moderately bad problem),
and a similar reduction was observed for the RADT group (–0.30; –0.61 to –0.00; p = 0.053).
Moderately bad or worse symptoms resolved signiﬁcantly faster (30%) in the clinical score group
(hazard ratio 1.30; 95% CI 1.03 to 1.63) but not in the RADT group (1.11; 95% CI 0.88 to 1.40). In
the delayed group, 75/164 (46%) used antibiotics, and 29% fewer used antibiotics in the clinical score
group (risk ratio 0.71; 95% CI 0.50 to 0.95; p = 0.018) and 27% fewer in the RADT group (0.73; 95%
CI 0.52 to 0.98; p = 0.033). No signiﬁcant differences in complications or reconsultations were found.
4. Qualitative study: Fifty-one participants took part in the study. Of these, 42 were HCPs (29 GPs and
13 NPs) and nine were patients. HCPs could see a positive role for RADTs in terms of reassurance, as an
educational tool for patients and for aiding inexperienced practitioners, but also had major concerns
about RADT use in clinical practice. A particular concern was the tension and possible disconnect with
clinical experience and intuition – a concern which was also raised about clinical scores. Other issues
included the validity of the tests (the role of other bacteria, and carrier states), the issues of time andNIHR Journals Library www.journalslibrary.nihr.ac.uk
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experience of using RADTs over time seemed to make some participants more positive about using the
tests. Moreover, patients were much more positive about the place of RADTs in providing reassurance
and in limiting their antibiotic use.
5. Cost-effectiveness analysis: As score 1 had not been shown to be effective but FeverPAIN appeared to
be effective, the cost-effectiveness results are only presented for the second part of the trial, when
FeverPAIN was used. There were 499 individuals who had both symptom severity and cost data from
case notes review. Costs for the initial visit and for the 1-month follow-up were similar at £51, £44 and
£52 for the delayed, clinical score and RADT groups, respectively. The clinical score group dominated
both other groups for both the cost/QALY and cost/change in symptom severity analyses, being both
less costly and more effective. Cost-effectiveness acceptability curves indicated the clinical score method
to be the most likely to be cost-effective in both cases.Conclusions
1. In vitro study: The IMI TestPack was suitable for use with high sensitivity, speciﬁcity and ease of use.
2. Clinical diagnostic study: Non-group A strains commonly cause streptococcal sore throats, and present
with similar symptomatic clinical features to group A streptococci. The variables that are predictive of
streptococcal infection vary between cohorts, and thus the conventional approach of a single
development cohort and then a subsequent validation cohort may not identify the optimal variables to
test in a clinical prediction rule. From the two cohorts, a ﬁve-item score (acronym FeverPAIN) is likely to
be valid (Fever during the last 24 hours, Purulent tonsils, Attend rapidly (≤ 3 days), very Inﬂamed
pharynx, No cough/coryza), but further validation is required.
3. Randomised controlled trial: Targeting antibiotic using a clinical score (FeverPAIN) improves control of
symptoms and reduces antibiotic use. A rapid antigen test combined with a clinical score provides
similar beneﬁts for antibiotic use, but no clear advantages over using a clinical scoring method alone.
4. Qualitative study: It is unlikely that RADTs will have a comfortable place in clinical practice in the near
future until health professionals’ concerns are met, and they have direct experience of using them. The
routine use of clinical scoring systems for acute upper respiratory tract illness also faces barriers related
to clinicians’ perceptions of their utility in the face of clinician experience and intuition.
5. Cost-effectiveness study: Using a clinical score appears to be an efﬁcient use of health-care resources
compared with either delayed antibiotic prescribing or the use of a RADT combined with a
clinical score.Overall conclusion
Rapid antigen detection tests that are inexpensive, accurate and easy to use are potentially widely available
for use in primary care. Although they will detect Lanceﬁeld group A streptococci, they are not designed
to detect non-group A strains that commonly cause streptococcal sore throats, and present with a similar
illness to group A streptococci. The variables that are predictive of streptococcal infection vary between
different samples, but from the two cohorts of patients a ﬁve-item score (acronym FeverPAIN) is likely to
be valid, but further validation is required. Targeting antibiotic using a clinical score (FeverPAIN) improves
control of symptoms, reduces antibiotic use and is very cost-effective. Using a rapid antigen test in addition
to using the clinical score provides no clear beneﬁts for patients over using the clinical score alone, and is
more costly, less cost-effective and faces several barriers from clinicians. The implementation of clinical
scoring methods in everyday practice will require health professionals’ issues related to the perceived utility
of clinical scores in the face of clinical experience and intuition to be addressed.xxv
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xxviSuggestions for further research
This study has demonstrated the limitation of using one data set to develop a clinical score. FeverPAIN,
derived from two data sets, appears to be valid and its use improves outcomes, but diagnostic studies to
conﬁrm the validity of FeverPAIN in other data sets and settings are needed.
Experienced clinicians need to identify barriers to the use of clinical scoring methods. Implementation
studies that address perceived barriers in the use of FeverPAIN are needed.Trial registration
This trial is registered as ISRCTN32027234.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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detection tests for group A beta-haemolytic
streptococcal sore throat infectionsG Lasseter, C McNulty, FDR Hobbs, D Mant and P Little on behalf of the PRISM Investigators.
Abstract
Background
Using accurate and easy-to-use rapid antigen detection tests (RADTs) to identify group A beta-haemolytic
streptococcus (GABHS) sore throat infections could reduce unnecessary prescription of antibiotics.
Although widely used in Finland, France and the United States, uncertainty regarding RADTs’ sensitivity
and ability to impact on prescribing decisions has resulted in limited uptake in the UK.Objectives
We aimed to evaluate current RADTs available in the UK in controlled, parallel in vitro trials, in order to
eliminate the spectrum bias and variability in sampling associated with many clinically based studies.Method
We compared the ease of use of ﬁve UK RADTs and their ability to detect different concentrations and
strains of GABHS: OSOM® Ultra Strep A (Bio-Stat Limited, Stockport, UK), QuickVue® Dipstick Strep A test
(TK Diagnostic, Oxford, UK), Streptatest® (DECTRA PHARM, Strasbourg, France), Clearview® Exact
(Inverness Medical Professional Diagnostics, Bedford, UK) and IMI TestPack® Plus Strep A (Inverness
Medical, Bedford, UK). We also measured whether the RADTs falsely identiﬁed common throat
commensals as GABHS. All kits were tested with single-tipped polyester swabs, rayon swabs and the kit
swabs provided by the manufacturer.Results
The IMI TestPack was the easiest RADT to use. The ability to detect all positive GABHS (the sensitivity of
the RADTs) varied considerably between kits from 62% [95% conﬁdence interval (CI) 51% to 72%] for
Clearview to 95% (95% CI 88% to 98%) for the OSOM and IMI TestPack at the highest GABHS
concentration. None of the RADTs gave any false-positive results with commensal ﬂora – they were 100%
speciﬁc. For most of the kits, the supplied swab performed well with the exception of the Clearview pack,
which performed much better with a polyester swab.Conclusion
The IMI TestPack is suitable for use in primary care, as it had high sensitivity, speciﬁcity and was the easiest
to use. If Clearview is used, a polyester swab rather than the manufacturer’s swab is preferable.BackgroundMost acute sore throats resolve in 1 week and are primarily viral in aetiology,1 but, still, the majority of
patients who present to UK general practitioners (GPs) are prescribed antibiotics.2 Current therapeutic and
diagnostic strategies aim to identify GABHS, which cause 5–10% of adult sore throats.
Microbiological diagnosis of GABHS sore throat infections is routinely performed by throat-swab culture.
Unfortunately, culture delays results for at least 18–72 hours and, therefore, treatment must be postponed
awaiting results or based on clinical characteristics present at patient consultation.11
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2The use of rapid point-of-care tests for GABHS offers an alternative to culture or empirical antibiotics.
RADTs provide results while a patient waits in the GP’s surgery and decisions regarding treatment can be
based on objective evidence. RADTs have the potential to reduce unnecessary or delayed antibiotic
treatment, eliminate laboratory involvement and reduce overall consultation times.
Although there is no international consensus on RADT use, these kits have been widely adopted in
Finland, France and the United States. The UK Clinical Knowledge Summaries, which provide the main
online guidance for GPs, do not encourage the use of RADTs, citing the limited evidence for any impact on
prescribing decisions (http://www.cks.nhs.uk/sore_throat_acute).
The reliability of RADTs is variable, and often inadequate when compared with carefully performed culture.3
Numerous clinical studies have reported the percentage of GABHS infections that RADTs can detect, which
varies from 48.0% to 98.9%.3 These discrepancies can be attributed to differences in study populations
(spectrum bias), sampling techniques, RADT kits, culture methods and variations attributable to the personnel
performing the tests. To ensure that RADTs are evaluated objectively, a standardised in vitro method using
known concentrations of GABHS would remove the inherent biases associated with these clinical studies.4
The majority of near-patient RADTs for the detection of GABHS are sold by manufacturers with kit swabs
provided. It is widely assumed that swab type has no impact on RADT performance, but this may be
unjustiﬁed, as the kit swabs provided are speciﬁcally manufactured and validated for each RADT.
Manufacturers recommend speciﬁc swab types to use in conjunction with their RADTs, safeguarding kit
sensitivity and speciﬁcity. Nonetheless, clinical validation studies routinely disregard these
recommendations by using a variety of swab types.
The purpose of this study was to evaluate in vitro the ease of use and accuracy (sensitivity and speciﬁcity) of
the ﬁve most commonly used RADTs in Europe, and explore the implications of using different swab types.Method
Rapid antigen detection kits
The kits tested represented the most commonly used kits in Europe, the most widely available kits in the
UK and those that performed reasonably in a previous study:4 Clearview Exact Test, IMI TestPack Plus Strep
A, OSOM Ultra Strep A, QuickVue Dipstick Strep A test and Streptatest (Figure 1).FIGURE 1 The five RADTs evaluated. Dipsticks, left to right: OSOM, QuickVue Dipstick and Streptatest. Cassettes, top
to bottom: IMI TestPack Plus and Clearview. Showing positive reactions for all.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Previous studies have shown that some RADTs are able to detect between 80% and 90% of GABHS
infections.5 Assuming that the best RADT in this study would achieve a sensitivity of 85–95%, and to
estimate with 95% conﬁdence that the sensitivity of a RADT was within ± 5% (i.e. to be conﬁdent that
the sensitivity was not < 80%, which would be less useful clinically), we estimated that 1460–3920
samples were required for all ﬁve RADTs.Sensitivity testing: ability to detect group A beta-haemolytic streptococcus
Four Streptococcus pyogenes strains were used that are associated with clinical sore throat infections from
the National Collection of Type Cultures (NCTC) (Health Protection Agency, Colindale, UK) (Table 1).
Streptococcal dilutions ranging from 102 up to 108 colony-forming units (CFU)/ml were tested against
RADTs in duplicate (for detailed culture methods, see Appendix 1). To mimic conditions used to undertake
RADTs in a GP surgery, each streptococcal dilution was administered as a 100-µl aliquot on to a swab and
these swabs were then used to perform the RADTs (as per manufacturers’ instructions).
These trials showed that all RADTs detected GABHS at 107 CFU/ml, whereas some kits failed to detect
streptococci at concentrations < 106 CFU/ml. These tests were duplicated to ensure accuracy. Subsequently,
each S. pyogenes stock solution was adjusted to achieve four dilutions of GABHS within this range:
2.5 × 106, 5 × 106, 7.5 × 106 and 10 × 106 CFU/ml. Each RADT was tested 20 times using the swab
technique outlined above at each dilution, with four GABHS strains (320 tests per RADT). The ﬁnal result
for each RADT investigation was interpreted in conjunction with the manufacturer’s instructions: positive,
slightly positive, negative or invalid (see Figure 1).Specificity testing: assessment of false-positives due to commensal flora
A panel of 23 commensal control strains normally found in the throat were obtained from the NCTC, the
American Type Culture Collection and the National Collection of Pathogenic Fungi (see Table 1). Strains
were evaluated in seven test solutions, which included several organisms from similar or identical genera.
The concentrations of these organisms were adjusted to represent the upper limits often found in clinical
samples, with each organism equal to 107 CFU/ml.6–9
Each RADT was tested 10 times with seven commensal groups (70 tests per RADT).Ease of use of rapid antigen detection tests
A biomedical scientist and consultant microbiologist evaluated 10 characteristics of each RADT
(Table 2) – these included packaging, shelf-life, test procedure, controls, interpretation and timing of
results. RADT instruction inserts were assessed on six main features: layout, font size, general clarity,
stand-alone clarity of visual instructions, clarity of instructions for determining ﬁnal results and inclusion of
all pertinent information (see Table 2 for scoring). Each test kit could score a maximum total of 22 points.
Price per test (2008) was calculated excluding company discounts for bulk purchases.
Swab type
The manufacturers’ instructions for the RADTs evaluated speciﬁcally recommended the use of either
polyester or rayon swabs (see Appendix 2). Consequently, all kits were tested in vitro with single-tipped
polyester swabs (Ref: 170C, Copan Diagnostic, Barloworld Scientiﬁc, Staffordshire, UK), rayon swabs (Ref:
141C, Copan Diagnostic) and the kit swabs provided by the manufacturer.Results
Sensitivity results: ability to detect group A beta-haemolytic streptococcus
All the test kits performed better with increasing concentration of GABHS (Figure 2). All RADTs were
positive at the highest concentration of GABHS of 10 × 106 CFU/ml, whereas at lower concentrations of
GABHS the kits varied in their ability to give positive results. At a GABHS concentration of 10 × 106 CFU/ml,3
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TABLE 1 Strains used for in vitro RADT investigation
Strains Group
Catalogue number
ATCC NCTC NCPF
Streptococcus pyogenes GABHS 12,696, 8312,
8308, 10,867
Streptococcus dysgalactiae subsp. equisimilis Group 1 35,666
Streptococcus anginosus Group 1 33,397
Streptococcus intermedius Group 1 11,324
Streptococcus constellatus Group 1 11,325
Streptococcus mitis Group 1 12,261
Streptococcus mutans Group 1 10,449
Streptococcus sanguinis Group 1 10,904
Streptococcus salivarius Group 1 11,389
Streptococcus pneumoniae Group 1 33,400
Staphylococcus aureus Group 2 31,153 8178
Staphylococcus epidermidis Group 2 14,990 11,047
Haemophilus influenzae Group 3 9332
Haemophilus influenzae type b Group 3 7279
Haemophilus parainfluenzae Group 3 11,607
Moraxella catarrhalis Group 4 3622
Neisseria pharyngis var. flavus Group 4 4591
Neisseria pharyngis var. siccus Group 4 4590
Escherichia coli Group 5 10,418
Pseudomonas aeruginosa Group 5 10,662
Candida albicans Group 6 3091
Bacteroides melaninogenicus Group 7 15,930 11,321
Fusobacterium nucleatum Group 7 11,326
Veillonella parvula Group 7 11,809
ATCC, American Type Culture Collection; NCPF, National Collection of Pathogenic Fungi.
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4the OSOM and IMI TestPack detected 95% of the test samples as positive, whereas Streptatest detected
79% (95% CI 67% to 85%), QuickVue 70% (95% CI 59% to 80%) and Clearview 62% (95% CI 51%
to 72%). The Streptatest, QuickVue and Clearview were all at least 15% less sensitive than OSOM and IMI
TestPack at all concentrations of GABHS. Detailed results are available in Appendix 3.
GABHS strain type caused only minor ﬂuctuations in RADT sensitivity; strain 8312 was associated with an
overall sensitivity of 41% (95% CI 38% to 44%), strain 8308 a sensitivity of 48% (95% CI 45% to 51%),
strain 12,969 a sensitivity of 49% (95% CI 46% to 52%) and strain 10,867 a sensitivity of 51% (95% CI
48% to 54%).NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 2 General ease-of-use classiﬁcation: for ﬁve RADTs for the detection GABHS, based on general
characteristics and the reader’s opinion
Characteristics of the test Score
Clearview
Exact Testa
IMI TestPack
Plusa
OSOM
Ultra
QuickVue
Dipstick Streptatest
Shelf-life
> 12 months 2 2 2 1 2 2
≤ 12 months 1
Number of tests per box
> 25 units 2 1 1 2 1 1
≤ 25 units 1
Storage volume (one box)
< 0.003m3 2 1 1 2 2 2
> 0.003m3 1
Steps needed
Additional extraction step 1 2 1 2 2 2
None 2
End point of test
Timed 5 minutes 1 1 2 1 1 1
Visual end point 2
Reading stability of end point
Read at 5 minutes only 1 2 2 1 1 2
Read at 5 minutes;
valid ≤ 10 minutes
2
Timer provided
Not needed 3 1 3 1 1 2
Yes 2
No 1
Internal controls
Positive and negative
control
2 1 2 1 1 1
Negative control only 1
Opinion of readers
Ease of performance
Very easy 2 2 2 1 1 1
Easy 1
Ease of interpreting results
Very easy 2 2 2 1 1 1
Easy 1
Score (max. total = 22) 15 18 13 14 15
max., maximum.
a Cassettes. All other RADTs were dipsticks.
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FIGURE 2 Sensitivity (with 95% CI) for five RADTs, in relation to swab type used; all GABHS strains
and concentrations.
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6Specificity
None of the RADTs gave any false-positives when tested 10 times with each commensal group. Thus, the
speciﬁcity of each RADT was 100% (95% CI 72% to 100%).Swab type
Combining the results from all RADTs demonstrated the impact of swab type: kit swabs were associated
with the highest sensitivity results overall at 55% (95% CI 53% to 57%), compared with polyester at 52%
(95% CI 50% to 54%) or rayon at 37% (95% CI 35% to 39%).
Figure 2 presents the compiled sensitivity results for all GABHS strain types and GABHS concentrations,
and demonstrates the most important two-way interaction between RADTs and swab type. The kit swabs
provided produced the highest sensitivity results with the OSOM, QuickVue Dipstick, IMI TestPack Plus and
Streptatest kits. However, Clearview sensitivity was notably better with polyester swabs at 77% (95% CI
67% to 87%); in comparison, the kits swabs provided had a sensitivity of only 38% (95% CI 28% to
48%) and rayon swabs of 23% (95% CI 13% to 33%).
Figure 3 shows the effect of swab type on RADTs when the inﬂuences of strain type and GABHS
concentration are removed. Overall, RADT sensitivity was best when using the kit swabs provided at 54%.
This is in comparison with polyester swabs at 52% and rayon swabs at 37%.0
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FIGURE 3 Sensitivity (with 95% CI) for each swab type; all RADTs, GABHS strains and GABHS concentrations.
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DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6Figure 4 demonstrates RADT sensitivities at all GABHS concentrations, minimising the effect of the least
important variable – GABHS strain. At 7.5 × 106 CFU/ml the OSOM/kit swab combination achieved a
sensitivity of 95% (95% CI 87% to 100%), which was matched only by Clearview using polyester swabs.
However, Clearview and polyester swabs achieved 100% (95% CI 96% to 100%) sensitivity at
10 × 106 CFU/ml, whereas the sensitivity of OSOM and kit swabs remained at 95% at this concentration.
However, it is worth noting that the sensitivity of Clearview when using the kit swabs provided was
considerably reduced, reaching a maximum sensitivity of only 62% (95% CI 51% to 72%) at
10 × 106 CFU/ml, which is lower than any other RADT.Ease of use/storage, cost and instruction clarity (see Tables 2 and 3):Ease of use/storage, cost and instruction clarity (see Tables 2 and 3):
suitability of rapid antigen detection tests for general practicesuitability of rapid antigen detection tests for general practice
As the study evaluated a selection of cassette and dipstick formats, all the kits had different characteristics,
with each RADT having a variety of strengths and weaknesses.
The OSOM Ultra kit had a shorter shelf-life than all the others and contained the most tests per kit
(n = 50). This may be important if surgeries are undertaking less than one test per week, as the tests may
not be used before the expiry date.
The Clearview and IMI TestPack kits were provided in larger boxes than those of the other RADTs. This
could present a storage problem for GP surgeries, particularly those practices with minimal storage space
or those storing numerous RADTs kits.
The IMI TestPack needed an additional sample extraction step, not required for the other RADTs, which
was simply the addition of another extraction reagent. However, this additional step was straightforward,
adding only seconds on to the total test procedure.
The IMI TestPack had an end point that could be read at between 5 and 10 minutes, with the availability
of the ﬁnal results conﬁrmed by a novel ‘end-of-assay window’ (see Figure 1). The other four kits had
timed end points at 5 minutes, and two of the four kit instructions stated it was essential to read the
results at 5 minutes. The IMI TestPack was deemed the easiest format for routine clinical practice because
of the ﬂexibility in reading the end point.
Overall, the cassette formats were preferred to the dipsticks, as they were easier to handle and discard. All
test reagents are absorbed into the cassette test device, thus eliminating the hazard of test reagent
spillages, a clear advantage for any point-of-care testing kit. Overall, the IMI TestPack achieved the highest
score for general ease of use, totalling 18 out of 22 points (see Table 2). Streptatest and Clearview both0
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8scored 15 points, QuickVue Dipstick 14 points and OSOM 13 points. Overall, the two cassette formats
achieved higher scores than the dipsticks.Clarity of kit instructions and price per test
The instruction clarity of the RADTs is outlined in Table 3, along with price per test. Notably there was no
standard format used by the RADT manufacturers and, consequently, the quality of the kit instructions
varied between RADTs. Streptatest was felt to have the best instructions overall: clear and simple, with a
logical layout. The IMI TestPack was a close second, losing marks on small font size and the inclusion of
too much information.
Overall, OSOM was the most expensive and judged to have the poorest instructions. Streptatest was the
cheapest kit, with the best instruction clarity. The IMI TestPack performed well overall, marred only by price
per test. Clearview was the second cheapest RADT, and had an average instruction manual. The difference
in price per test was more than threefold: Streptatest was the cheapest at £1.38 and OSOM the most
expensive at £3.46.DiscussionIn this in vitro study, the speciﬁcity of RADTs kits was very good. Sensitivity varied with streptococcal
concentration and two RADTs were more sensitive. Kits also varied considerably in their ease of use
and expense.Strengths and limitations
Clinical throat swabs are notoriously imprecise samples: two simultaneous swabs often vary in the number
of GABHS collected.10,11 With no standard method for throat swab collection, swab material, transport
medium and environmental factors can all affect GABHS collection and survival, and ultimately RADT
performance. Our in vitro study removed these biases by using precise GABHS concentrations and directly
comparing the performance of each RADT.
The GABHS strains used for sensitivity testing were chosen because of their association with sore throat
episodes and included two mucoid strains. Testing more strains of GABHS may have altered our sensitivity
ﬁndings; however, this seems unlikely, given that the four very different strains included in this study had
little impact on RADT sensitivity.
This study was undertaken by a biomedical scientist with laboratory training, as we wanted to minimise
any user bias in our method. Previous research has shown that the professional skills of the person
performing the RADT can affect its sensitivity. Consequently, the accuracy of these tests may be affected
when performed by untrained personnel in a general practice setting.TABLE 3 Classiﬁcation of ﬁve RADTs base on price per test and instruction insert clarity (April 2008 prices)
RADT Price per test (inclusive of VAT; £) Instruction clarity
Streptatest 1.38 Excellent
Clearview 1.87 Good
QuickVue Dipstick 2.35 Poor
IMI TestPack Plus 3.15 Very good
OSOM 3.46 Very poor
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6A signiﬁcant proportion of streptococcal sore throats are group C or G streptococci which probably
present with similar clinical features to group A streptococci.12,13 Investigating sore throat infections with
highly speciﬁc RADTs will result in cases of group C and G infections being undiagnosed and untreated.
The signiﬁcance and clinical relevance of this issue will be investigated further in the diagnostic studies
(see Chapters 2 and 3).Main findings and comparison with existing literature
The OSOM and IMI TestPack were 15% more sensitive (detected 15% more positive samples) than
Streptatest, QuickVue and Clearview at all concentrations of GABHS. The OSOM kit detected more strains
of GABHS at lower concentrations than the IMI TestPack. However, the OSOM kit was the most expensive
kit and had poor instructions. Overall, the simple and practical IMI TestPack outperformed the other kits
for ease of use, demonstrating the kit’s suitability for the general practice setting. None of the RADTs gave
any false-positive results with the commensal ﬂora [speciﬁcity 100% (95% CI 72% to 100%)]. Variation in
GABHS strain type had little effect on RADT sensitivity, whereas increasing streptococcal concentrations
improved the sensitivities of all kits.
Only one similar in vitro study has been identiﬁed, a French-language paper by Charlier-Bret et al.
published in 2004.4 Our ﬁndings were in line with this study, conﬁrming that RADT sensitivity typically falls
between 105 and 107 CFU/ml. Overall, Charlier-Bret et al. evaluated four of the ﬁve kits assessed in our
study, reporting the most sensitive RADT as the IMI TestPack, followed in decreasing sensitivity by
Streptatest, QuickVue Dipstick and Clearview. The OSOM kit was not evaluated.
The cost of each RADT is likely to be a barrier for its use in the health systems such as UK primary care, in
which doctors working in primary care do not pay for laboratory diagnostic tests. If health-care providers
wish to encourage the use of RADTs in primary care in similar environments, they are likely to need to
reimburse physicians for their use. This may well be a cost-effective policy if RADTs can be shown to
reduce antibiotic prescribing more effectively than the alternative strategies.Swab type
A previous report by Bourbeau14 noted that swab ﬁbre composition, swab tip preparation, swab tip
characterisation (ﬁbre, foam, ﬂocked), shaft type (hollow, solid) and transport medium can impact on swab
performance. In light of this information, and because the clinical validation part of the PRISM study used
rayon swabs for validation of all kits, despite three of the manufacturers recommending polyester swabs
(see Appendix 2), users of RADT should note that the ‘best’ swab type is not always that provided with the
RADT kit or recommended by the manufacturer.ConclusionThe OSOM and kit swab combination was the most consistently sensitive RADT but has some
disadvantages. This study provides sufﬁcient evidence that the IMI TestPack is suitable for use in primary
care (and the most suitable for use in the trial – see Chapter 4), as it had high sensitivity and speciﬁcity and
was easy to use. Our results showed that RADT sensitivity altered considerably depending on the swab
type used. The kit swabs provided by the manufacturer with each RADT gave the most sensitive results for
all RADTs except Clearview, which performed better with polyester swabs. Future clinical trials should
choose swab types carefully, and manufacturers should demonstrate that their swab types provide the
optimal results, as the sensitivity of RADTs can be signiﬁcantly impaired by swab type.9
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associated with streptococcal throat infectionsP Little, FDR Hobbs, D Mant, C McNulty and M Mullee on behalf of the PRISM investigators.
Abstract
Background
Management of acute sore throat is often based on features associated with GABHS, but the features that
best predict GABHS require clariﬁcation. Non-group A streptococcal strains share major similarities with
group A strains, but their clinical presentation and incidence has not been clariﬁed.Objective
The aim of this study was to assess the incidence and clinical features associated with streptococcal
infections.Design
This study comprised a prospective diagnostic cohort.Setting
The setting was UK primary care.Patients
The patients included in the study were aged ≥ 5 years and presented with acute sore throat and clinical
signs in the pharynx (acute pharyngitis).Methods
The presence of pathogenic streptococci isolated from throat swabs was documented.Results
Pathogenic streptococci were found among 204/597 patients (34%; 95% CI 31% to 38%). Of these,
33% (68/204) were non-group A streptococci – mostly C (29), G (18) and B (17); and rarely D (3) and
S. pneumoniae (1). Patients presented with similar features whether the streptococci found were group A
or non group-A. The features that best predicted A, C or G beta-haemolytic streptococci were the
patients’ self-reported assessment of severity (odds ratio for a bad sore throat 3.31; 95% CI 1.24 to 8.83);
absence of a bad cough (2.73; 95% CI 1.56 to 4.76), absence of coryza (1.54; 95% CI 0.99 to 2.41);
muscle aches rated moderately bad or worse (2.20; 95% CI 1.41 to 3.42); and clinicians’ assessment of
severity (severely inﬂamed tonsils 2.28; 95% CI 1.39 to 3.74).Conclusion
Non-group A strains commonly cause streptococcal sore throats, and present with similar symptoms and
clinical features to group A streptococci. The best features to predict streptococcal sore throat presenting
in primary care deserve re-examining.11
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12BackgroundAcute sore throat is one of the commonest presentations in clinical practice and most patients are treated
with antibiotics despite a Cochrane review suggesting modest symptomatic beneﬁt.15 A reasonable
strategy in reducing the public health threat of antibiotic resistance is to limit antibiotic use to the minority
of individuals with streptococcal infections who are more likely to beneﬁt13,16,17 and avoid treatment in
those unlikely to beneﬁt. GABHS is the most frequent major bacterial pathogen in pharyngitis.
Rapid streptococcal antigen tests to detect GABHS are used widely in developed countries to target
treatment, as GABHS is the most common major pathogen,1 and the use of rapid tests may help practitioners
to reduce prescribing.18,19 Much less emphasis has hitherto been placed on other Lanceﬁeld groups
(particularly C and G),20 and there are no rapid antigen tests available for detecting these groups. The
incidence of rheumatic fever, which is probably not caused by group C and G streptococci, has dramatically
declined in developed countries15 and antibiotic treatment to prevent rheumatic fever is an extremely
inefﬁcient use of health-care resources.17 The major virulence factors among group A streptococci are shared
by group C and G streptococci – particularly the M proteins, peptidase, hyaluronic capsule and
streptokinase,12,20 and similar numbers of cases of streptococcal septicaemia due to C and G and to A
streptococci are regularly reported.21 However, such complications are rare, and hence the major beneﬁt of
targeting streptococcal infections – which may apply to Groups C, G and A if clinical presentation is similar –
is likely to be in limiting antibiotic treatment to individuals who will beneﬁt from more rapid symptom
resolution15 and a shorter infective period.16 A small study in two Norwegian practices suggested that
Lanceﬁeld groups C and G presentations were similar to those of group A,12 which is supported by Tiemstra
et al.;13 conversely, a substantial study concluded that their clinical presentations were different.22 Therefore,
both the relevance of C and G streptococci in symptomatic presentation and the clinical predictors require
clariﬁcation. We report new data on the epidemiology of pathogens that cause pharyngitis and the predictors
of the presence of pathogenic streptococci for patients presenting with pharyngitis in primary care.Methods
Inclusion
Health professionals in general practices in the south and central areas of England recruited adults or
children aged ≥ 5 years presenting with acute sore throat (< 2 weeks), when the sore throat was the
predominant clinical feature (or when the clinician felt that the pharyngitis was driving the illness
presentation), and with an abnormality on examination of the throat (erythema with or without pus and
anterior cervical glands) – similar to a previous study in primary care.23 Exclusion criteria were as follows:
other non-infective causes of sore throat (e.g. aphthous ulceration, candida, drugs) or unable to consent
(e.g. dementia, uncontrolled psychosis).Clinical data
Following informed consent, baseline clinical data were collected by the recruiting health professional.24–26
The case report form collected information on age, gender, current smoking status and past history of
quinsy27 as well as data on symptom severity for the symptoms of sore throat, difﬁculty swallowing, fever,
cough, coryza (‘runny nose’), headache, muscle ache, abdominal pain, diarrhoea, vomiting, earache (each
symptom was rated by the patient as follows: 0 = no problem, 1 = slight problem, 2 = moderately bad
problem, 3 = severe problem). The doctor or nurse documented examination ﬁndings for oral temperature
using Tempa•DOT™ thermometers (3M, St Paul, MN, USA)28 the severity of tonsillar and pharyngeal
inﬂammation, and the presence of cervical glands, tonsillar exudate, fetor and palatal oedema.24–26NIHR Journals Library www.journalslibrary.nihr.ac.uk
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At the training session in each practice, clinicians were instructed in standard study procedures, including how
to take a throat swab. Swabs were taken by the clinician and sent to a central laboratory for culture of and
sensitivity testing to all signiﬁcant pathogens, in line with national standard operating procedures.29,30 Mean
time between specimen collection and receipt at laboratory was 2.9 days (data incomplete for 13 samples).
The swabs were inoculated on to a blood agar plate and staph/strep agar plate (E&O Laboratories Ltd,
Bonnybridge, Scotland) and spread for single colonies. Plates were incubated anaerobically for 48 hours.29,30
Plates were read after 24 hours of incubation and negative cultures reincubated for an additional 24 hours.
Suspected beta-haemolytic streptococcal isolates were identiﬁed via visual analysis of colony morphology and
Lanceﬁeld grouping (PathoDx Strep Grouping Kit, Oxoid), in accordance with the national standard operating
procedures.29,30 Antibiotic sensitivities were conducted using disc diffusion techniques.31Sample size
In order to determine the predictive value of clinical variables, we estimated that a subgroup of 139 patients
with a clinical presentation not associated with streptococcal infection would provide estimates of a negative
predictive value of 90% with 95% CIs of ± 5%, and a subgroup of 93 individuals with streptococcal infection
would provide estimates of a positive predictive value of 60% with 95% CIs of ± 10%. We estimated that a
sample size of 455 patients would be sufﬁcient to detect an odds ratio of 2 (assuming α = 0.05 and β = 0.2)
for variables with a prevalence of 20–65% among patients without streptococcal infection.Analysis
Clinical variables were included in a logistic regression model to assess their association with the presence
of streptococci. Forward selection was used: variables were included if signiﬁcant at the 10% level and
retained in multivariate analysis if they remained signiﬁcant at the 5% level, with no evidence of
collinearity. All variables signiﬁcant in univariate analysis were checked again in the ﬁnal model. Cases with
missing data for a particular analysis were excluded. For variables with several levels (e.g. sore throat), to
facilitate use in a simple clinical score (i.e. ease of implementation), a cut-off was normally made at or near
an odds ratio of 2. Continuous variables were dichotomised using previous cut-offs (age ≤ 10 years; prior
duration longer than the median of 3 days).25 For duration, there was a progressive reduced likelihood of
infection with group A streptococci. With longer prior duration, however, we dichotomised at the median
for ease of implementation. We also present a version of the ﬁnal model with more categories for each
variables (i.e. not dichotomised, using ordered categorical variables). Such a model could potentially be
used with computerised practices to document more precisely risk of streptococcal infection (Appendix 4).
Although for non-group A streptococci to date we assumed Lanceﬁeld groups B and D and also
Pneumococcus were not to be counted as signiﬁcant pharyngeal pathogens (Tables 2 and 3 and
Appendix 4), given the ongoing debates about this issue,13 we also present the multivariate analysis when
these streptococci are included as potentially signiﬁcant pathogens (see legends to Tables 2 and 3). Given
the higher asymptomatic carriage rates of streptococci in children, we did not include age in the ﬁnal
multivariate models.ResultsIn total, 70 GPs and practice nurses in south and central England recruited 606 patients from March 2007
until January 2008. Recruitment took a year because of the limited duration of recruitment in many
practices – the median time spent recruiting was 3 months. However, the median recruitment rate (the
number of patients/months recruiting) was 4.7 patients per month – close to the expected rate from
national data.32 Sixty-seven out of 605 (11%) patients were under age 10 years, 106/604 (18%) were
smokers and 109/605 (32%) were male.13
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14Of the 606 patients recruited, 592 had microbiology results and 567 had useable baseline clinical data.
Pathogenic streptococci were found in 202 patients (34%): of these, 136 had GABHS, and 66/202 (33%)
had non-Lanceﬁeld group A streptococci – mainly groups C (27), G (18) and B (17), but also D (3) and
Pneumococcus (1).
Patients who had GABHS strains were more likely than all other patients to have a short duration of illness
(≤ 3 days), anterior cervical glands, be aged < 10 years, have a moderately bad or worse sore throat, have
moderately bad or worse muscle aches, have had fever during the last 24 hours and not have a bad cough
(Table 4). Although purulent tonsils were predictive in univariate analysis, they did not independently
predict the presence of GABHS in this cohort (see Table 4).
Patients with group C and G beta-haemolytic strains presented with similar clinical features to individuals
with GABHS strains (Table 5 and Figure 5) – with the exception of age, as children were very unlikely to
have C and G strains and more likely to have GABHS strains. Many of the features associated with GABHS
strains were associated with the presence of C and G streptococci.
The independent clinical features associated with combined group A, C and G streptococci were as
follows: rapid attendance (prior duration ≤ 3 days), moderately bad or worse muscle aches, moderately
bad or worse sore throat, the absence of a bad cough, severely inﬂamed tonsils, age < 10 years, fever
during the last 24 hours and anterior cervical glands (Table 6). The absence of a ‘runny nose’ (coryza) was
also very close to signiﬁcance in multivariate analysis (p = 0.054). There were too few patients with group
B infections to assess the strain with conﬁdence but many had similar features in terms of a severe sore
throat (17/17; 100%), purulent tonsils (10/17; 59%), cervical glands (13/16; 81%), short prior duration
(9/17; 53%), the absence of a bad cough (14/17; 82%) and no runny nose (13/17; 76%); however, the
rate of fever in these patients (10/17; 59%) was similar to that observed in those patients from whom no
streptococci were isolated and only 3/17 (18%) had severely inﬂamed tonsils. A fuller model – in which the
variables in Table 6 are not dichotomised – is presented in Appendix 4, which supports the overall ﬁndings
from the simpler models, with the exception of coryza (which is no longer signiﬁcant).
There is considerable variation as to how well each indicator performs in helping to rule in or rule out the
presence of streptococci (Figure 6).
Recruitment bias
Comparing patients of higher-recruiting doctors (higher than the median – average 11.8 patients per
month) with patients of lower-recruiting doctors (an average of 2.6 patients per month), there was no
difference in the number of features that predicted streptococcal infections in multivariate analysis
(see Table 6 for signiﬁcant features, respectively a mean of 3.3 features and 3.4 features), suggesting little
or no recruitment bias based on clinical characteristics.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 5 Percentage of symptoms and signs at presentation for patients infected with GABHS, group C or G
streptococci or no group A, C or G streptococci.
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FIGURE 6 Log-univariate likelihood ratios [log of likelihood ratio for a negative test (log-LR–) and log of likelihood
ratio for a positive test (log-LR+)] for individual symptoms and signs at presentation for patients with group A, C or G
beta-haemolytic streptococci.
DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6DiscussionThis study documents that non-GABHS strains are a common cause of streptococcal sore throat in primary
care and have similar symptomatic presentations to GABHS and that the best predictors of streptococcal
infection may not include some of the features traditionally used.Strengths and limitations of the study
The power to detect variables associated with groups C and G streptococci was limited; however, this is
one of the largest studies to assess a broad range of clinical variables, and we found similar features to a
smaller study reported previously.11 Missing data were minimal (< 5% for any analysis), and, although
consecutive recruitment of cases was difﬁcult to enforce in practice, very little evidence of recruitment bias
was found when recruitment rates were compared with expected rates of recruitment from national
samples. Selection bias is a potentially important issue among low-recruiting doctors, but we found no
evidence of clinical differences between patients of higher- and lower-recruiting doctors. Overall, fewer
children than expected from historical data sets2 were recruited, which probably reﬂects the reluctance of
parents and/or GPs to expose children to a throat swab, but, as we elected not to include age per se in the
model, the impact of this should be slight. The time between taking a swab and receipt at the laboratory
was slightly longer than expected, but Lanceﬁeld groups A, C and G are not particularly sensitive to
transport conditions, and we found relatively high percentages of streptococci compared with previous
literature. As there was no indication from sentinel practices or microbiology laboratories of a streptococcal
epidemic, the higher streptococcal percentages and more ﬂorid clinical signs than previous studies in a
similar geographical area33 may indicate changing consultation thresholds. Although the study indicates
that clinical features not traditionally incorporated in making diagnostic assessments may possibly not be
important, further data sets are needed before recommending a key variable set. The way variables are
operationalised may also be important: McIsaac et al.34,35 use tonsillar swelling or exudate, Centor et al.24
just exudate and we chose exudate, as swelling is not necessarily an acute feature. We used intermediate
cut points when indicated rather than the extremes of each scale; however, as the judgement of
intermediate points may be more variable, using the extremes (none or very) may be more reliable for
developing a clinical prediction rule.19
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20Main findings and comparison with existing literature
Traditionally clinicians have been predominantly interested in GABHS because of their association with
major non-suppurative adverse outcomes – particularly rheumatic fever.1 Therefore, the clinical predictors
of GABHS infection1,25,36 – especially pus, cervical nodes, a history of fever and no history of
cough37 – have been widely used in clinical guidelines.16,17,38 Historical comparisons tentatively suggest that
these variables may identify a group of patients who are more likely to beneﬁt from antibiotics.15 We
conﬁrmed the importance of cervical glands and the absence of a bad cough and of fever.25,34 However,
this study documents that, although the feature of purulence is associated with the presence of GABHS in
univariate analysis, in this data set it is not independently predictive – and other features may be
important, particularly the severity of both the sore throat and the inﬂammation, the prior duration
(reﬂecting a more rapid, severe onset), muscle aches and possibly the absence of coryza. Some of these
features were identiﬁed previously in studies in typical primary-care settings,12,25 but previous studies were
limited by a lack of multivariate analysis or limited power.
The clinical presentation of infection with group C and G streptococci suggests strongly that not only are
these presentations unlikely to be due to commensal carriage, but they are causing a similar clinical
syndrome to GABHS. This supports those studies that observed similar symptomatic presentation.12,13
If group C and G streptococci are clinically important, then rapid streptococcal antigen tests (which are
targeted at GABHS only) will miss a signiﬁcant proportion of streptococcal infection.ConclusionGroup C and G streptococcal infections present with symptomatic illness in a similar manner to GABHS.
RADTs, which are widely used in many developed countries to detect GABHS, will miss these organisms.
The best features to predict streptococcal sore throat presenting in primary care also deserve revisiting,
as features not commonly used in diagnosis (e.g. rapid presentation, severity of inﬂammation) may be
useful clinically.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6Chapter 3 Two diagnostic cohorts to identify
clinical variables associated with Lanceﬁeld group A
beta-haemolytic streptococci and Lanceﬁeld
non-group A streptococcal throat infections
P Little, M Moore, FDR Hobbs, D Mant, C McNulty, I Williamson, MYE Cheng and M Mullee on behalfof the PRISM investigators.
Abstract
Background
Clinical variables traditionally associated with pathogenic streptococci – such as the presence of cervical
glands – and clinical scores derived from these variables are commonly used to minimise antibiotic use for
individuals with a low likelihood of pathogenic streptococci.Objective
The aim of this study was to assess the association between features of pharyngitis and the growth of
Lanceﬁeld group A, C or G streptococci from culture of a throat swab in two cohorts.Design
This was a diagnostic cohort study.Setting
The setting was general practices in the UK.Patients
Patients included in the study were aged ≥ 5 years and presented with acute pharyngitis. Patients were
recruited for a second cohort (cohort 2, n = 517) consecutively after the ﬁrst (cohort 1, n = 606) from
similar practices.Results
A, C or G beta-haemolytic streptococci were found in 40% of participants in cohort 2 (compared
with 34% in cohort 1). The clinical features that predicted the presence of these streptococci in
multivariate analysis in both cohorts were as follows: rapid attendance (short prior duration of ≤ 3 days;
multivariate-adjusted odds ratio 1.92 cohort 1, 1.67 cohort 2); fever in the last 24 hours (1.69, 2.40); and
severe inﬂammation as assessed by doctor [severely inﬂamed pharynx/tonsils (2.28, 2.29)]. Absence of
coryza or cough and purulent tonsils were also signiﬁcant predictive variables in univariate analysis in both
cohorts and in multivariate analysis in at least one cohort. A ﬁve-item score, based on Fever, Purulence,
Attend rapidly (≤ 3 days), severe Inﬂammation and No cough or coryza (acronym FeverPAIN), had
moderate predictive value [bootstrapped estimates of area under receiver-operating-characteristic (ROC)
curve: 0.73 cohort 1, 0.71 cohort 2] and performed well in identifying a substantial number of participants
at low risk of streptococcal infection (38% in cohort 1, 36% in cohort 2 scored ≤ 1, associated with
streptococcal percentages of 13% and 18%, respectively). A Centor score of ≤ 1 identiﬁed 23% and 26%
of participants, with streptococcal percentages of 10% and 28%, respectively.21
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22Conclusions
Items widely used to help identify presentations of streptococcal sore throat in primary care may not be
the most valid. A modiﬁed clinical scoring system (FeverPAIN), which requires further validation, may be
helpful clinically in identifying individuals who are unlikely to have major pathogenic streptococci.BackgroundAntibiotic resistance is a major public health problem, driven largely by antibiotic prescribing in primary
care,39 and it is imperative to minimise antibiotic use in patients who will not beneﬁt from it.40 However,
antibiotics are still prescribed to the majority of patients with acute sore throat, the most common upper
respiratory tract infection to present in primary care.2
The management of acute sore throat is often based on features associated with GABHS, and clinical scores
to predict GABHS have some promise to be useful,1,25,36 including the simple Centor criteria – three out of
four of pus, cervical nodes, a history of fever and no history of cough – which are widely advocated in clinical
practice guidance.16,17,34,41,42 However, these criteria have low speciﬁcity,34 leading to high rates of overall
antibiotic use.34 Furthermore, small studies in typical primary-care settings have suggested other features
might be useful in reﬁning the criteria – such as shorter prior duration, severity of pain and muscles ache.12,25
The issue of which variables most strongly predict streptococcal infections is, therefore, still not settled.
We previously reported evidence that group C and G streptococci present in a similar manner to GABHS
(see Chapter 2), and found that some of the variables that constitute very commonly used clinical
prediction rules (such as purulence) might not be signiﬁcant, and other variables not commonly used might
be important (such as speed of presentation, severity of inﬂammation), suggesting the clear need to assess
a wide range of potential variables in different data sets.
We compare ﬁndings from a new cohort with the original cohort (see Chapter 2) regarding the predictors
of the presence of pathogenic streptococci, including group A, C and G, in throat swab cultures from
patients presenting with sore throat in primary care.MethodsThe inclusion criteria, the clinical data collection, and the collection and transport of swabs are as
described in Chapter 2.Sample size
In order to determine the association of clinical variables with streptococcal infection, assuming that at
least one-third of individuals would have streptococci infection (based on our ﬁrst data set), and that
variables in the streptococcal group were found in 30–80% of individuals, the detection of a variable with
an odds ratio of 2 required 407 individuals with complete results.Analysis
As we found previously from the ﬁrst data set that patients with group C and G beta-haemolytic strains
presented with similar clinical features to individuals with GABHS, we assessed the independent clinical
features associated with combined group A, C and G streptococci in both data sets. Clinical variables were
included in a logistic regression model to assess their association with the presence of Lanceﬁeld group A,
C and G streptococci. Forward selection was used: variables were included if signiﬁcant at the 10% level
and retained in multivariate analysis if they remained signiﬁcant at the 5% level. Missing variables were not
imputed. Continuous variables were dichotomised using previous cut-offs (age ≤ 10 years; prior duration
longer than the median of 3 days).25 Given the higher asymptomatic carriage rates of streptococci in
children, we did not include age in the ﬁnal multivariate models. Clinical scoring systems or clinicalNIHR Journals Library www.journalslibrary.nihr.ac.uk
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variables should be used – preferably using a simple count of the predictive variables. We estimated the
increase in area under the ROC curve starting with the most predictive variables, with the aim of maximising
the area under the curve without including unnecessary variables, and generated a basic model using
variables that were signiﬁcant in multivariate analysis in both data sets. However, a clinical score using very
few variables will potentially limit the grading of risk (as there will be fewer categories) and variable
performance of one item in different cohorts will unduly affect reliability. Therefore, we also generated an
expanded score to include variables that were signiﬁcant in univariate analysis in both data sets and
multivariate analysis in at least one of the data sets.
Because any new model developed from a single data set may be overﬁtted, bootstrapped estimates are
provided for the area under the ROC curve for internal validation for the new model (see Table 8).43
For the Centor criteria (an established model), non-bootstrapped estimates are provided.ResultsFor the ﬁrst data set we recruited patients from 15 practices, and for the second data set 12 of these
15 practices participated. Patients were recruited from January 2007 until October 2008 (96% of patients
were recruited after January 2008, when the ﬁrst data set was completed). All 517 patients recruited in
the second data period had some useable data, and complete data were available for 460 patients. In the
second data set, pathogenic streptococci were found in 207 patients (40%) – mainly A (143), C (30) and
G (20), but some B (9), D (2) and F (3). These are very similar ﬁgures to the ﬁrst data set (see Chapter 2).
The independent variables associated with Lanceﬁeld group A, C or G streptococci in the second data set
are shown in Table 7, with the univariate and multivariate odds ratios also reported from the ﬁrst data set
for ease of comparison. The clinical features predicting the presence of group A, C or G beta-haemolytic
streptococci signiﬁcantly in multivariate analysis in both data sets were rapid attendance (a short prior
illness duration of 3 days or less; multivariate adjusted odds ratio in the ﬁrst data set 1.92; 1.67 in the
second data set), fever in the last 24 hours (odds ratios 1.69 and 2.40 respectively) and doctor assessment
of severity of inﬂammation (severely inﬂamed pharynx/tonsils: 2.28; 2.29). Additional variables signiﬁcant
in univariate analysis in both data sets and signiﬁcant in multivariate analysis in at least one of the data
sets were items suggesting a purely pharyngeal illness (the absence of coryza and the absence of cough),
purulent tonsils, and muscle aches. ‘Absence of coryza’ performed only marginally better than ‘absence of
cough’ in the two data sets, so based on the similarity of these items and their performance, the helpful
concept for clinicians of a purely oropharyngeal illness (i.e. when both cough and coryza are absent) and
the prior extensive use of ‘absence of cough’ in the Centor criteria, the consensus among the study team
was to use the combined variable ‘absence of cough or coryza’.
Table 8 shows the incremental performance, in terms of area under the ROC curve, as successive variables
are added to the models in both data sets. There is modest improvement in area under the curve after the
ﬁrst three variables are added, and no improvement when the sixth variable (muscle aches) is added.
However, if a basic score (model 3) is used, the grading of risk at lower scores is crude, as few patients can
be categorised as at low risk: only 19% of the ﬁrst data set and 22% of the second data set score 0, and,
respectively, 15% and 22% of these groups have streptococci (see Appendix 5 for full table).
A Centor score of ≤ 1 was identiﬁed among 23% of the ﬁrst cohort and 26% of the second cohort and
streptococcal percentages were isolated in 10% and 28% of these groups, respectively (Table 9). By
comparison, the extended ﬁve-point FeverPAIN (model 5 from Table 8) provides a ﬁner grading of risk and
signiﬁcantly more patients in both cohorts can be categorised as at low risk of streptococcal infection with
FeverPAIN (< 20% chance of streptococci, see Table 9): using the modiﬁed FeverPAIN score > 30% of
patients scored ≤ 1 (ﬁrst data set 38%; second data set 36%) and fewer of these patients (13% and 18%,
respectively) had streptococci. This is shown graphically in Figure 7.23
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ABLE 8 Sequential area under the ROC curve values as successive variables added (p-values given for comparison
ith previous model unless speciﬁed)
Data set
Model
1 2 3 4 5 6
Centor vs.
model 5
Very
inﬂamed
tonsils
+ Short
duration
+ Fever last
24 hours + Pus
+ No cough
or coryza
+Muscle
aches
Second
data set (p)
0.575 0.646
(0.006)
0.689
(0.003)
0.702
(0.104)
0.713
(0.803)
0.708
(0.334)
0.650
(0.123)
First data set (p) 0.602 0.676
(< 0.001)
0.706
(0.017)
0.713
(0.597)
0.735
(0.025)
0.738
(0.143)
0.716
(0.291)
ABLE 9 Number of individuals with Lanceﬁeld group A, C or G streptococci (%) at each level of clinical scores, and
he total number of individuals at each level (and per cent of the total sample)a
Clinical score
Score
Total0 1 2 3 4
First data set
FeverPAIN
Streptococci 7 (11) 21 (14) 45 (30) 40 (39) 62 (62) 175 (31)
Total 63 (11) 155 (27) 149 (26) 103 (18) 100 (17) 570 (100)
Centor score
Streptococci 3 (7) 10 (11) 45 (23) 65 (43) 55 (57) 178 (31)
Total 45 (8) 88 (15) 199 (34) 152 (26) 97 (17) 581 (100)
Second data set
FeverPAIN
Streptococci 9 (19) 22 (18) 46 (35) 41 (48) 49 (65) 167 (36)
Total 48 (10) 121 (26) 130 (28) 86 (19) 75 (16) 460 (100)
Centor score
Streptococci 0 (0) 36 (32) 36 (23) 69 (50) 47 (58) 188 (37)
Total 15 (3) 114 (23) 157 (31) 138 (27) 81 (16) 505 (100)
a For example, taking the second column, as regards FeverPAIN there were 63 individuals with score 0, which represents
11% of the sample, and, of those 63 individuals, seven (11%) had Lanceﬁeld group A, C or G streptococci.
Two clinical scores are shown: (1) a modiﬁed streptococcal score (model 5, ﬁve-point score, acronym FeverPAIN: one point
each for Fever during the last 24 hours, Purulent tonsils, Attend rapidly (≤ 3 days), very Inﬂamed throat and No cough or
coryza) and (2) for comparison the Centor score (one point each for pus, fever in the last 24 hours, cervical glands and the
absence of cough).
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26FDiscussion
This study provides evidence to conﬁrm that streptococcal sore throats are common in primary care, as
Lanceﬁeld groups C and G make up a quarter of streptococcal sore throats. The study also conﬁrms that
the best predictors of streptococcal infection may not include some of the features traditionally used, and
that traditional scoring systems may have limited clinical utility in identifying individuals who have a low
likelihood of streptococcal infection, that is individuals who do not need to have antibiotics.Strengths and limitations of the study
These data sets are some of the largest from a typical primary-care setting to have assessed the
importance of the range of streptococci, and to explore the range of potential clinical predictors of
streptococcal infection. There were few missing data (< 5% for any analysis), and little evidence of
recruitment bias, either in recruitment rates or in clinical characteristics. The conventional approach to
develop and validate a diagnostic model is to develop it in one data set and test it in another. However,
the variability of the performance of variables in these data sets – particularly striking for some variables
such as cervical glands – suggests that such an approach is unlikely to provide the most valid method of
variable selection for a clinical prediction rule, which is supported by similar ﬁndings in the development of
clinical prediction rules for other acute infections.44 The reason for this variation is unclear, but it may
reﬂect varying infective agents, populations or clinician factors (e.g. reliability of history taking or
examination). The variability suggests that the choice of variables to include in clinical prediction models
should be based either on very large single cohorts or on multiple cohorts at different times and/or
different settings. Over and above the most basic model (short prior duration, severe inﬂammation, fever)
the choice of additional variables to include (pus and ‘absence of cough and coryza’) was determined by
consensus, including a consideration of the strength of prior evidence. Although we have provided
bootstrapped estimates of the area under the ROC curve to limit overﬁtting, nevertheless the proposed
model should have further validation.12Main findings in the context of previous literature
GABHS have dominated previous literature because of their association with major non-suppurative
adverse outcomes – particularly rheumatic fever and glomerulonephritis.1 Therefore, the clinical predictors
of GABHS1,25,36 – especially pus, cervical nodes, a history of fever and no history of cough – have been
widely used in clinical guidelines.5,16,17 Trials using these as inclusion criteria may have larger effect sizes for
antibiotics than trials using less selected patients – although the validity of historical comparisons is
questionable.15 We were unable to conﬁrm the importance of cervical glands as a predictor of
streptococcal infection in the second data set, and in the ﬁrst data set we were unable to conﬁrm the
importance of purulence.25,34 From these two data sets the features that may be most important are
the speed of presentation (i.e. symptoms developing rapidly resulting in short prior duration of illness),
the severity of inﬂammation and fever. These variables have been identiﬁed in studies from typical
primary-care settings,12,25 but previous studies have been limited by a lack of multivariate analysis
or limited power.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Scoring systems are most helpful clinically for reducing antibiotic use if they identify as large a group as
possible of individuals unlikely to have streptococcus. From these data sets, the Centor criteria are likely to
identify relatively few such individuals who do not have streptococci: only 23% in the ﬁrst data set and
26% in the second data set had a score ≤1, and, of these, in the second data set the percentage of
patients with streptococci was high (28%). A low count (≤1) using a modiﬁed score (Fever SPIN) identiﬁed
> 35% of patients in both data sets as unlikely to have streptococci (between 13% and 18%).ConclusionItems traditionally used to help identify presentations of streptococcal sore throat in primary care may not
be valid. Conventional clinical scoring systems may not be very helpful clinically in identifying individuals
who are unlikely to have major pathogenic streptococci. A modiﬁed clinical rule developed for targeting
Lanceﬁeld groups A, C and G streptococci requires further validation, but should enable clinicians to both
target those at high risk of streptococcal infections and identify more than one-third of those presenting
with sore throat as being at low (< 20%) risk of streptococcal infection.27
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score and rapid antigen detection test for sore throats
P Little, M Moore, FDR Hobbs, D Mant, C McNulty, I Williamson, MYE Cheng, P Glasziou and M Mulleeon behalf of the PRISM investigators.
Abstract
Objective
The aim of the study was to compare clinical scores and RADTs with delayed antibiotic prescribing.Design
This was an open, adaptive, pragmatic, parallel-group randomised controlled trial.Setting
The setting was UK primary care.Patients
Patients included in the study were aged ≥ 3 years and had acute sore throat.Intervention
An internet program randomised patients to targeted antibiotic use according to (1) delayed antibiotics
(control group), (2) clinical score or (3) RADT used according to clinical score.Outcomes
The outcomes were as follows: self-reported antibiotic use, symptom duration and severity on seven-point
Likert scales (primary outcome was mean sore throat and difﬁculty swallowing score for the 2–4 days
following the consultation primary outcome).Results
A preliminary score to predict streptococcal infection (score 1; n = 1129) was replaced by a more valid
score [score 2; n = 631; features: Fever during previous 24 hours, Purulence, Attend rapidly (≤ 3 days), very
Inﬂamed tonsils, No cough/coryza (FeverPAIN)]. For score 1, there were no signiﬁcant differences between
groups. For FeverPAIN, symptom severity was documented in 80% of patients [delayed 168/207 (81%);
clinical score 168/211 (80%); RADT 166/213 (78%)]. Severity was lower in the clinical score group than in
the delayed prescribing group (–0.33; 95% CI –0.64 to –0.02; p = 0.039; equivalent to one in three rating
sore throat a slight rather than moderately bad problem), and a similar reduction was observed for the
RADT group (–0.30; –0.61 to –0.00; p = 0.053). Moderately bad or worse symptoms resolved signiﬁcantly
faster (30%) in the clinical score group (hazard ratio 1.30; 95% CI 1.03 to 1.63), but not in the RADT
group (1.11; 0.88 to 1.40). In the delayed group, 75/164 (46%) used antibiotics, and 29% fewer used
antibiotics in the clinical score group (risk ratio 0.71; 0.50 to 0.95; p = 0.018) and 27% fewer for the
RADT group (0.73; 0.52 to 0.98; p = 0.033). No signiﬁcant differences in complications or reconsultations
were found.Conclusion
Targeting antibiotics for acute sore throat using a clinical score improves symptoms and reduces antibiotic
use. RADTs used according to a clinical score provide similar beneﬁts, but no clear advantages over a
clinical score alone.29
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RCT OF A CLINICAL SCORE AND A RADT
30BackgroundSore throat is one of the unusual respiratory infections for which there are several reasonable diagnostic
strategies: RADTs are one of the most common near-patient tests in clinical use internationally, and clinical
scores to predict streptococcal infection are also widely used and advocated.17 Using clinical scores or rapid
tests has the potential to better target antibiotics, prevent progression of the illness and complications,
improve symptom control and reduce overall antibiotic use compared with empirical management
strategies such as delayed prescribing or no offer of antibiotics.45 However, there is a paucity of evidence
for clinical scores for most of these outcomes: recent evidence from a small Canadian trial suggests that
clinical scoring methods may not help modify antibiotic prescribing, and that RADTs can signiﬁcantly help
in limiting the use of antibiotics, but no important patient outcomes, such as symptom control or
progression of illness, were reported.19 Further evidence is needed to conﬁrm whether the use of RADTs
can modify antibiotic use and patient outcomes.
Our earlier studies, the ﬁrst in vitro and diagnostic phases of this project, provided the best evidence for
choosing a RADT that is valid and widely available and developed alternative clinical scores to predict
streptococcal infections. We report here the second phase of the project, which aimed to compare three
strategies for limiting and/or targeting antibiotic use for sore throat: delayed prescribing, the use of a
clinical streptococcal score (to predict streptococcal infection) and the targeted use of RADTs.MethodsThe trial used an adaptive design: the ﬁrst part used the clinical score developed from the earliest
diagnostic data from phase 1 (score 1), and the second part used a modiﬁed clinical score which included
a new diagnostic cohort from phase 1 (score 2: FeverPAIN). Score 1 was used at the start of the trial, and,
when FeverPAIN became available – following agreement with both the funders and the ethics committee
to an adaptive design – score 2 was used in the second part of the trial.Development of clinical scores
The clinical score development has been reported in Chapter 3. In brief, two diagnostic cohorts prior to
this trial cohort were used to develop clinical scores to predict streptococcal infection.Score 1
The ﬁrst diagnostic cohort documented that Lanceﬁeld group C and G streptococci presented with very
similar clinical features to GABHS. We developed a clinical score (score 1) that ranged from 0 to 6 and was
based on a simple count of the variables that independently predicted the presence of A, C and G
streptococci: rapid attendance (short prior duration of ≤ 3 days), moderately bad or worse muscle aches,
moderately bad or worse sore throat, the absence of a bad cough and severely inﬂamed tonsils and
anterior cervical glands.Score 2
The second diagnostic cohort did not conﬁrm that all the above variables were signiﬁcantly associated with
streptococcal infection and also identiﬁed new variables, which suggests that a single cohort may not be a
valid enough basis to identify variables in order to generate a clinical score.
A modiﬁed score (score 2) was generated based on a simple count of ﬁve variables that were signiﬁcant in
univariate analysis in both cohorts and also signiﬁcant in multivariate analysis in one of the cohorts: Fever
during the last 24 hours, Purulent tonsils, Attend rapidly (prior duration ≤ 3 days), very Inﬂamed tonsils and
No cough or coryza (i.e. a purely pharyngeal illness) – giving the acronym FeverPAIN.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Patients presenting with acute sore throat were recruited by health professionals in general practices in
south and central England (mainly GPs but also triage practice nurses).Inclusion
Adults, and children aged ≥ 3 years, presenting with acute sore throat were recruited (with ≤ 2 weeks of
sore throat, and with some abnormality on examination of the throat – i.e. erythema and/or pus – as in
our previous studies in primary care).23Exclusion
Exclusion criteria were as follows: other non-infective causes of sore throat (e.g. aphthous ulceration,
candida, drugs), unable to consent (e.g. dementia, uncontrolled psychosis).Baseline clinical measures
The recruiting health professional completed clinical details at baseline on temperature (using Tempa•DOT
thermometers), the presence and severity of baseline symptoms (sore throat, difﬁculty swallowing, fever
during the illness, runny nose, cough, feeling unwell, diarrhoea, vomiting, headache, muscles ache,
abdominal pain, sleep disturbance, interference with normal activities) on four-point Likert scales (none,
a slight problem, a moderately bad problem, a bad problem) and the presence of the following signs: pus,
nodes, tender nodes and temperature.24–26,37 Clinicians were asked to complete non-recruitment logs, but,
owing to time pressures in acute clinics, this was often not done. Clinicians documented the most common
reasons why patients were not approached and why they declined in an end-of-study questionnaire.Randomisation
Following the baseline assessment, patients were individually randomised using a web-based computer
randomisation service – with permuted block sizes of 3, 6, 9 and 12 also randomly chosen – to one of
three groups (see below). Originally, the protocol included stratiﬁcation by clinician belief in the likelihood
of bacterial infection, but following discussion with the funder this was judged to be unnecessary.Intervention groups
The aim of the trial was to compare methods of targeting antibiotics, by comparing a RADT or a clinical
score with the empirical strategy of patient choice in the use of a delayed prescription.
(a) Delayed antibiotics (control) A prescription was prepared and left in reception with advice to the
patient to collect the prescription after 3–5 days if symptoms were not starting to settle, or sooner if
symptoms became signiﬁcantly worse.33 The rationale for using delayed prescribing is that it is safe, it
should, according to previous data, result in rates of antibiotic use similar to those when there is no
initial offer of antibiotics, it changes belief in antibiotics as effectively as not prescribing and it modiﬁes
reconsultation more effectively than not prescribing (based on our previous studies both of sore
throat46 and lower respiratory tract infections47). It has been incorporated widely into routine practice in
the UK since our 1997 trial33 without any increase in complications of sore throat.48
(b) Clinical score Antibiotics were not offered to those with very low scores (0 or 1). For high scores
(≥ 4, 63% streptococci), immediate antibiotics were offered, and for intermediate scores (2 or 3, 39%
streptococci) delayed antibiotics were offered.
(c) RADT group Health economic modelling of the phase 1 results was used to estimate the most efﬁcient
use of RADTs. The modelling indicated that RADTs would be best targeted at those with intermediate
and high clinical scores, for whom prescription of antibiotics was most likely. Thus, using score 2
(FeverPAIN), those with low clinical scores (0 or 1) were not offered antibiotics or a rapid test (< 20%
streptococci from the ﬁrst phase); those with a clinical score of 2 (33% streptococci) were offered
a delayed prescription and those with higher scores (≥ 3, 55% streptococci) had a rapid test on
surgery premises, and following the test patients with negative results were not offered antibiotics.
All patients – as in the other groups – were advised to use analgesia (regular paracetamol and/or
ibuprofen). The original intention was that the choice of RADT (the IMI test pack) would be based on31
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32both a clinical study and an in vitro study. However, there was sufﬁcient evidence of validation
characteristics from in vitro studies, which provided better evidence of validity by avoiding sampling
biases. Ease of use was another important consideration and was assessed during the in vitro study and
also conﬁrmed by a small panel of GPs and nurses (see Appendix 7 at the end of the report). Taking
the swab and performing the test takes approximately 5–7 minutes to get an answer.
As this was a pragmatic trial, clinicians were asked to use the intended strategy when this could be
agreed with the patient, but clinicians were given ﬂexibility to negotiate other strategies, as would
happen in practice. Thus, for example, not all those randomised to delayed prescribing were given a
delayed prescription.Data collection
Patients were blind to the precise details of the groups being tested, but the pragmatic interventions, and
the key outcomes (reported symptom severity and duration), made full blinding impossible. Data collection
by the research team (telephone or notes review) was blind to group as far as possible, but details of
patient management were available in the notes. No changes in planned outcome measures were made
following trial commencement.Daily diary
Symptoms
Patients completed a symptom diary each night until symptoms resolved or for up to 14 nights.23,33 Each
symptom was scored 0 = no problem to 6 = as bad as it could be: sore throat, difﬁculty swallowing, feeling
unwell, fevers, sleep disturbance. A telephone call from the research assistant in the ﬁrst few days aimed
to resolve any problems the patient may have had ﬁlling out the diary. Temperature was taken by patients
and documented on a daily basis in the diary using Tempa•DOT thermometers, as in previous studies.23,49
If a diary was not received after 3 weeks, a brief questionnaire was sent to elicit key outcomes, and then a
telephone call was made if the brief questionnaire was not received. The diary comprised information on
the following:
l Symptom severity A two-item score (sore throat, difﬁculty swallowing) was chosen as the main
symptomatic outcome for symptom severity, as it is more reliable than either item alone and is
internally reliable (Cronbach’s α = 0.92).
l Duration of illness The diary permitted documentation of the duration of illness, particularly the
duration of more signiﬁcant illness (illness rated moderately bad or worse),47 which is more likely to be
signiﬁcant for both patients and health professionals in deciding management strategies.
l Antibiotic use Patients reported whether antibiotics were used, as we previously showed that
self-report from diary data agreed well with whether delayed prescriptions were collected.3
l Side effects Diarrhoea and skin rash were documented in the diary, and also from the notes review
(see below).
l Medicalising beliefs Patients’ belief in the importance of seeing the doctor for future episodes was
documented using Likert scales completed by patients,33 which we have shown to be reliable.33Notes review
During the available follow-up time (which varied from 1 month to 2 years), all of the patients’ notes were
reviewed to document returns, time to return, reasons for returns, complications, side effects, economic
data (see below) and any subsequent referrals.23Sample size calculations
We used the NQUERY multiple group sample size programme for the three groups for all calculations.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The time when a RADT is most likely to help patients is when the inﬂammation due to bacterial infection is
likely to be at its greatest in the ﬁrst few days after seeing the doctor. We assumed the minimum effect
size for the symptom severity score was a 0.33 standardised effect size [i.e. 0.33 standard deviation (SD)]
on days 2–4, when patients rate their sore throat at its worst. We estimated that to detect a
0.33 standardised effect size difference between the RADT group and the other groups (assuming both
control groups are 0.33 SD higher than the RADT group) required a minimum of 134 per group (for
α = 0.05, β = 0.2) or 495 in total, allowing for a 20% loss to follow-up (which was the target for the
second phase of the trial). For α = 0.01 and β = 0.1, 242 per group, or 909 patients in total, were needed,
allowing for 20% loss to follow-up of diary information.33,47 A standardised effect size of 0.33 is classiﬁed
as a small effect size; 0.33 SD we estimated was equivalent to approximately half of the patients rating
sore throat a mild rather than moderately bad problem,47 or a difference between groups of the duration
of symptoms rated moderately bad or worse of 1–2 days.‘Medicalising’ effect of using RADT (α = 0.05, β = 0.2)
A possible proxy for ‘medicalising’ behaviour is the change in beliefs about the need to see doctors in
future episodes. Assuming a 15% differences between groups (57% in delayed and clinical score groups
and 72% in RADT group),33 152 patients per group were needed. To assess the medicalising effect on
reattendance, we assumed RADTs might change subsequent attendance by 11% (RADT 38%, clinical
score 27%, delayed prescribing 27%) – as observed with the medicalising effect of antibiotic prescribing
strategies in a previous trial over a similar follow-up period33 – which would require 254 patients per group
or 849 in total, allowing for 10% loss to follow-up of notes.49Analysis
The analysis plan was ﬁnalised by the trial management group prior to performing the analysis. Analysis of
covariance was performed for the main continuous outcomes (diary scores) and Cox regression for the
duration of symptoms rated moderately bad or worse. Logistic regression was used for dichotomised
outcomes [e.g. belief in the need to see the doctor for future episodes and return to the surgery
(controlling for follow-up time)]. Odds ratios were converted to risk ratios using the method of Zhang and
Yu.50 The models controlled for baseline severity (a strong predictor of all outcomes), and for potential
confounders if appropriate (in this case, fever during the last 24 hours). The primary analysis was an
intention-to-treat analysis based on complete data sets – given the problem of imputing modest
differences for rapidly changing symptomatic outcomes when no outcome data are available. Although a
per protocol analysis was initially considered, given the pragmatic nature of the study and the leeway
given to GPs to negotiate management, it was difﬁcult to operationalise what per protocol might mean,
so a per protocol analysis was not performed. The clinical and demographic characteristics of those not
followed up were compared to assess, respectively, possible selection and non-response bias.
Non-differential selection bias to the trial was assessed by a comparison of the clinical features in the
current trial with those in the previous diagnostic study, and also with a parallel observational cohort
among a wide range of practices which used the same clinical proforma [the MRC (Medical Research
Council) DESCARTE (decision rule for severe symptoms and complications of acute red throat in everyday
practice) study, Little et al., University of Southampton, which recruited nearly 12,000 patients]. No interim
analysis was performed, and no subgroups speciﬁed in advance. To assess the differences between the
two phases of the trial, interaction terms were used in the models, and, as signiﬁcant interactions were
found, the data from both phases were presented separately. The study team agreed in advance that, if
there were signiﬁcant differences between score 1 and score 2, score 2 results would be presented
separately as the main results (i.e. using score 2, FeverPAIN), with the detailed results from the ﬁrst part of
the trial being documented in Appendix 6.33
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34ResultsPatients presenting in primary care were recruited from 23 October 2008 until 18 April 2011 from
48 practices overall, 46 of which recruited for the ﬁrst part of the trial and 21 for the second part of the
trial (see Figure 8 for score 2; Appendix 6, Figure 19, for score 1). These practices recruited 1760 patients
(1129 in the ﬁrst part of the trial and 631 in the second part of the trial).
Evidence of differential effectiveness of the first and second parts of the trial
Improvement in symptom scores in the ﬁrst 3 days following the index consultation was signiﬁcantly
greater with the second clinical score than with the ﬁrst score (interaction term –0.38, 95% CI –0.76
to –0.01; p = 0.043), and less with the rapid test group (interaction term –0.18, –0.55 to 0.19; p = 0.345).
There was also a signiﬁcantly larger effect on symptom resolution when using the second score
(interaction term hazard ratio 1.35, 95% CI 1.01 to 1.79; p = 0.043), but little difference when the rapid
test was used (interaction term hazard ratio 1.01, 0.76 to 1.35; p = 0.93). Similarly, there was a
signiﬁcantly greater effect on antibiotic use when using the second score (interaction term odds ratio 0.43,
95% CI 0.24 to 0.76; p = 0.004) and a lesser effect for the rapid test group (0.74, 0.42 to 1.32; p = 0.31).
Thus, the results of the trial when using the second score (FeverPAIN) are presented in the text as the main
ﬁndings, and the results of the ﬁrst score shown in Appendix 6 – which show no signiﬁcant differences for
any outcome despite good compliance with the intended strategies in each group (see below).Patients assesseda
(n = 870)
Eligible patients
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(n = 631)
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(n = 207)
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Follow-up notes
review
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FIGURE 8 The CONSORT (CONsolidated Standards Of Reporting Trials) flow diagram for the second phase of the trial
(using FeverPAIN). a, Estimates or those not assessed or declined based on physician report.
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Group characteristics
Most baseline characteristics of the groups were similar (Table 10), except that fever reported in the last 24
hours was more common in the clinical score group, and, as fever did modestly change the estimates, all
results are controlled for fever in addition to baseline severity of sore throat and difﬁculty swallowing.
Female patients were slightly less common in the clinical score group, but including gender in the model
made no difference to the estimates, so results are presented without controlling for gender.
Compliance with prescribing strategy
Table 10 also shows the prescribing strategy used at the baseline consultation, and demonstrates that
groups were well differentiated. Compliance with the intended strategy in the clinical score and rapid test
groups depended on the clinical score for each patient, and reasonable compliance with the intended
strategy was demonstrated: overall, the intended strategy was undertaken in 83% of consultations (520/
629) – 79% (162/205) in the delayed group, 85% (179/211) in the clinical score group and 179/213
(84%) in the rapid test group. When delayed prescribing was advised, the advice of the doctors in each
group was similar: 129/162 (80%) in the delayed prescribing group, 73/89 (82%) in the clinical score
group and 37/48 (77%) of patients in the rapid test group were advised to wait 5 days. More than 90%
of patients in each group were advised to wait at least 3 days. Compliance with the intended strategies
was also good for score 1 (see Appendix 6, Table 21).Main findings
Symptom severity (the mean score of soreness and difficulty swallowing in
days 2–4)
The mean rating of sore throat and difﬁculty swallowing in days 2–4 was slightly > 3 in the delayed
prescribing (control) group (3 being a moderately bad problem) (Table 11). Both the clinical score and the
rapid test groups had better symptom control [about one-third of a point; this is equivalent to one personTABLE 10 Baseline clinical assessment and prescribing strategy used by the GP at the baseline consultation
Data taken from CRF
Group 1: delayed
prescription (control)
Group 2: Clinical
score only
Group 3: RADT
plus clinical score
Clinical assessment
Mean severity of sore throat/difﬁculty swallowing
on a four-point Likert scale
3.2 (SD 0.72) 3.2 (SD 0.72) 3.2 (SD 0.71)
Prior duration (days) 4.9 (SD 3.9) 4.5 (SD 3.8) 5.0 (SD 4.6)
Age (years) 29 (SD 16) 31 (SD 17) 29 (SD 17)
Female gender (n) 139/207 (67%) 127/210 (60%) 138/212 (65%)
Smoker (n) 31/207 (15%) 39/210 (19%) 44/212 (21%)
Fever in last 24 hours (n) 111/207 (54%) 135/211 (64%) 112/212 (53%)
Temperature (°C) 37.0 (SD 0.72) 36.9 (SD 0.70) 36.9 (SD 0.69)
Pus on tonsils (n) 54/206 (26%) 56/210 (27%) 53/212 (25%)
Strategy used by clinician
No offer of antibiotics (n) 21/207 (10%) 87/211 (41%) 126/213 (59%)
Immediate antibiotics (n) 21/207 (10%) 33/211 (16%) 38/213 (18%)
Delayed antibiotics (n) 164/207 (79%) 91/211 (43%) 48/213 (23%)
35
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TABLE 11 Symptom severity, antibiotic use, intention to consult in the future (moderately likely or more likely) and
reconsultations with sore throat
Outcome
Delayed antibiotics
(control) Clinical score RADT
Mean severity of sore throat and difﬁculty swallowing on days 2–4 (seven-point scale: 0 = no problem;
6 = as bad as it could be)
Crude mean 3.11 (SD 1.49) 2.88 (SD 1.52) 2.83 (SD 1.62)
Adjusted mean differencea –0.33 (95% CI –0.64 to
–0.02; p = 0.039)
–0.30 (95% CI –0.61 to
0.004; p = 0.053)
Duration of symptoms rated moderately bad or worse
Median duration
(interquartile range; days)
5 (3 to 7) 4 (2 to 6) 4 (2 to 7)
Hazard ratioa 1.00 1.30 (95% CI 1.03 to
1.63; p = 0.028)
1.11 (95% CI 0.88 to
1.40; p = 0.372)
Antibiotic use
Crude percentage [n (%)] 75/164 (46) 60/161 (37) 58/164 (35)
Risk ratioa 1.00 0.71 (95% CI 0.50 to
0.95; p = 0.018)
0.73 (95% CI 0.52 to
0.98; p = 0.033)
Belief in the need to see the doctor in future episodes (slightly likely or less)
Crude percentage [n (%)] 62/163 (38) 54/155 (35) 64/161 (40)
Risk ratioa 0.97 (95% CI 0.71 to
1.27; p = 0.847)
1.03 (95% CI 0.76 to
1.32; p = 0.855)
Return within 1 month with sore throat
Crude percentage [n (%)] 17/207 (8) 17/210 (8) 13/212 (6)
Risk ratioa 1.00 0.91 (95% CI 0.47 to
1.72; p = 0.777)
0.74 (95% CI 0.36 to
1.47; p = 0.397)
Return after 1 month with sore throat (mean follow-up 0.73 years)
Crude percentage [n (%)] 31/207 (15) 26/210 (12) 34/211 (16)
Risk ratioa 1.00 0.79 (95% CI 0.47 to
1.29; p = 0.353)
1.06 (0.66 to
1.63; p = 0.813)
a All models controlled for baseline symptom severity (of sore throat and difﬁculty swallowing) and fever during the
previous 24 hours.
Model for return within 1 month also controlled for prior antibiotic use; model for returns after 1 month additionally
controlled for prior attendance with sore throat, and follow-up duration.
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36in three rating sore throat and difﬁculty swallowing a slight rather than a moderately bad problem
(see Table 11), although the rapid test group just failed to reach signiﬁcance].
Duration of moderately bad symptoms
In the delayed prescribing (control) group, symptoms rated moderately bad or worse lasted a median of
5.0 days. Resolution was signiﬁcantly faster (30%) in the clinical score group [risk ratio 1.30 (95% CI 1.03
to 1.63)] – equivalent to saving a day of moderately bad symptoms. Resolution was 11% faster in the
rapid test group but not signiﬁcantly (see Table 11).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Of the delayed prescribing group, 46% reported using antibiotics. The other two groups had even lower
antibiotic usage: 37% in the clinical score group and 35% in the RADT group – an estimated 29% relative
reduction (risk ratio 0.71) and 27% relative reduction (risk ratio 0.73), respectively (see Table 11).Belief in the need to see the doctor in future
There was a trivial difference in belief in the need to see the doctor when either treated as a continuous
variable or dichotomised (see Table 11).Return to the surgery
There were no signiﬁcant differences in return to the surgery during the following month or the
subsequent follow-up.Complications
There were no suppurative complications (otitis media, sinusitis, quinsy or cellulitis) in any group in either
phase of the trial. Fewer than 1% of patients returned with either skin rash or diarrhoea within a month
of the index consultation in any group for FeverPAIN (delayed prescribing 0/207, clinical score 2/210, rapid
test 1/211), and there were similar ﬁndings for score 1 (delayed prescribing 5/374; clinical score 0/380;
rapid test 1/359).Selection and attrition bias
There was no evidence of clinical selection bias when comparing the patients in the two parts of the trial:
score 2 and score 1 patients were similar for mean severity of sore throat and difﬁculty swallowing at
baseline (3.20 vs. 3.12, respectively), as well as mean prior duration of illness (4.77 vs. 4.41 days),
purulence [163/628 (26%) vs. 294/1124 (26%)], fever [358/630 (57%) vs. 645/1126 (57%)], mean age
(29 vs. 29 years) and female gender [404/629 (64%) vs. 732/1128 (65%)]. Follow-up for diary information
was also similar [502/631 (80%) vs. 901/1129 (80%)].
Based on clinician report, most patients who were assessed and approached agreed, which suggests the
major issue for selection bias is likely to be which patients clinicians assessed and approached. The most
common reasons given for not approaching patients were too little time to consent and recruit (87% of
health professionals rated this the most common reason), followed by patients being too unwell (10%).
Similarly, the most common reasons given for patients declining were having too little time to complete
study materials (75%) or too little time to consent and be recruited (16%). The characteristics of patients
recruited by GPs at high-recruiting surgeries [> 80 patients per year, contributing 49% (309/631) of score
2 patients] were similar to those of patients from lower-recruiting surgeries (mean sore/difﬁculty
swallowing scores at baseline 3.2 vs. 3.2), although the mean number of streptococcal score features was
slightly higher for those from high-recruiting surgeries (1.9 vs. 1.6, respectively). There was some evidence
of modest clinical selection bias found in the trial population when it was compared with the previously
described diagnostic studies. Although the diagnostic study used to generate FeverPAIN was similar for
fever (59%), mean temperature (36.9 °C) and mean sore/difﬁculty swallowing score (diagnostic 3.1, trial
3.2), the baseline mean number of streptococcal score features was slightly lower in the trial population
(diagnostic 2.1 vs. trial 1.7, SD 1.3). Furthermore, the purely observational cohort (MRC DESCARTE) had
very similar patient characteristics to the diagnostic study (mean sore/difﬁculty swallowing score 3.0; mean
number of streptococcal features 2.0). Given the similarity of patient-rated severity in all these studies, the
slightly lower number of streptococcal features in the trial population may represent some recruitment bias
in some practices based on recruiting fewer patients with more ﬂorid clinical signs. However, if practices
that recruited patients with lower mean streptococcal scores (< 1.33) are excluded (leaving 448 patients),
the baseline streptococcal scores for the trial are similar (2.1 diagnostic vs. 2.0 trial), and sore throat and
difﬁculty swallowing symptoms are signiﬁcantly better for the clinical score group (interaction term –0.60,
95% CI –1.01 to –0.20; p = 0.004), and also better for the rapid test group, but not signiﬁcantly
(interaction term –0.26, –0.67 to 0.16; p = 0.223). If this group of practices is then selected (i.e. excluding
practices with low streptococcal features), the mean severity of sore throat and difﬁculty swallowing is37
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38improved by half a point in the clinical score group (–0.51, –0.87 to –0.15; p = 0.005), which is equivalent
to one patient in two rating sore throat a slight rather than a moderately bad problem, with a similar
effect in the rapid test group (–0.38, –0.75 to –0.01; p = 0.042) (see Table 11 for comparison). Thus, the
estimates for the trial are probably conservative.DiscussionTo our knowledge, this is only trial to date to compare the impact of using a RADT and clinical scoring
methods on both symptom control and antibiotic use for acute sore throat, which is the most common
upper respiratory tract infection managed in clinical practice. It demonstrates that there are likely to
be improvements in both symptom control and antibiotic use compared with empirical delayed prescribing
when using either a clinical scoring method or a RADT. These results also suggest that combining the
RADT with the clinical score confers no additional beneﬁt over using the clinical score alone.Strengths and potential limitations
Type II error (power)
We were constrained to score 2 (FeverPAIN) results for our main ﬁndings, which reduced the power to
assess dichotomous outcomes, although the trial was adequately powered for symptomatic outcomes.Type I error (chance)
Symptomatic outcomes and antibiotic use changed signiﬁcantly in the same direction in both the clinical
score and rapid test groups, which suggests that these results are unlikely to be due to chance.Confounding
Although the overall trial population (both scores) was well balanced, the groups for score 1 and score 2
were slightly unbalanced (in opposite directions) for fever reported in the last 24 hours. However, the
estimates controlled for this in analyses, and in other respects trial groups were similar.Selection bias
An important limitation of all trials is that health professionals may use their judgement in selecting trial
patients. Time pressures were the main reason given for not recruiting patients, but there was some
evidence of modest clinical selection: the baseline severity scores and the number of streptococcal features
were slightly lower in the trial than in the prior observational studies. However, differences were modest
(mean streptococcal score at baseline 15% lower), and excluding practices with low scores did not alter
the inferences and, if anything, increased the estimates – suggesting that the trial results are likely to
be conservative.Compliance
This was a pragmatic trial, so, although clinicians were encouraged to use the intended strategy, there was
variation as happens in negotiation with patients in everyday practice; nevertheless, compliance with the
intended intervention was good. In particular, the results for score 2 cannot be explained by greater
compliance of clinicians over time, as score 1 compliance was as good, if not slightly better than
for score 2.Main results in context of previous literature
Using either RADTs or a clinical score (FeverPAIN) is likely to improve symptom control moderately
compared with an empirical management strategy of delayed prescribing. As the score requires two
examination components, it will be more difﬁcult to use in telephone triage or out-of-hours contexts; it is
likely to be difﬁcult for patients to assess the severity of inﬂammation, although it might be feasible for
patients to report the presence of pus. The effect on symptoms of the score in the ﬁrst few days after
seeing the doctor is to make a difference of one person in three rating sore throat and difﬁcultyNIHR Journals Library www.journalslibrary.nihr.ac.uk
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both of the intervention groups. These results also suggest there is likely to be little additional beneﬁt
either for symptom management or antibiotic use when using a strategy for rapid antigen testing targeted
by clinical score when compared with using a clinical scoring method alone. This might be because the
diagnostic advantage in RADTs that identify GABHS is in part matched by the disadvantage of not
identifying group C and G streptococci, which provide similar symptom burden to GABHS. The additional
disadvantages of RADTs are the costs of the test (although most RADTs cost less than £5, and the one
chosen for the current study was approximately £3) and the staff time taken to get a result (5 minutes).
A previous small trial of RADTs19 demonstrated that using the Centor score with or without rapid tests on
its own did not modify antibiotic use, but this trial unfortunately did not report symptomatic outcomes.
The difference between these trials may be that the current trial used a slightly more valid score: we have
shown that individual items from the Centor score and score 1 did not perform optimally in our two prior
diagnostic cohorts in terms of identifying patients with a low likelihood of streptococcal infection.
Based on the results of the previous diagnostic study, the limited performance of score 1 in ruling out
streptococcal infection might help explain the differences in antibiotic use, but it is less clear why symptom
management should be signiﬁcantly better with FeverPAIN than with score 1. It may be that the particular
combinations of more ﬂorid symptoms in FeverPAIN (e.g. fever, pus) are more important in determining
symptom burden, and/or better in determining symptom response to antibiotics due to either
microbiological or patient factors (e.g. the differential nature of organisms on the surface and in the crypts
of the tonsils, or the relation between symptoms, the immune response and prognosis).1,51 Furthermore, as
our qualitative data suggest, doctors prefer clinical intuition to rigid use of clinical scores, it is also possible
that FeverPAIN has greater clinical face validity for clinicians or patients. This could perhaps facilitate
stronger advocacy and potentially better adherence to the proposed prescribing strategy – although our
relatively crude data concerning what health professionals did (but not how they did it) suggest health
professionals complied reasonably well with the proposed prescribing strategies.
The rate of antibiotic use reported in the current trial with delayed prescribing (> 40%) is signiﬁcantly
higher than previous research,33 but the number of features associated with streptococcal infection is also
higher (e.g. 15% had purulent tonsils in the previous trial compared with 26% in this trial), so it may be
that more patients with milder sore throats are now self-caring rather than consulting their GP compared
with 15 years ago. This trial also recruited in slightly different settings: the ﬁrst trial recruited
predominantly in deprived inner-city settings, whereas the current trial had a wider range of practices.
We were unable to demonstrate any difference in belief in the need to see the doctor, or reconsultations
either within a month or with longer follow-up (i.e. no apparent ‘medicalising’ effect of the RADT
strategy). This contrasts with a dramatic medicalising effect of prescribing antibiotics.23,33 However, the lack
of an effect with a RADT in a trial setting in which RADTs are not used routinely may mean that it is
difﬁcult to demonstrate medicalisation in the short term. Longer-term implementation studies or possibly
international comparison studies may be needed.ConclusionCompared with empirical delayed antibiotic prescribing for acute sore throat, a clinical score improves both
symptoms and antibiotic use. Using the clinical score combined with targeted use of a RADT provides
similar beneﬁts, but no clear advantages compared with using a clinical score alone.39
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practitioner, nurse practitioner and patient views
about the use of rapid streptococcus antigen
detection tests in primary care: ‘swamped with
sore throats?’
G Leydon, L McDermott, M Moore, I Williamson, FDR Hobbs and P Little on behalf of thePRISM investigators.
Abstract
Background
The use of clinical scoring methods and RADTs could help target antibiotics at those who are most likely to
beneﬁt from them and help reduce antibiotic use, but there has been little exploration of what the key
issues might be for patients and health-care practitioners (HCPs).Objective
The aim of this study is to explore patient and HCPs’ views of clinical scores and RADTs.Method
This was a qualitative study carried out in the primary-care setting. Semi-structured face-to-face and
telephone interviews were conducted with GPs and nurse practitioners (NPs) from general practices across
Hampshire, Oxfordshire and the West Midlands.Results
In total, 51 participants took part in the study. Of these, 42 were HCPs (29 GPs and 13 NPs) and nine were
patients. HCPs could see a positive role for RADTs in terms of reassurance, as an educational tool for
patients and for aiding inexperienced practitioners, but also had major concerns about RADT use in clinical
practice. Particular concerns included the validity of the tests (the role of other bacteria, and carrier states),
the tension and possible disconnect with clinical assessment/intuition, the issues of time and resource use,
and the potential for medicalisation of self-limiting illness. In contrast, however, experience of using RADTs
over time seemed to make some participants more positive about using the tests. Moreover, patients were
much more positive about the place of RADTs in providing reassurance and in limiting their antibiotic use.Conclusions
It is unlikely that RADTs will have a (comfortable) place in clinical practice in the near future until health
professionals’ concerns are met, and they have direct experience of using them. The routine use of clinical
scoring systems for acute upper respiratory tract illness also faces important barriers related to clinicians’
perceptions of their utility in the face of clinician experience and intuition.BackgroundAt present, RADTs are widely used internationally. However, there are concerns about the use of RADTs
based on anecdotal evidence that suggests that the procedure may be time-consuming and increase
patient expectation for the test, and thus result in increased levels of patients consulting with a sore
throat.52 Limited qualitative work has been carried out regarding patients and practitioners’ use of41
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42point-of-care tests for respiratory infections. Qualitative work with both patients and HCPs across Europe
suggests both patients and HCPs may be willing to use CRP (C reactive protein) as a point-of-care test in
lower respiratory tract infection, but major issues for HCPs are questionable test performance, problems
interpreting results, a detraction from clinical reasoning, costs, time and patients not wanting, or
demanding, the tests.53 We are unaware of any qualitative research that has documented and explored
HCPs’ or patients’ perceptions of RADTs.
This study provided a nested qualitative component to the PRISM trial, which aimed to provide insight into
the use of RADTs and clinical scoring methods.ObjectiveThe study aimed to explore HCPs’ (NP and GP) and patients’ experiences of and attitudes towards RADTs.Methods
Participants and procedure
Participants were identiﬁed and recruited (by JB, JK, KM) from practices across the south and south-east of
England, aiming for a mix of inner-city and rural locations (Table 12). HCPs were eligible for inclusion if
their practice had consented to take part in the PRISM trial. NPs were eligible for inclusion if they had
responsibilities that would involve using a RADT in practice. Patients were eligible for inclusion if they had
experienced a RADT during a consultation.
The interviews
Trained interviewers (TL, RC, HH) conducted both face-to-face and telephone interviews (according to
participants’ preference) with each lasting approximately half an hour. All interviews were audio recorded
and transcribed verbatim in preparation for analysis.
Qualitative interviews provided the best method for gathering insights into participants’ individual
experiences of using RADTs, and their views about the RADTs. The interview guide was amended before
the ﬁnal 11 interviews were conducted in order to include a question that asked about experiences ofTABLE 12 Practice demographics
Registered practice population size
Mean 4049
Range 3272–16,596
IMD score
Mean 11.55
Range 2.70–36.92
England IMD score
Average 21.7
Lowest 2.6
Highest 68.9
IMD, Index of Multiple Deprivation.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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while also providing ﬂexibility to explore unanticipated issues.Analysis
Inductive thematic analysis54 was conducted on all transcripts to determine HCPs and patients’ experiences
and views of RADTs in practice. The ﬁrst phase involved ‘immersion’ in the data, that is transcripts were
read and reread a number of times in order for the researchers to become as familiar as possible with the
data. The transcripts were then read again and meaningful sections of each transcript were systematically
assigned a code to reﬂect issues which were represented within them. Each code label referred directly to
the operationalisation of the theme discussed. This process was repeated after initial coding was complete
and themes that consistently occurred within the data were identiﬁed and labelled. The codes and
deﬁnitions were reﬁned during a continuing process, which involved themes being linked, grouped,
moved, relabelled, added and removed to produce a set of themes and subthemes that adequately ﬁtted
and thoroughly explained the data. Two qualitative researchers (LM and GL) iteratively developed the
themes through discussion and adjustment when appropriate, before reaching ‘inter-rater’ agreement on
the ﬁnal themes and descriptions.Findings
Participants
In total, 51 participants took part in the study. Of these, 42 were HCPs (29 GPs and 13 NPs) and nine were
patients. GPs/NPs were recruited from 15 practices across Hampshire, Oxfordshire and the West Midlands.
Registered practice population size varied from 3272 to 16,596. Surgeries were recruited from both
inner-city and rural locations, with the Index of Multiple Deprivation score ranging from 2.7 to 36.9.Themes
The analysis identiﬁed ﬁve main themes, and a total of 18 subthemes (Table 13).
In the following sections we describe each theme in turn, using exemplary quotations for
illustrative purposes.Practicalities
When invited to discuss their practical experiences of the rapid tests, HCPs’ views highlighted ﬁve key
subthemes, all relating to the practicalities of RADTs.Reduces antibiotic prescribing
In terms of positive practical feedback, a few practitioners in the trial reported a reduction in their
antibiotic prescribing rates for sore throat as a result of using the RADTs:© Que
This is
suitab
Journa
SO16It [use of antibiotic] has substantially decreased since I started the trial.
Int. 43, GPEasy to use
Despite concerns about the tests increasing consultation lengths (reported in a later section), HCPs
reported that the tests were easy to use once they were familiar with them:It was not that it was a particularly difficult test, it was just the first time you use something you need
to know what to do.
Int. 29, GP43
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TABLE 13 Themes identiﬁed in analysis
Theme Subtheme
(1) Practicalities Beneﬁts:
l Reduces antibiotic prescribing
l Easy to use
l Useful for inexperienced staff
Concerns:
l Time concerns
l Cost concerns
(2) Accuracy of diagnosis Beneﬁts:
l Conﬁrmation of diagnosis
Concerns:
l Conﬂict of opinion
l Identiﬁcation of carriers
l Alternative bacteria not detected
(3) Patient outcomes Beneﬁts:
l Reassurance for patient
l Education tool for patient
Concerns:
l Medicalisation concerns
(4) Experience of using clinical scores Beneﬁts:
l Useful for inexperienced practitioners
Concerns:
l Unnecessary for experienced practitioners
l Time-consuming
(5) RADT trial participation Trial participation increases positive views
Negative perceived views of non-trial practitioners
Positive views of trial practitioners
(6) Patient views Reassured by test
No change in GP attendance
Preference for no antibiotics
A QUALITATIVE STUDY ABOUT THE USE OF RADTS
44Useful for inexperienced practitioners
In terms of the practicalities or perhaps skill of appropriate prescribing, some of the more experienced
interviewees suggested that the tests could support prescribing decisions for new or inexperienced
staff members:NIHRIf you’re in a teaching or training practice, then it’s useful, to get the clinicians to learn.
Int. 48, GPJournals Library www.journalslibrary.nihr.ac.uk
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Perhaps unsurprisingly, given the time pressures and short consultation times in general practice and the
challenges of incorporating new practices within them, time concerns were commonly reported. In short,
interviewees reported concerns that the RADTs took up too much time during a consultation. However,
HCPs did acknowledge that, as the RADT use in this instance formed part of a trial, some of the additional
time involved in explaining the study had added considerably to the burden of the test and, outside of a
trial context, use of the test may not be as time-consuming:© Que
This is
suitab
Journa
SO16It’s the additional time that’s needed to do it, is the major problem.
Int. 47, GPUsually the longest bit is the patient reading through all the information about the test.
Int. 30, GPPractitioners who took part in the trial also reported that their concerns relating to time constraints were
reduced once they had started using the test and were clearer on what to do:. . . my first thought when the girls [trial researchers] came to talk to us about it was, oh gosh, how
long is it going to take? And then once you realize that, if you were doing it regularly, you could do it
much quicker and that’s not a problem.
Int. 25, GPCost concerns
Practitioners were consistently also concerned about the cost implications of using the tests. In particular,
participants were concerned that RADTs would increase the expenditure of the surgery:I don’t think we would use them, if there was a cost issue. Why do I say that? Because all our other
pathology is free.
Int. 26, GPAccuracy of diagnosis
One of the key potential beneﬁts of using RADTs in practice is the promise of improving the accuracy of
diagnosis. Four subthemes related to the accuracy of diagnosis when using the RADT were identiﬁed, and
each is taken in turn.Confirmation of diagnosis
When congruent with a HCP’s diagnosis or management disposal, the RADT result could work to reassure
the HCP and conﬁrm their opinion of the diagnosis:It’s been reassuring and it reinforces my credibility of making a clinical judgement
Int. 27, GPConflict of opinion
In contrast, HCPs reported that they would ﬁnd their treatment decisions difﬁcult when there was a
conﬂict between the RADT results and their opinion of the most likely diagnosis:If it’s a negative test and that person’s got clinical signs of a bacterial sore throat . . . you then have to
say, err, what do I do here?
Int. 43, GPI haven’t yet evolved, because it’s not available to me . . . a way of handling a positive test that I
actually don’t want to treat.
Int. 42, GP45
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46This resonates with other supported decisions in general practice, such as the use of severity measures for
the diagnosis and management of depression, for which GPs have described a careful weighing of the
measured evidence versus their GP intuition based on experience.55Identification of carriers
Practitioners reported concern that the RADT would produce a positive test result for patients who were
only carriers for GABHS, and could result in an unnecessary prescription of antibiotics:NIHR. . . I think they’re quite limited really because, because of the fact that streptococcal, you know, that
strep is carried so widely anyway . . . .
Int. 15, GPFailure to detect alternative bacteria
Practitioners were also concerned about the fact that the RADT cannot detect all forms of bacteria:This test just checks for streptococcal, it doesn’t check for the other bacteria.
Int. 46, GPI mean it doesn’t cover everything does it? It just covers some of the streps doesn’t it. . . . don’t know
how many it covers.
Int. 29, GPPatient outcomes
Practitioners were invited to reﬂect on the impact the RADTs might have on patient outcomes. Three
subthemes referring to patient-related outcomes were identiﬁed; again, each is taken in turn.Reassurance for the patient
Linked to views that a test score can enhance the credibility of a treatment disposal, HCPs described how
the RADT might quickly provide reassurance for patients in the consultation:I think . . . they find it very reassuring, as it’s so rapid.
Int. 28, GPYou’ve got your answer. . . . and you can reassure the patient that you’ve got the answer, rather than
what we tend to say is “well, this may or may not be”.
Int. 51, NPEducation tool for patient
In a related fashion, interviewees described how they had used the RADT as a tool to assist in patient
education. More particularly, such tests could be used to explain why antibiotics were not always necessary
for sore throat:It [RADT] helps us to explain to patients why we’re not prescribing for a condition that, hopefully, is
going to be self-limiting.
Int. 47, GPYou are also able to enter into the discussion with them about the, you know, the supposed benefits
of antibiotics, the fact they won’t work for everything and it allows you to open this door or viral
versus bacterial.
Int. 14, GPJournals Library www.journalslibrary.nihr.ac.uk
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Practitioners reported concern that the increased availability of RADTs could lead to patients viewing all
sore throats as more serious and thereby increase consultations because of demand for the test:© Que
This is
suitab
Journa
SO16I think people would be, oh, and when I went to the GP surgery they did this special test and I think
. . . if you were a surgery who were offering it you’d be swamped with sore throats, and if you were
a surgery who weren’t offering it, you’d be swamped with, when my friend up the road gets a
special test. So, yeah, I think it might medicalise . . . something that will go away on its own anyway.
Int. 04, GPThe problems come when people then start to think they have to have it done every time.
Int. 27, GPExperience of using clinical scores
The last 11 interviewees were asked to discuss their views and experiences of the use of the clinical score.
None of the HCPs reported using the clinical scoring method prior to taking part in the trial. Although
there were some positive perceptions of the scoring, the majority of comments and views on the scores
were negative. Three subthemes relating to experiences of using the clinical scores were identiﬁed and
these are described below.Useful for inexperienced practitioners
Although most practitioners felt that the scoring was unnecessary for experienced members of staff, it was
consistently reported that the clinical score did have a ‘place within primary care’ as a useful educational
tool for inexperienced practitioners:If you’re a teaching or training practice, then it’s useful to get the clinicians to learn and think about
this in a much more systematic manner.
Int. 48, GPUnnecessary for experienced practitioners
By contrast, the most common complaint regarding the clinical scores was that they were unnecessary for
an experienced HCP. GPs felt that the questions that form part of the score should be asked when taking
the history and the additional documentation of these was unnecessary. However, it was noted that NPs
did not support this view and felt that the scores would be a useful tool:One doesn’t want to complicate incredibly minor medicine with tools and scanning on bits of paper.
Int. 44, GPThere’s scores for everything at the moment and I think sometimes, you know, if I’m honest, you
don’t need a doctor to be scoring things.
Int. 47, GPTime-consuming
Some practitioners felt that the clinical scoring was too time-consuming to ﬁt into usual practice. In
particular, it was the time taken to document the score, as opposed to conducting the score itself, that
was viewed as a problem.It’s very time consuming, you know, you’re whizzing through a busy surgery . . . one would hope one
knew the right questions to ask.
Int. 44, GPRapid test trial participation
All participants were invited to discuss their views and opinions following participation in the RADT trial.
Three subthemes were identiﬁed.47
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48Trial participation increases positive views
Practitioners described how their views about RADTs had changed positively since being in the trial:NIHR. . . my first thought when the girls [trial researchers] came to talk to us about it was, oh gosh, how
long is it going to take? And then once you realize that, if you were doing it regularly, you could do it
much quicker and that’s not a problem
Int. 25, GPNegative perceived views of non-trial practitioners
Practitioners suggested that GPs and NPs who had not been part of the PRISM trial would be reluctant to
use the RADT:My worry is that if you try to sell it to people who have not been part of the PRISM trial, they won’t
do the test at all.
Int. 26, GPPositive views of trial practitioners
In contrast, practitioners who had taken part in the trial reported that in general they would use the RADT
in general practice, if available:. . . by doing the rapid test, you are [likely] to have less consultations and repeat consultations and
that again gives me a personal benefit
Int. 28, GPPatient views
Three subthemes relating to patient experiences with the RADT emerged.Reassured by test
Patients described feeling reassured with their diagnosis and the treatment option that had been
provided because of having had the RADT, which was congruent with the HCPs’ views of the tests
providing reassurance:. . . it was quite reassuring being the patient and having the right test for the right medicine . . . .
Int. 32, patientNo change in general practitioner attendance
Patients reported that the provision of the RADT would not inﬂuence their decision to attend the GP’s
surgery for a sore throat:I would still see how it went before I sought medical advice . . . I wouldn’t just run straight to the
doctors. I would wait, see how it developed
Int. 29, patientTherefore, patients’ views were in contrast to GPs’, who described concerns that the routine use of the
RADTs would encourage increased patient attendance.Preference for no antibiotics
Patients reported that they would prefer not to take antibiotics unless needed, and they perceived the RADT as
assisting in supporting their no-antibiotic preference, ruling out medication when it is not clinically indicated:If they need to be prescribed and they can help you, then that’s fine but if they’re not really going to
make any difference then I don’t see the point.
Int. 02, patientJournals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6DiscussionThe study identiﬁed three key areas surrounding HCPs’ views of the use of RADTs: practicalities relating to
the tests; the accuracy of diagnosis provided by the RADT; and patient-related outcomes. Participation in
the trial was also identiﬁed as strongly inﬂuencing attitudes towards the use of RADTs. In addition,
patients’ views of the RADT relating to future GP attendance, antibiotic expectation and reassurance were
also identiﬁed.Strengths and limitations
One of the main strengths of the study is its attempt to include both HCPs and patients, to capture a dual
view of the RADT in practice. As both groups had used the RADT, the study was able to directly examine
the experience of conducting the RADT as a HCP and the experience of receiving the test as a patient. This
process was able to reveal differences between HCPs’ perceptions of patient attitudes towards the RADT
and actual patient views. The sample size was relatively large for a qualitative study; however, as the
patient sample size was small, further work could usefully focus on this group to conﬁrm and provide
additional insight to the present ﬁndings. The NP sample was smaller than the GP sample, but consensus
in most views was clear within the NP sample and NPs reported similar views of the RADTs to the GP
sample. The only clear difference between the samples was identiﬁed in a view that was widely held by
GPs but not NPs: that the RADT may be ‘unnecessary for experienced practitioners’.
Nesting qualitative interviews into the PRISM trial provided in-depth views, which help interpret the results
obtained from the main trial. In terms of limitations, three researchers conducted the interviews and the
level of exploration varied. Nonetheless, all interviews explored the key questions/topics and this permitted
comparative analysis across the data corpus. Transparency of the analysis process and agreement on
themes across the team ensured that ﬁnal themes were robust.Main findings
Overall, the interviews suggest that taking part in the PRISM trial had inﬂuenced the HCPs’ attitudes
towards the use of RADTs, in that the tests were now viewed more positively than before participation in
the trial. Positive views towards the RADTs related to patient outcomes, such as the test results providing
reassurance to the patient that they do not need antibiotics and also providing an educational tool to
indicate why antibiotics may not always be necessary. HCPs also felt that the test could provide a useful
conﬁrmation of diagnosis, which reassured them and supported their prescribing decisions. In relation to
the practicalities of conducting the RADT, HCPs reported that it was easy to use and possibly a useful tool
for less experienced staff members and that they felt it had reduced their antibiotic prescribing for sore
throat – hence, potentially useful for experienced and less experienced staff.
There were also some negative views and concerns relating to the RADT. HCPs reported concerns
regarding the additional costs to the practice and time taken to conduct the RADTs. However, the
interviews also suggested that concerns relating to time were most likely to be reduced after the HCP had
conducted the tests a few times and had become familiar with the procedure. Concerns were also raised
in relation to the accuracy of diagnosis in terms of the possible identiﬁcation of GABHS carriers who may
be unnecessarily prescribed antibiotics, and the possible presence of alternative forms of bacteria that the
RADT could not detect. HCPs were concerned with the difﬁculty in making a prescribing decision when
the RADT result differed from their own opinion of diagnosis; however, it was also reported that the RADT
could reassure them if they were in doubt over the diagnosis. Finally, there was some concern that the use
of RADTs could increase the ‘medicalisation’ of sore throat and increase patient attendance to the GP for
this condition. However, patient interviews suggested that tests would be unlikely to increase their GP
attendance, and that patients valued the use of the RADT, reporting that they felt reassured by it.49
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50Comparison with existing literature
It was reported that HCPs viewed the RADTs positively as a tool that could provide a conﬁrmation of their
own diagnosis and, therefore, support their prescribing decision. However, HCPs reported a negative view
of the RADT if it presented evidence for a diagnosis that differed from their own opinion. Similar ﬁndings
were also reported in a study that used a computer-based clinical intervention to assist with antibiotic
prescribing decisions for respiratory tract infection.56 GPs reported acceptance of use of the system if it was
perceived as a tool that could support their own decisions. However, if the system were perceived as a
method of enforcing a prescribing decision, the GPs viewed it negatively and did not wish to use it during
consultations. In a similar vein, a study exploring the use of severity measures for the diagnosis of
depression described the measures as beneﬁcial when they conﬁrmed a GP diagnosis and treatment
disposal, but as of limited value when the score was not congruent with the GP’s view founded on clinical
experience and intuition.57
Practitioners also reported concern that use of the RADT could increase patient pressure for tests and GP
consultations for sore throat. However, patients reported that, although they felt reassured by the tests,
they would be unlikely to increase their GP attendance for the condition or their expectation for
antibiotics. These ﬁndings are analogous to perceptions about prescriptions: GPs often perceive a pressure
from patients to prescribe, investigate and refer despite the fact that patients do not report such
expectations.58 More recent ﬁndings from a qualitative study of patients attending with suspected
urinary tract infection also identiﬁed patients’ reluctance to rely on antibiotics to ameliorate symptoms,
whereas GP interviews highlighted belief in patient pressure or desire for antibiotic prescriptions,44,59
thus suggesting an ongoing disconnection between HCPs’ views of patients’ expectations and
patients’ expectations.Implications for clinical practice
Practitioners reported that being in the PRISM trial had resulted in them viewing RADTs more positively
than before their participation. It was also reported that GPs who had not taken part in the trial were likely
to view RADTs more negatively than their participating counterparts. This suggests that offering GPs the
opportunity to pilot or trial the tests before agreeing to implement them in practice could enhance how
the RADTs are subsequently embedded into routine primary care. Practitioners who discussed the clinical
scoring method widely held the view that it was time-consuming, unnecessary and beneﬁcial only for
inexperienced staff. These perceptions may hinder acceptance of the score by experienced clinicians
in the future and would need to be addressed in future initiatives aimed at incorporating these tests
into practice.
Patients’ views of using the RADTs were generally positive, which suggests that patients would not object
to their use in primary care. A larger sample of patients would be useful to further test and conﬁrm the
acceptability of the RADTs. HCPs were concerned that the RADT would increase consultations, but patients
reported that their likelihood of attending the GP would, in fact, remain the same. This ﬁnding could be
further explored with patients and, if conﬁrmed, could usefully be presented to GPs to reduce their
concerns about using RADTs in relation to the effects on patient attendance.ConclusionIt is unlikely that RADTs will have a place in clinical practice in the near future, until HCPs’ concerns are
addressed, and, importantly, until they have direct experience of using them in real consultations. The
routine use of clinical scoring systems for acute upper respiratory tract illness also faces important barriers
related to clinicians’ perception of their utility in the face of their clinical experience and intuition.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6Chapter 6 Health economic analysis of the
randomised controlled trialD Turner, R Pinedo-Villanueva, J Raftery, R Hobbs and P Little on behalf of the PRISM investigators.
Abstract
Aims
The aim of this study was to assess resource use and health-related quality of life (HRQoL) associated with
clinical scores and RADTs and to show whether these can represent an efﬁcient use of NHS resources.Methods
A cost-effectiveness study (cost/change in symptom severity) and a cost–utility study [cost/quality-adjusted
life-year (QALY)] were carried out as part of the randomised controlled trial. Resource use data were
obtained from GP case notes and from study clinicians. QALYs were estimated by means of EQ5D scores
obtained from the 14-day diary.Results
The cost-effectiveness results presented are for FeverPAIN compared with control and RADT. In total, 498
individuals had both symptom severity and cost data from case notes review. Costs for the initial visit and
for the 1-month follow-up were similar at £51, £44 and £49 for the delayed prescribing, FeverPAIN and
RADT groups, respectively. FeverPAIN dominated both other groups for the cost/change in symptom
severity analyses, being both less costly and more effective. Cost-effectiveness acceptability curves (CEACs)
indicated the clinical score group to be the most likely to be cost-effective. The cost–utility analysis showed
considerable uncertainty around change in QALYs, but FeverPAIN appeared to be the most likely to be
cost-effective, particularly for lower values of QALY.Conclusion
FeverPAIN is a more efﬁcient use of health-care resources than the other approaches.IntroductionWe are aware of no randomised trials of RADTs in which an economic evaluation has been performed.
There have been modelling studies in children60 and adults,61 but these studies did not collect resource use
or quality of life data, and the studies came to opposite conclusions.
Economic evaluations explore whether any particular intervention represents a good use of scarce
health-care resources. They do this by measuring both the costs and the beneﬁts generated by any
particular intervention(s). This obviously applies to interventions with high resource implications, such as
high-cost drugs and complex therapies. However, the same principle also applies to interventions that are
much simpler and have low resource implications. The total impact of these low-resource interventions
may also be important if they are for common conditions that are responsible for large numbers of
consultations in primary care.
The work presented here examines two low-cost interventions. FeverPAIN, a clinical scoring algorithm, and
a near-patient test designed to better manage the care of individuals with acute sore throat. Both were
expected to have low resource implications, particularly the FeverPAIN algorithm. Those patients offered
the RADT had this in addition to the clinical score. Both of these interventions could have implications for
the use of other health-care resources and for the health of individuals receiving them.51
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52The work presented here reports on an economic analysis conducted alongside the clinical trial reported
previously in this report. The aim of this economic analysis was to assess the resource and health impacts
of both of the above interventions, compared with a control group comprising the strategy of delayed
antibiotics, to assess whether either of these interventions would represent an efﬁcient use of
health-care resources.Methods
Data sources for economic evaluation
A number of sources were used to derive data for the economic evaluation. Information regarding the
initial (randomisation) contact was entered directly into the website by study practitioners. This included
duration, whether a RADT had been performed and prescription of antibiotics. Information on health-care
resource use was obtained by a review of practice notes, carried out by a study researcher who visited
each participating practice, using a data collection proforma. Resource use data collection was limited to
upper respiratory tract-related contacts. Data collected included the following: GP and NP visits; antibiotics;
practice visits for complications of infections and antibiotic complications; and hospital admissions related
to infections. Data were collected in three time periods: ﬁrst, the 12 months prior to recruitment
(antibiotics; GP and NP visits); second, the 4 weeks following recruitment (GP and NP visits; antibiotics;
visits for complications; secondary-care resource use); and, third, resource use in the period from 4 weeks
after recruitment up to the end of data collection.
The ﬁnal important source of health economics data was the 14-day diary completed by study participants.
This included the EQ5D62 completed at baseline and at 14 days. This was used to calculate QALYs. If
individuals did not return this diary, then data on symptoms were obtained from a short questionnaire or
a telephone interview. However, these sources did not include the EQ5D.Analysis of costs
Recruitment visit and cost of intervention
As the interventions evaluated in this study could be expected to have implications for the duration of the
initial consultation, we measured this duration as part of the study. As noted above, practitioners entered
the length of contact into the study database, which was costed using pound per minute of GP time.63
The costs associated with the clinical score intervention itself were limited to any differences in length of
consultation required for this intervention. The costs associated with the clinical score plus near-patient
test group comprised the additional time required to provide the intervention as well as the cost of the
near-patient test itself, of £3.25 per test, obtained via correspondence with the manufacturer as £65 for
20 tests. However, this test was used only if the clinical score indicated sufﬁcient severity (FeverPAIN ≥ 3),
so this cost of £3.25 per test was applied only to the subset of participants in the RADT group who
actually had the test.Case notes review
In addition to the resources needed to directly provide the interventions (practitioner time and cost of test),
the study groups may have had differences in use of health-care resources associated with acute sore
throat. To examine this we collected resource use data directly from general practice patient notes. Data
were obtained for the previous 12 months to test the equivalence of the three groups in terms of baseline
resource use for respiratory tract infections. Data were collected for the 12-month follow-up period to test
whether there were any long-term differences in costs. However, we found no statistically signiﬁcant
differences between any groups for these two time periods. For this reason, the analysis presented here
uses resource use in the recruitment visit as well as in the 4-week follow-up period after this visit. The
reviewer identiﬁed if the participant had seen a GP or a NP in the relevant time period. They also identiﬁed
if any symptoms or diagnoses had been reported. These symptoms and/or diagnoses were identiﬁed only if
a visit had been made. There was a small discrepancy between these two types of data, with some casesNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6in which symptoms/diagnosis had indicated a visit and no data were available on the type of contact. We
assumed that a visit would be recorded if either condition applied, that is a diagnosis or symptom had
been reported or a visit to a GP or NP had been noted. Reported contacts with either a GP or a NP were
costed using unit costs from the PSSRU (Personal Social Services Research Unit), a widely used source of
unit cost data.63 In those cases in which diagnosis or symptom data indicated that a contact had been
made but it was not clear who had been seen, a cost for either a GP or a NP contact was randomly
assigned. This was done in the same ratio as that observed for those contacts for which type of contact
was speciﬁed: 85% of reported contacts in the follow-up period were with a GP. This method was used as
data were obtained by a researcher from practice notes. Therefore, we had no a priori reason to suppose
that missing data were related to any patient characteristic.
For non-complicated visits to the practice, the notes review indicated whether antibiotics had been
prescribed, but no information was obtained on the type of antibiotic used. We had no reason to believe
that choice of antibiotic varied by arm. We assumed a cost equal to 28 tablets of amoxicillin.64 The costs of
all drugs prescribed also included a prescribing fee of £1.26 (NHS Drug Tariff: www.ppa.org.uk/edt/
December_2012/mindex.htm). In addition, the case notes review also identiﬁed visits resulting from
complications, either of the illness or from treatment. Complications of the illness included the following:
otitis media, quinsy/peritonsillar cellulitis; cellulitis; sinusitis; scarlet fever; and pneumonia. Complications of
treatment reported in the case notes review included the following: rash and diarrhoea. In these cases,
more information was collected: including who was seen, where they were seen, type of antibiotic and
whether a hospital stay had occurred. Again, any community care contacts were costed using PSSRU unit
costs.63 However, secondary-care contacts, such as inpatient stays, visits to accident and emergency (A&E),
and visits to hospital doctors were costed using NHS reference costs.65 The types of resource use included
in this study and the unit costs that were used to cost these are described in Table 14.
In the event that an individual suffered a complication, a named antibiotic was used and the appropriate
cost was used. For a visit to A&E, a cost was obtained from NHS reference costs using a weighted average
of all costs for A&E services leading to admission. One individual had a short inpatient stay, which was
costed at £473, based on a weighted average of respiratory-related short-stay episodes. All costs used
were in 2010/11 UK pounds.TABLE 14 Types of contacts and unit costs used
Cost item Value (£) Source
Visit to GP 31 PSSRU63
GP home visit 104 PSSRU63
Per minute of GP time 2.67 PSSRU63
Visit to NP 13 PSSRU63
Antibiotics (amoxicillin) 1.29 BNF64
Antibiotics (other) 1.35 to 2.04 BNF64
Prescribing cost 1.26 NHS Drug Tariff
Visit to A&E 108 NHS reference costs65
Overnight hospital stay 473 NHS reference costs65
BNF, British National Formulary.
53
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54Participants
Two clinical scoring algorithms were used in the clinical study. Score 1 was used at the start of the study
and was used with 1129 participants. This was replaced as planned by FeverPAIN in the second part of the
study (for 613 participants). The results of the clinical trial indicated no statistically signiﬁcant results for
score 1, but did ﬁnd statistically signiﬁcant results for FeverPAIN compared with delayed antibiotics (see
Chapter 4). We conﬁned our economic analysis to FeverPAIN, as this was the score tested in the clinical trial.Outcome data used
Outcomes in the economic analysis were the symptom severity score (primary outcome measure in trial)
and QALYs based on EQ5D.62 EQ5D was obtained from the patient-completed diary. Values were obtained
at baseline and at 14 days after recruitment. However, as EQ5D scores were obtained from the 14-day
diary, we did not have EQ5D values for the end of the 28-day follow-up period. We assumed that health
obtained at the end of the 14-day period persisted to the end of the study period, that is the last value
obtained was carried forward for 14 days. However, we also calculated QALYs for the 14-day period to
test the effect of this assumption on generated results. These were scored using the standard UK tariff
(www.euroqol.org). Values obtained were converted into QALYs using ‘area under the curve’, that is
values obtained were multiplied by duration spent in those health states. The estimates of QALY used in
the analysis presented here are differences from baseline EQ5D, calculated by estimating ‘area under the
curve’, then subtracting the area that would be generated if baseline EQ5D had been maintained for 28
days. The same method was used for the 14-day QALY estimates, but the baseline QALY for the 14-day
period was subtracted. The estimated QALY gain was compared with baseline values of EQ5D.
This ‘area under the curve’ method assumes a linear relationship between values at different time points;
that is, if the EQ5D score changes between baseline and 14 days, a straight line would be drawn between
the two points (i.e. HRQoL changes at a uniform rate between the two time points). There is no guarantee
that HRQoL would change in this manner, particularly with an acute illness. A number of alternative patterns
of recovery would be possible. Two are considered here. First, individuals recover quickly in the ﬁrst few
days, with only minor improvements in health for the rest of the 14-day period. Second, individuals have
poor health for the majority of the 14-day period and then recover quickly. Linear interpolation between the
two EQ5D scores would understate the QALYs generated in the ﬁrst case and overstate them in the second.
It was not clear at the design stage how individuals’ health would change and what the effect of the proﬁle
of health change might be. It was not considered feasible to ask participants to complete the EQ5D daily
without dramatically complicating and lengthening the short diary, possibly reducing completion rates. We
included a page in the patient diary with a number of visual analogue scores (VAS). These were modiﬁed
slightly in order to ﬁt VASs for 14 days over two pages in the diary. However, the scales and the description
of end points were not changed. Individuals were asked to complete these until they felt better and these
scores were used to describe the proﬁle of recovery from acute sore throat.
As VASs were completed only until recovery, we lacked scores for the full 14 days for most respondents.
Conﬁning analysis to complete data for each day would mean that only cases that took longer to recover
would appear in the estimates for the later days. This would bias estimates downwards, and give a
misleading picture of, the proﬁle of potential recovery. Therefore, we assumed that the last value given
when the individual had deemed themselves to be ‘fully recovered’ could be carried forward to represent
the score they would have given in the remaining time period. These were calculated for individuals for
whom we had both baseline and 14-day EQ5D, that is those individuals who we were able to calculate
QALY scores for. Examination of the health proﬁles obtained from this process indicated that change in
health did not differ markedly from a straight line recovery (Figure 9), although there did appear to be an
increased rate of recovery in the ﬁrst 8 days compared with the next 6. Linear interpolation between EQ5D
scores at 0 and 14 days was used in our analysis.
The primary outcome measure was the symptom severity score used in the main clinical study. This was the
mean rating of sore throat and difﬁculty of swallowing for days 2–4. A higher score indicates worse symptoms.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 9 Daily VASs for the 257 participants used in the cost–utility analysis.
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We present results for both a cost-effectiveness study using cost per point change in symptom severity score
and a cost–utility analysis based on incremental cost per QALY. The time frame of the analysis is for 1 month
after randomisation and the perspective that of the NHS. Costs included those associated with the initial visit
as well as those in the 1-month follow-up. Data were analysed in PASW v. 18 (SPSS, Quarry Bay, Hong
Kong), Stata v. 11.2 (StataCorp LP, College Station, TX, USA) and Microsoft Excel (Microsoft Corporation,
Redmond, WA, USA). Mean and 95% CIs were generated for use cost variables. For outcome variables
(both symptom score and QALYs), mean values were estimated using regression equations which allowed us
to control for baseline characteristics (fever and baseline symptoms). Mean QALY gain at 14 and 28 days
(with 95% CI) for each arm are adjusted by baseline sore throat/swallowing clinical score and fever. To do
this, we estimated a linear model for the QALY gain controlling for the clinical score and fever, replicating
the method used in the clinical study. We then predicted mean values and 95% CIs. Analyses were
performed using the regress and adjust commands in Stata v. 11.2. Bootstrapping using 5000 samples was
used to generate CEACs. These show the probability that each intervention is cost-effective at different
values placed upon the outcome variable. The regression methods previously described were used to adjust
for baseline characteristics when producing these bootstrapped estimates. These present results that allow
for the uncertainty arising from trial data. Bootstrapping was also used to generate scatterplots on the
cost-effectiveness plane. These also show the uncertainty inherent in study data.ResultsIndividuals were included in the economic analyses if they had data for the relevant outcome measure and
cost results from the case notes review. Two outcome measures were used in our analysis. First, we used the
clinical symptom score used in the clinical study. This comprised a cost-effectiveness study. Second, we used
the EQ5D to derive QALYs; this comprised a cost–utility study. Included in the cost-effectiveness study were
498 individuals for whom we had both cost and clinical symptom scores, with 168, 167 and 163 individuals
included in the delayed prescribing, FeverPAIN and RADT groups, respectively. However, as individuals only
had an EQ5D score if they returned the diary and also completed the EQ5D question in the diary, we only
had EQ5D scores for 274 individuals at baseline (55%) and 262 individuals at 14-day follow-up (53%).
There were 257 (52%) patients for whom we had complete EQ5D data for both baseline and follow–up and
for whom an estimate of QALY could be calculated. This gave 80, 85 and 92 cases in the three study groups
(delayed, FeverPAIN and RADT, respectively). For this reason, the cost–utility study was carried out on a
smaller sample than the cost-effectiveness study.
Cost results were obtained for these three groups and are presented in Table 15. These results concern the
498 individuals who constitute the cost-effectiveness study. Mean cost was modest in each group at £4455
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DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6to £51 for the 1-month period, the majority of which is attributable to the ﬁrst (recruitment) visit.
GP-reported duration of contact was similar between the delayed and clinical score groups, but was
slightly longer in the RADT group at 15.9 minutes. This difference, and the cost of the test, results in a
slightly higher cost for the recruitment visit, £44 compared with around £40 in the other two groups.
t-Tests indicated statistically signiﬁcant differences between costs for the FeverPAIN group and the RADT
group (p < 0.05).
Costs in the 4-week follow-up period were low, with only around 15% of individuals having
reconsultations. Complications were low with only three complications of illness and two complications of
treatment reported. Quinsy was associated with one short hospital stay (one night) and one A&E visit.
Both cases occurred in the delayed prescribing group.
The prescribing of antibiotics differed between groups. We did not have data from case notes review or
clinician report on whether delayed prescribing prescriptions had been dispensed. Both the clinical score
group and the RADT group appeared to be associated with lower use of antibiotics. Costs were calculated
for all prescribing cases as if they had been dispensed. This could overstate prescribing costs, but this
effect would be small because of the low cost of antibiotics. We use t-tests to examine differences
between total costs. These showed a statistically signiﬁcant difference in costs between the delayed
prescribing and the clinical score groups.Cost-effectiveness analysis
Table 16 shows the results based on the symptom score for the 498 individuals included in the
cost-effectiveness study. Means for symptom score were adjusted for differences in baseline symptoms
and fever, as detailed earlier. In terms of point estimates, the FeverPAIN group dominated the other two
groups, being more clinically effective (having a lower symptom score) and less costly. However, for the
comparison of FeverPAIN against RADT, it can be seen that the point estimates of symptoms are very
similar with overlapping CIs. Therefore, it is important to consider uncertainty around these results.
This can be seen in the CEAC (Figure 10). The value of a point change in the symptom score was varied
between £0 and £500 in this analysis. For this entire range, the clinical score group was the most likely to
be cost-effective. This was most marked at lower values of a point change on the symptom score, as the
FeverPAIN approach was associated with lower costs. Although estimated symptoms were similar between
FeverPAIN and RADT, FeverPAIN had a higher probability of being the most cost-effective option at each
value of a point change in symptoms because it had lower costs.
Scatterplots for the cost-effectiveness analysis are given in Figures 11–13. In these scatterplots, a negative
value of incremental effectiveness indicates a better outcome, as lower symptom scores are preferable.
Figure 11 shows that the FeverPAIN group have lower symptom scores than the delayed group for most
simulations and, for the vast majority of simulations, the costs of FeverPAIN are lower than those of
delayed prescribing. Figure 12 shows that the RADT group appears to generate lower symptom scores
than the delayed prescribing group. However, costs were very similar and are distributed fairly evenly over
the x-axis. Finally, Figure 13 shows that the RADT appears to show similar effectiveness, but at increased
costs, to the clinical score group.ABLE 16 Cost per point change in symptom score results (means and 95% CIs)
Treatment group Symptom Total costs (£) Incremental analysis
Delayed prescribing 3.15 (2.93 to 3.37) 51.30 (43.30 to 59.20) Dominated
FeverPAIN 2.83 (2.61 to 3.05) 44.20 (41.30 to 47.00)
RADT 2.84 (2.62 to 3.07) 49.30 (46.00 to 52.50) DominatedT57
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DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6Cost–utility analysisAdjustment for baseline for estimated QALY gain
We used regression analysis on the QALY measure used to test any associations between QALY gain and
baseline characteristics. This replicated methods used in the clinical study on the clinical outcome
measures. However, in this case this regression analysis was carried out on only the 257 individuals in the
complete case analysis. As in the clinical study, we found statistically signiﬁcant associations between
QALY gain and baseline measures of fever and severity score.
Bootstrapping to produce CEACs also included adjustment by baseline symptom severity and fever.
The results for the complete case analysis for the outcome measures used in the cost–utility analysis can be
seen in Table 17. EQ5D scores for both baseline and 14 days were obtained from the patient-completed
diaries. EQ5D scores were very similar in all three groups. It can also be seen that there is a marked
increase in EQ5D score in all groups between baseline and the 14-day follow-up. This indicates that the
individuals’ sore throats were having a marked effect on their self-reported EQ5D score. The estimated
14- and 28-day QALY gains compared with baseline are also shown in this table. We show results
adjusted for baseline characteristics. As stated earlier, a linear relationship is assumed between the baseline
and 14-day EQ5D scores to generate QALY gain at 14 days. The QALY gain is, therefore, the area of a
triangle formed by the difference between the 14-day EQ5D and the baseline EQ5D multiplied by 14 days.
As we assumed that the 14-day EQ5D score is carried forward to estimate QALYs gained for 28 days, the
QALY gain generated in the 14- to 28-day period is represented by a rectangle formed by the difference
between the EQ5D scores multiplied by this 14-day period. Therefore, the QALY gain in the second 14-day
period is twice that of the ﬁrst. The QALY gain estimated in the total recruitment to 28-day period is,
therefore, three times that estimated in the 14-day period.TABLE 17 Cost–utility outcomes data (95% CI)
Measure Control (n = 80) FeverPAIN (n = 85) RADT (n = 92)
EQ5D – Baseline 0.63 (0.57 to 0.69) 0.61 (0.54 to 0.68) 0.65 (0.59 to 0.72)
EQ5D – 14 Days 0.92 (0.89 to 0.95) 0.94 (0.92 to 0.97) 0.94 (0.92 to 0.96)
14-day QALY 0.0057 (0.0044 to 0.0070) 0.0058 (0.0045 to 0.0071) 0.00584 (0.0046 to 0.0071)
28-day QALY 0.0171 (0.0131 to 0.021) 0.0174 (0.0135 to 0.0213) 0.0175 (0.0138 to 0.0212)
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60Results of cost–utility study
The results presented are for the 257 individuals included in the cost–utility complete case analysis.
Table 18 shows the results of the cost per QALY analysis for the 14-day results. The QALY difference from
baseline ranged from 0.0057 to 0.0058. There were no clear differences in generated QALYs among the
three groups, as can be seen from the wide and overlapping CIs. The costs per patient were very similar to
those generated for the larger data set of 498. However, as there was considerable uncertainty in these
data, no clear conclusion should be drawn from this. The 28-day results are presented in Table 19 and
these are similar (although larger in magnitude) with no clear differences among groups in QALY scores.
As the QALY gain is marginally higher in the RADT group than in the FeverPAIN group, RADT generates
additional QALYs at between £74,286 to £24,528 per QALY, depending on which QALY measure is used.
To take account of uncertainty, CEACs were generated for these results (Figures 14 and 15). These both
show considerable uncertainty. This is largely generated by uncertainty around the QALY estimate. At a
value of £30,000 per QALY, the probabilities that the three groups are cost-effective are 25%, 40% and
35%, for the delayed prescribing, FeverPAIN and RADT groups, respectively, for the 14-day QALY gain. For
the 28-day QALY gain, the same values are 28%, 38% and 35%. As can be seen from the scatterplots
(Figures 16–18), the distribution of estimated incremental QALYs is fairly evenly distributed around the100
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FIGURE 14 Cost-effectiveness acceptability curve for 14-day QALY difference.
TABLE 19 Cost-utility results for FeverPAIN using adjusted QALY data for 28-day period (means and 95% CIs)
Treatment
group QALY Total costs (£)
Incremental
effect
Incremental
costs (£) ICER (£)
Delayed prescribing 0.0171 (0.0131 to 0.0211) 49.70 (43.30 to 56.00) Dominated
FeverPAIN 0.01741 (0.0135 to 0.0213) 45.90 (41.50 to 50.20)
RADT 0.01752 (0.0138 to 0.0212) 48.50 (45.00 to 52.00) 0.000106 2.60 24,528
TABLE 18 Cost–utility results for FeverPAIN using adjusted QALY data for 14-day period (means and 95% CIs)
Treatment
group QALY Total costs (£)
Incremental
effect
Incremental
costs (£) ICER (£)
Delayed prescribing 0.0057 (0.0044 to 0.007) 49.70 (43.30 to 56.00) Dominated
FeverPAIN 0.0058 (0.0045 to 0.0071) 45.90 (41.50 to 50.20)
RADT 0.00584 (0.0046 to 0.0071) 48.50 (45.00 to 52.00) 0.000035 2.60 74,286
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62y-axis. These scatterplots are for the 14-day QALY analysis. The 28-day analysis plots are very similar, apart
from the magnitude of the QALY difference, so are not shown here.
DiscussionStatement of main findings
The cost-effectiveness analysis showed that the clinical scoring algorithm used in the FeverPAIN group was
effective in reducing symptoms. Costs in all three groups were similar and modest, but the FeverPAIN score
group was associated with lower costs. This indicates that the use of the FeverPAIN score may be an
efﬁcient use of health-care resources. However, for the cost–utility analysis (cost/QALY) there was a less
clear message, as differences in QALYs generated were very small with wide CIs, and therefore there was
no statistically signiﬁcant differences between any groups. The CEACs for the cost–utility study indicate
that FeverPAIN is the most likely to be cost-effective over all values of a QALY examined; however, they
also indicate considerable uncertainty. The cost/QALY offers weak support for the conclusions of the
cost-effectiveness analysis.Strengths and potential limitations
A strength of the current work is that it used a clinical measure of symptoms as well as the QALY. The
former was plausibly more sensitive to changes in participants’ symptoms of sore throat. Its administration
ensured it picked up changes day to day. Another strength concerns the costs obtained from a case note
review being comprehensive. A weakness of the current study is that the 14-day diary had EQ5D data only
at two time points (0 and 14 days) and for 52% of all participants. We did not ﬁnd any statistically
signiﬁcant differences in terms of QALY differences for participants. There could be a number of reasons
for this. First, the smaller data set for which we had QALY score may not be representative of the larger
group of individuals in the cost-effectiveness study. Second, it may be that many individuals would have
recovered before the 14-day QALY was asked and thus their health may have returned to normal. For this
reason, the 14-day EQ5D score and hence the QALY difference at 14 days may not be well correlated with
changes in symptom scores. It may also be the case that the EQ5D is not sensitive in assessing HRQoL
related to change in sore throat-related symptoms. The true impact of RADTs in practice may not be fully
captured in our estimation of costs: we estimated an additional 4.5 minutes in consultation time on
average when a test was performed, which may be an underestimate of the time taken to do a
RADT – the pack and reagents have to be prepared, a throat swab taken, the antigen extracted from the
swab, reagents mixed, the resulting mixture applied to the test pack, and then for a negative result
there is a 5- to 10-minute wait (see Appendix 7). The reason for this possible underestimate is unclear, but
clinicians may have been able to be more rapid with trial paperwork when they knew they had to do aNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6RADT. The time taken to feed back the results may also not have been captured. Furthermore, the ‘costs’
of the stress of a longer consultation, and the knock-on effect for other consultations, are not included in
costs. Thus, it is likely that RADTs are, if anything, less cost-effective than we have estimated.
The estimates of both clinical effectiveness and cost-effectiveness may be modiﬁed by alternative
algorithms for using RADTs (e.g. using a RADT at lower FeverPAIN scores). However, a more widespread
use of RADTs would probably not be acceptable to clinicians in the UK based on our qualitative work, and
the targeting of RADTs in the current study was based on modelling to determine the most efﬁcient use of
the tests in identifying patients with streptococci, so more widespread use of RADTs is likely to be a less
efﬁcient policy.Relation to existing literature
Webb60 used decision analysis for a paediatric population and compared immediate treatment, culture,
RADT and RADT and culture and concluded that empirical treating was most cost-effective. Neuner et al.61
modelled ﬁve strategies (no treatment; immediate treatment; culture and delayed antibiotics until results;
RADT with culture for negative results; and RADT alone) and, in contrast to Webb, found empirical
treatment to be the least cost-effective, but all others to have a similar QALY gain, and culture to be the
least expensive so the most cost-effective. Neither of these studies collected prospective data from a trial
and neither performed direct measurement of quality of life or the change in quality of life over time.ConclusionThe FeverPAIN algorithm enabled an efﬁcient use of health-care resources compared with the other two
groups based on changes in symptoms, the primary outcome. As it appears to be more clinically effective
and less costly than delayed prescribing and less costly than RADT, it would appear reasonable to prefer it
to both alternatives on economic grounds. The cost per QALY analysis gave a less clear message, but did
not contradict the cost-effectiveness analysis.63
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beta-haemolytic streptococcus and commensal
stock cultures
Each S. pyogenes strain was grown on Columbia agar with horse blood (CBA) (Oxoid, Hampshire, UK)for 18 hours in 5% CO2 at 37 °C. From the resulting cultures, one colony was inoculated into 10ml of
brain–heart infusion (BHI) broth (Oxoid) and incubated for 18 hours in 5% CO2 at 37 °C. The resulting
suspension was diluted by transferring 1 ml of it into 100ml of stock BHI broth. This solution was
incubated at 37 °C without shaking until an optical density of 1.0 was reached at 600 nm, as measured
with a Sanyo-Gallenkamp SP50 spectrophotometer (Integrated Services, NJ, USA). To accurately determine
the CFU per millilitre of the solution, any clumped bacteria were separated. Each solution was centrifuged
for 10 minutes at 3000 r.p.m., the supernatant was discarded and the resulting pellet resuspended in
100ml of sterile saline (Oxoid). This suspension was vortexed to resuspend the bacteria, producing a stock
solution with an approximate concentration of 5 × 109 CFU/ml. Performing 1/10 serial dilutions into
additional sterile saline produced a range of suspensions from 102 to 108 CFU/ml. Exact bacterial
concentrations were determined by spreading 100-µl aliquots from each dilution on to duplicate CBA
plates (Oxoid). After incubation for 18–24 hours in 5% CO2 at 37 °C, the colonies formed were counted
and the bacterial concentration of each suspension calculated. Aliquots of 50ml stock solution were
prepared in sufﬁcient numbers to carry out the total evaluation. Solutions were stored for a maximum of
4 months at –20 °C (Refrigerator Global 48F; ESTA, Vibocold A/S, Viborg, Denmark).
The culture method outlined above for sensitivity testing was repeated for the commensal organisms. The
method was modiﬁed for the anaerobic commensals by substituting the BHI broth for Schaedler anaerobe
broth (Oxoid) and incubation in anaerobic conditions (MACS MG500 Anaerobic Workstation, Don Whitley
Scientiﬁc Ltd, Shipley, UK).73
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recommendations for five rapid antigen detection testsKit Swab type Additional suggestions
Clearview Exact Test Polyester Use swabs such as those provided
Plastic shafts only, such as those provided
Do not use calcium alginate, cotton-tipped or wooden-shaft swabs
OSOM Ultra Strep A Rayon Only use swabs provided
Do not use swabs from other suppliers – not validated
QuickVue Dipstick Strep A Test Rayon Any rayon-tipped swabs, on solid-plastic shafts
Do not use calcium alginate, cotton-tipped, hollow or wooden-shaft swabs
Streptatest Polyester Only use swabs provided
IMI TestPack Plus Strep A Polyester Polyester-tipped swabs only
Do not use calcium alginate, cotton-tipped, hollow or wooden-shaft swabs75
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The OSOM with its kit swabs was the most sensitive kit at GABHS concentrations of 2.5 × 106 CFU/mland 5 × 106 CFU/ml: sensitivity was 59% (95% CI 48% to 69%) and 82% (95% CI 73% to 89%),
respectively (see Figure 2). At a concentration of 7.5 × 106 CFU/ml, the OSOM/kit swab combination
achieved a sensitivity of 95% (95% CI 88% to 98%), matched only by Clearview with polyester swabs.
However, Clearview and polyester swabs achieved 100% (95% CI 96% to 100%) sensitivity at
10 × 106 CFU/ml, whereas the sensitivity of OSOM and kit swabs remained at 95% at this concentration.
The IMI TestPack with its kit swabs achieved a sensitivity of 21% (95% CI 14% to 31%) at
2.5 × 106 CFU/ml, yet its sensitivity improved at higher GABHS concentrations, matching the OSOM/kit
swab 95% sensitivity at 10 × 106 CFU/ml. The sensitivities of QuickVue and Streptatest kits were poor
overall, with the best performances achieved with the integral kit swabs: maximum sensitivities at
10 × 106 CFU/ml of 70% (95% CI 59% to 80%) and 79% (95% CI 67% to 85%), respectively. Notably,
the sensitivity of Clearview when using the kit swabs provided was considerably reduced, reaching a
maximum sensitivity of only 62% (95% CI 51% to 72%) at 10 × 106 CFU/ml.77
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group A, C or G beta-haemolytic streptococci
compared with patients with no growth of C, G or
A beta-haemolytic streptococci using more levels
for variablesSymptom
or sign
CGA
[n (%)]
No CGA
[n (%)]
Univariate
OR (95% CI) p-value
Multivariate
OR (95% CI) p-value
Prior duration
5+ days 32/180 (18) 181/409 (44) 1.0 1.0
3–4 days 74/180 (41) 131/409 (32) 3.2 (2.0 to 5.1) < 0.001 2.0 (1.2 to 3.5) 0.010
1–2 days 74/180 (41) 97/409 (24) 4.3 (2.7 to 7.0) < 0.001 3.6 (2.0 to 6.5) < 0.001
Glands
None 15/178 (8) 114/404 (28) 1.0 1.0
Small 58/178 (33) 125/404 (31) 3.5 (1.9 to 6.6) < 0.001 2.4 (1.2 to 5.0) 0.019
Medium 93/178 (52) 145/404 (36) 4.9 (2.7 to 8.9) < 0.001 3.0 (1.5 to 6.1) 0.002
Large 12/178 (7) 20/404 (5) 4.6 (1.9 to 11.2) 0.001 1.2 (0.4 to 3.6) 0.768
Tonsils inﬂamed
None 21/177 (12) 109/397 (27) 1.0 1.0
Slight 29/177 (16) 110/397 (28) 1.4 (0.7 to 2.5) 0.322 1.2 (0.6 to 2.4) 0.670
Moderately bad 71/177 (40) 133/397 (34) 2.8 (1.6 to 4.8) < 0.001 1.5 (0.8 to 2.9) 0.187
Severe 56/177 (32) 45/397 (11) 6.5 (3.5 to 11.9) < 0.001 3.3 (1.6 to 7.0) 0.002
Runny nose
Severe 4/180 (2) 17/409 (4) 1.0 1.0
Moderately bad 12/180 (7) 63/409 (15) 0.81 (0.2 to 2.8) 0.741 0.9 (0.2 to 3.9) 0.904
Slight 34/180 (19) 106/409 (26) 1.4 (0.4 to 4.3) 0.599 1.1 (0.3 to 4.4) 0.853
None 130/180 (72) 223/409 (55) 2.5 (0.8 to 7.5) 0.109 1.6 (0..4 to 5.8) 0.506
Age group
21+ years 93/181 (51) 265/411 (64) 1.0 1.0
11–20 years 56/181 (31) 114/411 (28) 1.4 (0.9 to 2.1) 0.097 1.1 (0.7 to 1.8) 0.741
≤ 10 years 32/181 (18) 32/411 (8) 2.8 (1.7 to 4.9) < 0.001 2.4 (1.2 to 4.7) 0.015
Sore throat
Slight 6/181 (3) 51/409 (12) 1.0 1.0
Moderately bad 80/181 (44) 199/409 (49) 3.4 (1.4 to 8.3) 0.006 3.0 (1.1 to 8.5) 0.033
Severe 95/181 (53) 159/409 (39) 5.1 (2.1 to 12.3) < 0.001 3.8 (1.3 to 10.9) 0.012
79
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Little et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
Symptom
or sign
CGA
[n (%)]
No CGA
[n (%)]
Univariate
OR (95% CI) p-value
Multivariate
OR (95% CI) p-value
Cough
Severe 1/181 (1) 34/410 (8) 1.0 1.0
Moderately bad 21/181 (12) 108/410 (26) 6.6 (0.9 to 51.0) 0.070 3.7 (0.5 to 30.0) 0.225
Slight 42/181 (23) 94/410 (23) 15.0 (2.0 to 115.0) 0.008 6.6 (0.8 to 53.0) 0.077
None 117/181 (65) 174/410 (42) 23.0 (3.0 to 169.0) 0.002 8.6 (1.1 to 68.0) 0.041
Pus on tonsils 95/180 (53) 126/409 (31) 2.5 (1.8 to 3.6) < 0.001 0.79 (0.5 to 1.3) 0.365
Fever (24 hours)
None 38/181 (21) 175/410 (43) 1.0 1.0
Slight 59/181 (33) 114/410 (28) 2.4 (1.5 to 3.8) < 0.001 1.7 (1.0 to 2.9) 0.073
Moderately bad 63/181 (35) 88/410 (21) 3.3 (2.0 to 5.3) < 0.001 1.5 (0.8 to 2.7) 0.184
Severe 21/181 (12) 33/410 (8) 2.9 (1.5 to 5.6) 0.001 1.0 (0.4 to 2.2) 0.946
Muscle aches
None 61/180 (34) 206/409 (50) 1.0 1.0
Slight 49/180 (27) 105/409 (26) 1.6 (1.0 to 2.5) 0.044 1.5 (0.9 to 2.5) 0.166
Moderately bad 50/180 (28) 75/409 (18) 2.3 (1.4 to 3.6) 0.001 2.6 (1.5 to 4.6) 0.001
Severe 20/180 (11) 23/409 (6) 2.9 (1.5 to 5.7) 0.001 3.7 (1.6 to 8.8) 0.002
Headache
None 46/181 (25) 166/409 (41) 1.0 1.0
Slight 55/181 (30) 127/409 (31) 1.6 (1.0 to 2.5) 0.054 1.2 (0.7 to 2.2) 0.484
Moderately bad 59/181 (33) 85/409 (21) 2.5 (1.6 to 4.0) < 0.001 1.7 (0.9 to 3.2) 0.079
Severe 21/181 (12) 31/409 (8) 2.4 (1.3 to 4.7) 0.006 1.3 (0.6 to 3.0) 0.538
CGA; growth of A, C or G beta-haemolytic streptococci; OR, odds ratio.
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Number (%) of patients with Lanceﬁeld group A, C or G streptococci according to each level of athree-point ‘basic’ score (model 3), including the variables signiﬁcant in multivariate analysis in both
data sets (one point each for short prior duration, fever in the last 24 hours and severely inﬂamed tonsils).
The total number at each level, and the percentage of the total sample in brackets, is also shown.Score
Total0 1 2 3
First data set
Streptococci 16 (15) 43 (19) 80 (43) 37 (67) 176 (31)
Total 109 (19) 221 (39) 187 (33) 55 (10) 572 (100)
Second data set
Streptococci 22 (22) 46 (25) 81 (52) 18 (82) 167 (36)
Total 100 (22) 183 (40) 156 (34) 22 (5) 461 (100)81
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DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6Appendix 6 Data for score 1TABLE 20 Symptom severity, antibiotic use, intention to consult in the future (moderately likely or more likely) and
reconsultations with sore throat for score 1. Results are risk ratios (95% CIs) or mean differences (95% CIs)
Measure Delayed prescribing (control) Clinical score RADT
Mean severity of sore throat and difficulty swallowing in the 2–4 days after seeing the doctor (0 = no problem,
6 = as bad as it could be)
Crude mean 2.95 (SD 1.44) 3.05 (SD 1.49) 2.83 (SD 1.50)
Mean differencea 0.06 (–0.15 to 0.28;
p = 0.560)
–0.12 (–0.34 to 0.10;
p = 0.270)
Duration of symptoms rated moderately bad or worse
Hazard ratio 1.00 0.95 (0.80 to 1.13;
p = 0.543)
1.10 (0.92 to 1.31;
p = 0.282)
Antibiotic use
Crude percentage [n (%)] 111/284 (39) 137/294 (47) 98/281 (35)
Risk ratioa 1.00 1.20 (0.99 to 1.42;
p = 0.059)
0.88 (0.69 to 1.09;
p = 0.265)
Belief in the need to see the doctor in future episodes
Crude percentage [n (%)] 91/278 (33) 79/285 (28) 76/273 (28)
Risk ratioa 0.85 (0.64 to 1.09;
p = 0.205)
0.86 (0.65 to 1.10;
p = 0.248)
Return to the surgery within 1 month with sore throat
Crude percentage [n (%)] 43/374 (11) 34/380 (9) 46/359 (13)
Risk ratioa 1.00 0.76 (0.49 to 1.16;
p = 0.205)
1.11 (0.74 to 1.62;
p = 0.618)
Return to the surgery after 1 month with sore throat (mean follow-up 0.73 years)
Crude percentage [n (%)] 75/374 (20) 84/380 (22) 69/359 (19)
Risk ratioa 1.00 1.10 (0.83 to 1.44;
p = 0.488)
0.95 (0.70 to 1.27;
p = 0.728)
a All models controlled for baseline severity of sore throat and difﬁculty swallowing and fever during the
previous 24 hours.
Model for return within 1 month also controlled for prior antibiotic use. Model for returns after 1 month additionally
controlled for prior attendance with sore throat, and follow-up duration.
83
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Little et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
Patients assessed
(n =1630)
Eligible patients
approached
(n =1247)
Randomised
(n =1129)
Delayed group
(n = 376)
Received intervention
as allocated
(n = 376)
Symptom severity
recorded
(n = 300)
Follow-up notes
review
(n = 374)
Clinical score group
(n = 386)
Received intervention
as allocated
(n = 386)
Symptom severity
recorded
(n = 307)
Follow-up notes
review
(n = 380)
Rapid test group
(n = 367)
Received intervention
as allocated
(n = 367)
Symptom severity
recorded
(n = 294)
Follow-up notes
review
(n = 359)
Declineda
(n = 118)
Not inviteda
(n = 383)
FIGURE 19 The CONSORT (CONsolidated Standards Of Reporting Trials) trial flow diagram for first phase of the
trial (score 1).
APPENDIX 6
84Compliance with intended strategy for score 1
As with score 2, there was good compliance with the intended strategy in each group: overall, in 88%
(982/119) of consultations the intended strategy was adhered to, and, when delayed prescribing was
advised, 468/612 (76%) of patients were advised to wait at least 5 days.TABLE 21 Strategy used by clinicians when using score 1
Strategy used by clinician
Control (delayed prescription)
[n (%)] Clinical score [n (%)] Rapid test [n (%)]
No offer of antibiotics 30/376 (8) 122/385 (32) 200/367 (55)
Immediate antibiotics 20/376 (5) 74/385(19) 53/367 (14)
Delayed antibiotics 326/376 (87) 189/385 (49) 114/367 (31)NIHR Journals Library www.journalslibrary.nihr.ac.uk
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streptococcal antigen detection test kits for ease of use
A panel of 10 health practitioners (GPs and NPs) did further testing of ease of use of the ﬁve RADTs kits.Each kit was tested four times consecutively by each participant, who were given test bacterial
solutions to use as in the in vitro study (Chapter 1). The order of testing was balanced between individuals.
The time taken to do the test was recorded after the ﬁrst use and also after the last use, when
practitioners were more practised. After each reading, the practitioners rated ease of reading the result
and ease of use on seven-point scales (1 = very easy, 2 = easy, 3 =moderately easy, 4 = neither easy nor
difﬁcult, 5 = moderately difﬁcult, 6 = difﬁcult and 7 = very difﬁcult).
All tests performed well. The time taken to perform the tests on the fourth repetition was documented
and was around 5 minutes for all tests (Clearview 4.6 minutes, OSOM 6.0 minutes, IMI TestPack
4.7 minutes, Quickview 5.5 minutes, Streptatest 4.9 minutes). The time in practice to use the test would
probably be nearer 8–10 minutes, as it would need to include the time taken to explain the test to the
patient, prepare the test pack and reagents, take the swab and feed back the results. In terms of ease of
use, on the fourth repetition the tests were all rated on average easy or moderately easy to use
(mean ratings, respectively, 2.4, 1.6, 2.8, 2.6 and 2.0) and easy to interpret (mean ratings, respectively,
1.8, 1.5, 1.9, 1.5 and 1.8).85
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Project title: PRImary care streptococcal management study (PRISM) (05/10/01) rapid tests forstreptococcal sore throat) (Protocol version 1 7/7/06)
Planned investigation
Our Research Objectives are:1. to assess which RADT is the most accurate in predicting the presence of group A streptococcus by
throat swab in a clinical sample from primary care;
2. to estimate the error from sampling bias by performing parallel standardised in vitro studies;
3. to assess the validity of a scoring system based on the throat swab as the reference standard (such as
the Centor criteria) in a UK population;
4. to assess the effectiveness and cost-effectiveness of rapid tests when compared to clinical scoring rules
and delayed antibiotic prescription;
5. to explore the effect of additional beneﬁt from the RADT use on GP diagnostic prediction accuracy and
treatment decisions.Existing research.
Overview
Antibiotic resistance is a major threat to public health: the key to reducing the risk from antibiotic
resistance is to reduce use for those patients who will not beneﬁt. Equally it is important for patients and
society – particularly in terms of sickness absence – not to deny health beneﬁt to those who will suffer
severe or prolonged symptoms, and where possible to ﬁnd effective alternatives to antibiotics. Sore throat
is the commonest URTI managed in primary care, and primary care is where the majority of antibiotics are
prescribed i.e. where the battle to improving targeting of antibiotics must be won.
This project, in providing key information about the most effective way of targeting antibiotics, has the
potential to make a signiﬁcant impact in improving clinical diagnosis for everyday clinical practice for
patients with URTI. URTI is the only respiratory infection where there are good range of diagnostic
alternatives (including both clinical scores and near patient tests), although there have been very few
randomised trials of diagnostic methods. The impact is likely to be in improving the short term health – by
minimising unnecessarily severe or prolonged symptoms and reducing side effects from unnecessary
antibiotics; minimising the long term public health risks of inappropriate antibiotics; and providing a model
for different management strategies for other RTIs.Antibiotics
A Cochrane review suggests modest symptomatic beneﬁt of antibiotics for sore throat and that antibiotics
prevent complications,15 which is supported by recent ecological data.66 The solution is not to increase
antibiotic use indiscriminately but to better identify individuals who are likely to beneﬁt.Better targeting?
Sore throat is one of the rare respiratory infections where there are several reasonable diagnostic
alternatives. Showing which of these help best in managing symptoms and minimising inappropriate
antibiotic prescribing will be invaluable for the management of sore throat – where antibiotics are still
prescribed in 50–60% of patients.67 Demonstrating what works in URTI may also be a model for what is
possible for other RTIs. The available methods of diagnosis have been systematically reviewed:187
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88Throat swab
This is the standard diagnostic method and the traditional clinical ‘gold standard’, but results take days, it
increases costs, may miss signiﬁcant infection (due to the organisms in the tonsillar crypts being different
to those on the surface) and is not speciﬁc (due to prior ‘carriage’ of organisms in the pharynx1).Near patient tests (NPTs)
Rapid streptococcal antigen detection tests (RADTs) are a practical alternative to throat swabs in managing
sore throat. Although RADTs (and swabs) have the same limitations as throat swabs – i.e. they cannot
differentiate infection from prior carriage, and may miss infection in the tonsillar crypts – they nevertheless
have the potential to halve antibiotic prescribing for acute sore throat, and signiﬁcantly improve targeting
of antibiotics.1,25,34,36 The potential disadvantage of rapid tests is that they may foster the belief that
patients need to see their doctor in order to have the test in order for decisions to made about treatment
i.e. potentially ‘medicalising’ URTI.68Which RADT and how to assess them?
The MHRA3 recently identiﬁed 5 RADTs marketed in the UK. Evidence from the previous
literature suggests:
l accuracy of RADTs has mostly been evaluated in microbiological labs3(67% of studies); the fewer
clinical studies have rarely compared all the commonly available tests in the UK, nor among typical UK
primary care populations – which is particularly important in view of ‘spectrum bias’ when not using
primary care populations;69,70 thus a clinical sample in the intended setting is important to assess
overall performance characteristics of RADTs;
l sampling bias has rarely been fully addressed: the key issue determining performance of RADTs is the
number of organisms harvested since the performance is strongly related to the number of colonies
growing on the agar plate;71 furthermore, the agreement of a test versus standard is not likely to
exceed the comparison of the standard versus itself72 – and in the case of throat swabs well taken
throat swabs taken from the same individual only achieve 83%–91% sensitivity when compared to
each other;73–75 ﬁnally, since the sensitivities from previous studies comparing RADTs to throat swabs
suggest that the better RADTs are likely to be in the above range (i.e. 85%+), sampling bias is likely to
provide the main error in any clinical validation study of RADTs, and a clinical validation study alone
may well not provide deﬁnitive answers regarding the best RADT to use; to get round this problem the
performance in standardised conditions i.e. in vitro performance can also be estimated;4
l comparison of ease of use by practitioners have rarely been performed.4
Any assessment of an RADTs therefore has to assess performance in clinical settings (which includes the
performance of the test in the intended setting and sampling error), performance excluding sampling error
(by assessing performance in standardised conditions), and ease of use (time taken, ease of use and clarity
of reading).Clinical scoring methods
Existing clinical scores also have most promise to be useful in practice1,25,36 – the major candidate being the
‘Centor’ criteria, which has been operationalised in two recent primary care trials23,37 as 3 out of 4 of pus,
cervical nodes, a history of fever and no history of cough.Is it plausible that benefit exists from using clinical scores?
Even with the key limitations of validity identiﬁed above, preliminary indirect evidence indicates that
existing scores may predict beneﬁt. Clinical scoring methods which predict bacterial infection not only have
the potential to predict symptomatic beneﬁt from antibiotics, but also are likely to predict an increased risk
for complications.23,37 The trials included in the systematic review suggest 8–12 hours symptomatic beneﬁt
from antibiotics, whereas in two trials among selected patients with 3 out of the 4 ‘Centor’ criteria,NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 61–2 days mean beneﬁt was documented.37 However this is indirect historical comparison: the patients in
the systematic review were not necessarily comparable, and historical comparisons are notoriously
unreliable. Other problems with the Centor criteria are:
l that there has been no robust validation in a typical UK population (i.e. the issue of spectrum bias since
studies did not use typical primary care populations; the study in Ireland (Dobbs25,34)with a similar
population used univariate analysis only and thus was overinclusive);
l the criteria very probably have low speciﬁcity in primary care populations – 44% in a recent Canadian
study34 which would result in rather high rates of overall antibiotic use (46% of adults).34
This would suggest that using the Centor criteria alone will not signiﬁcantly improve antibiotic targeting;
that a modiﬁed approach should be considered based on validation using UK data if the Centor criteria are
to be used. Once the best RADT and best clinical scores have been decided, this does not necessarily
translate into predicting beneﬁt for patients. It is thus crucial to test the performance of the best
performing RADT and clinical score in a pragmatic trial against each other and against other
treatment strategies, especially since the RADT strategy is likely to increase costs and may have
‘medicalising’ consequences.MRC DESCARTE study
Since the submission of this application our group has also been funded by the MRC to undertake the
DESCARTE study (DEcision rule for the Symptoms and Complications of Acute Red Throat in Everyday
practice). This is a large cohort study and is very simple – using a one-page tick box clinical proforma only,
and then subsequent documentation of adverse events. The great advantage to PRISM of the overlap
between the studies is that we will be in a unique position of being able to compare the characteristics of
patients and outcomes in PRISM with a wider clinical population to assess issues of generaliseability and
spectrum bias. Furthermore both studies will provide important and overlapping scientiﬁc information; the
results of DESCARTE (which will tell us about ‘at risk’ groups of patients) will be used in assessing the
management and symptomatic outcomes of such ‘at risk’ patients in Phase II of PRISM; conversely PRISM
will allow assessment of the potential for rapid tests and clinical scores to target antibiotics to individuals at
risk of adverse events in the DESCARTE data set. Providing data to address this issue (i.e. the potential for
the PRISM strategies to modify adverse events) will provide an additional dimension to PRISM that would
not be possible unless DESCARTE was funded, and is made possible by compatible clinical proformas. We
will be able to include the potential for the PRISM strategies to modify adverse events in our modelling
exercise at the end of Phase II. Thus there are signiﬁcant scientiﬁc advantages in the overlap between
studies and little direct competition between these studies.Research methods
Design summary
This study is in two phases:
Phase I is a validation and development phase and will include ﬁve components:
1. a clinical study to determine the ease of use and overall the performance in clinical settings of the ﬁve
currently available RADTs using the throat swab as the reference standard;
2. nested data from the same sample will be used to assess whether the a scoring system based on the
throat swab as a reference standard (such as the Centor criteria) requires modiﬁcation, and to explore
the feasibility of developing a clinical scoring rule based on immunological evidence of bacterial
infection as the reference standard;
3. in vitro studies to assess the performance of RADTs in standardised conditions and thus assess the issue
of sampling bias when using RADTs;
4. a qualitative study to explore patients and GPs’ perceptions about the use of RADTs;89
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90Phase II. This trial will compare management using a) the best RADT deﬁned from phase 1 compared with
b) a clinical scoring rule (a Centor-like criteria based on predicting the results of throat swabs) and c) with
the empirical strategy of delayed antibiotic prescription. Phase II will include a cost consequences analysis,
which along with a review of the longer term effects of reduced antibiotic resistance will feed into a
simple cost effectiveness model.Methods
Phase 1
1) Clinical study of RADTs
Inclusion: Adults/children aged 5 and over presenting with acute sore throat (< 2 weeks; and with some
abnormality of examination of the throat – i.e. erythema and or pus – as in our previous studies in primary
care).23 Although there some evidence that those presenting acutely are more likely to have bacterial
infection51 and more likely to beneﬁt from antibiotics it is important that the performance and use of tests
reﬂect the generalisable population presenting in primary care. Exclusion: other non infective causes
of sore throat (e.g. aphthous ulceration, candida, drugs), unable to consent (e.g. dementia,
uncontrolled psychosis).
Throat swabs Despite the theoretical potential for either overgrowth, failed growth, or poor operator
performance of tests, evidence suggests that:
l the performance of a test based on a swab done in the doctors practice are equivalent to the results
from the same swab in the laboratory;3,76,77
l one swab can also be used for more than one plate – providing identical numbers of colonies on up to
5 plates;3,78
l two double swabs can be done in adults.73
Thus any clinical validation study can take advantage of using two double swabs in each adult, using the
same swab for both RADT and culture, and can minimise practice disruption by letting laboratory staff
perform the tests. In adults two double throat swabs will be taken (allowing four tests for each adult), but
in children only one double swab is likely to be acceptable.
Based on the above evidence each swab will be sent to a central laboratory (which was shown to be
feasible in piloting). Each swab will be used for both conventional microbiology (culture and
sensitivity – using Todd-Hewitt broth, which provides the best reference standard in this context),3
and also for one rapid test. Our piloting in 60 patients has also conﬁrmed that using the same swab for
one RADT and the culture is both feasible, and minimises sampling variation.
Analysis The rationale of the rapid test is to replace the need for a throat swab, and obtain the same
clinical information as the throat swab, but in a much more timely manner. Thus the primary analysis of
the accuracy of the RADTs will be the analysis of 2 × 2 tables comparing RADTs with the results of the
throat swab as the reference standard, calculating sensitivity, speciﬁcity, predictive values and likelihood
ratios. Secondary analysis will also allow us to explore the relationship between RADTs and evidence of
bacterial infection using a rise in immunological titres as the reference standard (see below).
The criteria for choosing RADTs are a) acceptable sensitivity (> 80%) from previous in vitro or clinical
studies (based on the systematic review by the MHRA3 and the recent French Agency assessment)4 b) ease
of use4 c) availability and EU ‘CE’ marking. In terms of availability in the UK and CE marking, a recent
review this year by the MHRA identiﬁed 5 tests as being available and marketed in the UK3 (Signify Strep A
(Abbott); Directigen 1, 2, 3, (Beckton/Dickinson);OSOM Ultra Strep A (Genzyme); QuickVue in line (Quidel)
Strep A OIA MAX (Thermo Biostar)). However, since the MHRA review Directigen 123 and Signify Strep A
are no longer available. Instead of Abbott Signify strep A we propose using the better performing AbbottNIHR Journals Library www.journalslibrary.nihr.ac.uk
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TestPack plus Strep A. The Directigen test we propose replacing with Streptatest (Dectrapharm,
Strasbourg) which is available for UK use, CE marked, and performed very well in the French Health
Products Safety Agency tests.4 Streptatest performed very well both the in vitro studies (in the top 3), and
was also rated as easiest to use of all 16 tests compared. All our proposed tests performed acceptably for
ease of use (range 24–35 out of a maximum 38, with the OIA max test performing worst and the
Streptatest best) 4 and sensitivity.3,4Summary of performance of proposed rapid tests for Phase I clinical study
*Sensitivity (compared
to throat swab)3
In vitro studies % detection of
low bacterial counts (105 cfu/ml)4
Ease of use score
(maximum 38)4
Streptatest 96% (from company) 75% 35
OSOM Ultra 91% no data4 (from company website: Mass.
General Hosp. study = equivalent to QuickVue)
no data4 (similar tests
averaged 30+)
Strep A OIA Max 92% 50% 24
QuickVue 87% 50% 34
TestPack Plus 89% 100% 28
*The studies were mostly not based in primary care and for the few clinical studies that have been performed in typical
primary-care settings the sensitivities are lower79 than reported in the review.3Sample size Most RADTs are very speciﬁc.3 Sensitivity is the limiting factor, and the sensitivity from better
performing previous studies is in the range of 80–90%.3 However we will be comparing a rapid test versus
the results from the same throat swab which should provide higher sensitivities. Assuming 25% of the
sample have streptococcus (based on our piloting) and a sensitivity of 85%–95% for the best RADT to
estimate, with 95% conﬁdence, sensitivity to within +/–5% (i.e. to be conﬁdent that the sensitivity is not
less than 80% which would be less useful clinically) then 73 to 196 samples with streptococcus are
required for each RADT (see table below), or 292–784 in total, 1,460- 3,920 allowing for the 5 RADTs, or
1,500–4,000 allowing for some leeway in the assumptions. If each adult provides four comparisons and
each child two, then 400–1,200 patients are required. Thus our minimum sample size is 438 and
maximum 1,176.Sample size to estimate sensitivity with 95% conﬁdence intervals of +/–5%
Sensitivity
85% 90% 95%
Sample with streptococcus present 196 139 73
Sample for each RADT (assuming 25% have streptococcus) 784 556 292
Total number of tests (for 5 RADTs) 3,920 2,780 1,460
Number of patients required (assuming two double swabs in adults and
one double swab in children)
1,176 834 438
91
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922) Development of clinical rule
Confirming the validity of the Centor criteria in a modern UK primary care population This study
provides an opportunity to modify a clinical rule (such as Centor) which aims to predict the results of
throat swabs. The rationale for this is that there have been no UK studies which have independently
predicted the presence of Streptococcus (the Dobbs score used univariate analysis only, hence was over
inclusive and rather unwieldy);25 furthermore multivariate analysis of our pilot data in 120 individuals
suggest the key independent variables to predict the presence of streptococcus were a history of fever at
any time in the illness, a history of fever in the last 24 hours, the absence of cough, anterior cervical glands
and muscle aches i.e. different from Centor. There are no additional costs to this aspect of the study since
we will be documenting clinical details and taking throat swabs anyway. All patients in this phase will be
offered a delayed prescription (antibiotics to be used after 3–5 days collected from the GP practice
reception if symptoms worsen or not starting to settle33). We have used this approach in piloting which
was acceptable to patients and clinicians.3) In vitro study of RADTs
The number of organisms harvested crucially determine the performance of the RADT,71 and two well
taken samples from the same individual will predict the other results with a sensitivity of 83%–91%.73–75
Variation in RADT performance eliminating sampling bias will be assessed by in parallel in vitro studies
(using different antigen loads comparable to the data coming from clinical studies, and also controls). The
most recent and comprehensive of in vitro studies compared 16 tests but only included 4 of the 5 tests
proposed,4 and performed very few tests for each RADT. Thus, more comprehensive comparative
data are needed.
As in the most recent in vitro study4 we will compare the performance of RADTs using 4 strains of group A
beta-haemolytic streptococci and a control strain (a Group C streptococcus, or Moraxella), in three dilutions
each (105, 106, and 107 Colony forming units per ml) corresponding to the range of growths normally seen
from throat swabs in the community. We will perform 20 tests for each RADT at each dilution and for each
strain (i.e. 200 tests for each RADT) which will provide similar power to the clinical study.
Assessing ease of use of RADTs by clinicians Most of the in vitro tests will be carried out by laboratory
personnel who will rate ease of use, but we will also arrange a panel of 10 GPs and practice nurses – who
will perform the tests in clinical practice – to perform four tests with each RADT, and the order of RADTs
will be randomised. Several tests are required so that each clinician gets used to doing each test
competently. For each test the clinician will document time to do the test, time to get the result (seconds),
overall ease of use (on a ﬁve-point Likert scale – very easy, easy, neither easy nor difﬁcult, difﬁcult, very
difﬁcult) and clarity of result (clear, unclear). After using all the RADTs each clinician will be asked to rank
the RADTs in order of their overall preference.4) Qualitative study
The qualitative study will be based on grounded theory methodology80 to clarify patients’ and primary care
professionals’ understanding and concerns about the use of RADTs in both phase 1 and phase 2.
Grounded theory provides a framework for guiding decisions about sampling, data collection and analysis.
It is furthermore a powerful method for discovering, understanding and developing explanatory concepts.
A maximum variety sample of 15–20 patients and 15–20 GPs and nurses will be recruited. The purposive
sample of patients will include both sexes, a range of ages, people from different socio-economic classes
and minority ethnic groups. In keeping with grounded theory we will undertake further theoretical
sampling to: a) extend information on the concepts identiﬁed, b) contrast/conﬁrm/challenge the data
already collected and c) to ﬁll in any missing gaps in the data. An interview guide will be designed to
reﬂect the study’s objectives and existing literature in the area. The interview guide will be ﬂexible and
responsive to the respondent’s narrative. This means that the results of earlier interviews will inform theNIHR Journals Library www.journalslibrary.nihr.ac.uk
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questions asked will explore the following general areas: the experience of sore throat or managing sore
throat, decision-making or perceived decision making about consulting the general practitioner, perceived
outcomes of consultations, decision-making about RADTs, and the consequences of treatment. In this way,
the interview will follow the respondents’ agenda as far as possible, while remaining relevant to the issues
of the use of RADTs. Open ended face-to-face, in-depth interviews will be carried out and audiotaped for
transcription; ﬁeld notes will be kept and memoranda written to aid with analysis. Transcripts will be
analysed systematically through constant comparison analysis. Each interview will be analysed to identify
primary issues and categories, a process known as open coding. These categories will then be compared
with others within the transcript and across other transcripts, as well as to categories and concepts within
the existing literature. The next stage, axial coding, will cross-link the concepts to generate new meanings
and concepts. The ﬁnal stage, selective coding, will cross-link the concepts to generate themes that will
represent the most theoretically abstract unit of analysis from which theoretical explanations can be
generated. The qualitative research will provide explanatory models clarifying understandings and concerns
around the use of RADTs for both patients and doctors, sensitive to the context within which they
experience and manage the illness. The model will inform the implementation of the randomised
controlled trial – as well as the treatment and management of sore throat and the use of RADTs more
generally. The qualitative work will start in phase 1 but continue in phase 2. The purpose of the qualitative
work in the trial phase is twofold a) to help understand issues surrounding the process and experience of
intervention early on in the trial to be able to modify trial procedures and trial documentation in the
feasibility phase b) to understand attitudes and experiences of the health-care professionals and patients
involved in the trial that can help to explain the quantitative outcomes.Outcomes from Phase I
The aim of Phase I is to provide sufﬁcient outputs to inform the randomised trial. We anticipate the
outputs will be the estimates of sensitivity and speciﬁcity of RADTs and the Centor criteria (or modiﬁed
criteria); ease of use of RADTs; a qualitative model to understand patients’ and GPs perceptions and to
inform strategies for phase 2.Phase 2
Planned interventions
Patients will be individually randomised using a web based randomisation service – with permuted block
size of 3, 6, 9, and 12 being randomly chosen – to three groups, stratiﬁed by physician belief in the
likelihood of streptococcal infection (rated as either a probable bacterial infection or probably not a
bacterial infection).
(a) RADT using the best RADT from phase 1. Depending on Phase I results and our modelling exercise,
we provisionally assume the most efﬁcient use of RADTs will be by targeting them to those with
intermediate clinical scores. Thus those with low clinical scores (e.g. 0/1 Centor) will be unlikely to have
bacterial infection; those with very high clinical scores (e.g. 4 Centor) much more likely to have
bacterial infection. Only patients with a positive result from the RADT will be offered antibiotics.
All patients – as in the other groups – will be advised to use analgesia (regular paracetamol
and/or ibuprofen).
(b) A clinical scoring rule – either the Centor criteria, or the clinical rule developed from Phase I
(whichever performs best from Phase I). The precise strategy to use the clinical score will be based on
the results of Phase I and the modelling exercise. However we anticipate that it is likely that antibiotic
will not be offered at all to those with very low scores (e.g. Centor 1), for high scores (e.g. Centor 4)
then immediate antibiotics will be advised unless symptoms settle rapidly within 48 hours, and for
intermediate scores delayed antibiotics will be offered (see c). Such a modiﬁed use of the criteria is
necessary since using a single cut-off leading to antibiotic use (e.g. 3+ Centor) from recent data nearly
would mean 50% of patients are likely to need antibiotics.3493
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94(c) The empirical strategy of delayed prescribing (prescription to be collected from reception after
3–5 days if symptoms are not starting to settle, or sooner if symptoms get signiﬁcantly worse). Based
on previous work this is likely to result in 25% taking antibiotics.33 The rationale for delayed prescribing
is that it is safe – and arguably safer than not prescribing at all since it provides a back up for unwell
individual or those deteriorating, and changes belief and reconsultation behaviour as effectively or
possibly more effectively than not prescribing (based on both our previous study in sore throat46 and
recent data in lower RTIs47). It has been incorporated widely into routine practice in the UK since our
1997 trial33 without any increase in complications of sore throat.48Arguments for individual versus cluster randomisation.Overview We will make a ﬁnal decision on the method of randomisation by undertaking pilot work in
phase 1 and before the main recruitment for phase 2. We set out the arguments for and against the two
possible methods (individual or cluster) below. There is no doubt that individual randomisation is optimal
and it is our preferred method (the proposed design and sample size is therefore currently based on this
approach) and we have implemented individual randomisation before in several previous trials. However,
we recognise that this is logistically more difﬁcult to implement than a cluster design in a study of this
scale. If individual randomisation proves logistically impossible, we will adopt a cluster design but with
rotation of intervention within practices in different seasons to try to minimise bias. Obviously any logistic
beneﬁt of cluster randomisation will have to be traded-off against the increased sample size required. We
propose patient based randomisation (i.e. individual) rather than practice based (i.e. cluster) randomisation
based on the following arguments and practical experience:
Cluster randomisation This works well when there are no differential pressures on recruitment between
groups. For this trial a cluster randomised trial (i.e. randomising by practice) would very probably result in
differential recruitment bias between groups. This study may well change such perceptions of clinicians,
but we have to go from where we are: RADTs are used widely in Europe and the USA, but not currently in
much use in the UK,3 and the RADT group is likely in the current climate to be less attractive since it is
more time-consuming, involves some minor discomfort for patients (and in some, gagging and vomiting).
Practices in the UK randomised to use RADTs alone would therefore very probably recruit less well, and
with different patients in RADT and control groups. The issue of differential recruitment in cluster trials is
not theoretical – it occurred recently in the MRC UKBEAM trial both in terms of differential numbers and
differential characteristics of patients – where there were considerably fewer incentives for differential
recruitment than the current proposed trial – and the cluster design element of the trial had to be
abandoned. The other disadvantage of cluster randomisation is the additional design effect requiring
inﬂation of the sample size.
Individual randomisation The potential disadvantage of individual randomisation (i.e. by patient within
practices) relates to concerns about group differentiation: however each group will be administered using
a standardised manualised approach. Our group now has extensive experience in the successful
completion of 13 such trials
including several recent behavioural trials, antibiotic prescribing strategy trials very similar to the current
trial proposed81–83 and a lifestyle intervention trial.84 The manualised approach maintains clear group
differentiation despite individuals being randomised to different groups by the same health
professional81–84 and the data suggest that using such an approach the health professional and practice
cluster effects are minimal.49,81,85
Thus our aim will be to use individual randomisation and only if this proved unfeasible in the feasibility
phase then use practice-based randomisation.
Planned inclusion criteria Previously well subjects with acute illness (2 weeks or less), presenting with
sore throat as the main symptom, with an abnormal examination of the pharynx (similar criteria to
previous studies of sore throat in this group).23 Most patients present within 5 days, but a smaller minorityNIHR Journals Library www.journalslibrary.nihr.ac.uk
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representative of those patients presenting to GPs,33 and prior duration predicts subsequent illness
duration86 (i.e. an important group to help) we do not wish to exclude those with longer prior duration
of illness.
Exclusion criteria Quinsy, previous rheumatic fever and glomerulonephritis. Serious chronic disorders
where antibiotics are needed (e.g. cystic ﬁbrosis, valvular heart disease), or mental health problems
(e.g. learning difﬁculties – unable to complete outcome measures).
Informed consent Parents will have to sign a consent form on behalf of children. Some of the older
children e.g. the 4 and 5 year olds who have some language will be able to understand the patient
information leaﬂet, and will be encouraged to sign or mark the consent form. GCP (Good Clinical Practice)
training will be provided to all participating practices, with particular emphasis on the complexities of
randomising children in clinical trialsProposed time period for retention of relevant trial documentation
Trial documentation will be kept for 15 years.Proposed outcomes/data collectionClinical data Baseline clinical data will be collected24–26 as in phase 1.
Diary scores.23,33 Each symptom is scored 0 = no problem to 6 = as bad as it could be: sore throat,
difﬁculty swallowing, feeling unwell, fevers, sleep disturbance) which patients ﬁll out on all days until their
symptoms have resolved. A telephone call from the research assistant (RA) in the ﬁrst few days resolves
any problems the patient may have ﬁlling out the diary. We have chose the two item score (sore throat,
difﬁculty swallowing) as the main outcome as it is more reliable than either item alone and is internally
reliable (Cronbach’s alpha = 0.92); these simple diaries have been used in several of our studies33,47,49 and
are also more sensitive to change than criterion measures.87 Temperature will be taken by patients and
documented on a daily basis in the diary using tempadot thermometers as in our previous studies.23,49
Antibiotic use It is vital to document antibiotic use since rapid tests may achieve the same symptomatic
beneﬁt as the other strategies, but with the advantage of reduced antibiotic use. Our proposed method is
self-report, using a box at the front reception for delayed prescriptions, and also documenting prescribing
information from notes. One alternative is to trace prescriptions using stamps; this would require GPs to
use stamped prescriptions and possibly make them less likely to recruit given the ease of mislaying pads/
stamps (most GPs now print prescriptions); also cashing a prescription does not mean it is used.3 It is also
not feasible nor sensible to use more invasive methods of documenting antibiotic use (e.g. ‘smart’
containers, urinary antibiotic estimation etc.) since these are liable to artiﬁcially alter antibiotic compliance,
and thus potentially modify symptomatic outcomes. Thus our main outcome for antibiotic use is self report
(i.e. to give patients ‘permission’ to say whether they used antibiotics or not) backed by the evidence from
unused delayed prescriptions and notes review- as we have documented in our previous studies.3,4,6 We
have previously showed that self report from the diaries agreed well with whether delayed prescriptions
were collected,3 that self report correlated with weighed bottles for paracetamol use4 – supported by
another study in our group which has compared self report and weighing (Prof. Mant personal
communication).
Side effects It is also important to document side effects of antibiotics since rapid tests may achieve the
same symptomatic beneﬁt as the other strategies but with the advantage of reduced side effects by
minimising antibiotic use. Diarrhoea and skin rash will be documented in the diary, and also – where these
are serious enough to contact the doctor – from the notes review (see below).95
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96Duration of illness The diaries will also allow us to document duration of illness (until very little/no
problem), the duration of moderately bad illness (until rated less than a moderately bad problem),47
antibiotic use, and use of over the counter medicines (also see notes review).
The medicalisation of illness Patients’ belief in the importance of seeing the doctor will be documented
using 5 point Likert scales completed by patients33 which we have shown to be reliable.33 We will also
document patients reconsultation behaviour by blinded notes review23 (see below).
Time We will document time taken in the consultation (on the same sheets as the clinical sheets). Patients
will document time off work and or time to resume normal activities in the diaries.
Socio-demographic data Age, gender, household income, social deprivation indices based on postcode
will be recorded.
Notes review During the available follow-up time (which will vary from 1 month to 2 years) all patient’s
notes will be reviewed to document returns, time to return, reasons for returns, complications, economic
data (see below) and any subsequent referrals.23Sample size Phase II. ‘Medicalising’ effect of using RADT. (alpha = 0.05,
beta = 0.2)
This is the limiting sample size calculation although not the primary outcome. A good proxy for ‘medicalising’
behaviour is the change in beliefs about the need to see doctors in future episodes – assuming there are
15% differences between groups (22% were observed in our previous trial)33 then only 152 patients per
group are needed (see table below). However a harder behavioural outcome is preferable: to assess the
medicalising effect on reattendance behaviour; if we assume that using RADTs may change subsequent
attendance by 11% (RADT 38%, clinical score 27%, delayed prescribing 27%) – as observed in the
medicalising effect of prescribing strategies in a previous trial over a similar follow-up period33 – then
254 patients per group are needed or 849 in total allowing for 10% loss to follow-up of notes.49 An alpha
of 0.01 and beta 0.1 would require an unfeasibly large sample (460 per group or >1500 patients in total) or
another 2 centres for the trial.Primary outcome: symptom severity (alpha = 0.01, beta = 0.1)Diary score The time when an RADT is most likely to help patients is when the inﬂammation due to
bacterial infection is at its greatest in the ﬁrst few days after seeing the doctor. We assume the minimum
effect size for the symptoms severity score is a 0.33 standardised effect size (i.e. 0.33 SD) on days 2–5 is
when patients rate their sore throat at its worst. To detect a 0.33 standardised effect size difference
between the RADT group and control groups (assuming both control groups are 0.33 SD higher than the
RADT group) requires a minimum of 134 per group (for alpha = 0.05, beta = 0.2) but preferably for (for
alpha = 0.01, beta = 0.1), 242 per group, or 909 patients in total allowing for 20% loss to follow-up of
diary information.33,47 A standardised effect size of 0.33 is classiﬁed as a small effect size, (0.33 SD is
equivalent to half patients rating sore throat a mild rather than moderately bad problem, or duration of
sore throat one days difference), and in this context this order of effect size was judged to be the smallest
worthy of treatment by general practitioners.47 A much smaller effect size (e.g. 0.25 standardised effect
size) would result in an unfeasibly large sample (see table below). We will explore in the phase 1 (including
the qualitative work) whether such an effect size (i.e. 0.33 SD) is regarded by patients as being the
minimal worth treating. An alpha of 0.01 is preferable since it allows for type I error – with 2 comparisons
between RADT and the other two groups, and also for multiple outcomes (severity/duration), and a beta
of 0.1 will help ensure that we do not miss an effect in our primary outcome.NIHR Journals Library www.journalslibrary.nihr.ac.uk
ample size in each group1 –range of options for Phase II trial (our proposed sample sizes for each outcome are
bold)
Difference between RADT group and
other two groups
Alpha
0.01
Beta = 0.1
Alpha
0.01
Beta = 0.2
Alpha
0.05
beta = 0.2
Standardised effect size
(continuous outcomes e.g.
symptom severity, duration, time
to ﬁrst return for sore throat)
0.5 (i.e. RADT 0.5 lower than other 2
groups)
107 85 59
0.33 242 193 134
0.25 420 335 233
‘Medicalisation’ and antibiotic use:
Proportions: behaviour (return to
surgery); antibiotic use
11% (38%, 27%, 27%) 460 366 254
15% (42%, 27%, 27%) 253 202 140
20% (47%, 27%, 27%) 146 117 81
Proportions: beliefs (in the need
to see the doctor; belief in
antibiotics)
15% (57%, 57%, 72%) 274 219 152
20% (57%, 57%, 77%) 152 121 84
1. We used the NQUERY multiple group sample size programme for three groups and assumed both clinical score and
control groups had similar ﬁgures; if the control group fares worse than the clinical score group (i.e. the spread of
observations is wider) fewer numbers will be needed in each group. The numbers in each cell are the numbers with
complete data required in each group.
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inStatistics analysis, type and frequency
We will perform analysis of covariance for the main continuous outcomes (diary scores, symptom
duration). Log-rank tests and Cox regression will be used to assess the time to return to the surgery with a
new episode of sore throat as we used in our previous trial23 (which will involve ‘censored’ data due to
variable follow-up time available). We anticipate logistic regression will be used for dichotomised outcomes
(e.g. belief in the need to see the doctor, belief in antibiotics) and Poisson regression for incidence rates
(e.g. rates of return to the surgery with sore throat – which more closely follow a Poisson distribution
rather than a normal distribution). The models will control for stratiﬁcation, and for confounders if
appropriate (although randomisation should ensure that confounders are balanced between groups). We
will present the results with 95% conﬁdence intervals. The primary analysis will be an intention to treat
analysis based on ﬁnding the differences proposed. We will also perform secondary analyses: a) a per
protocol analysis, and also b) an equivalence analysis if appropriate (having established in our qualitative
work what patients regard as equivalent). The clinical and demographic characteristics of a) eligible
patients not consenting, and also b) those not followed up, will be compared to assess respectively
possible selection and non-response bias.
Our key presentation of the data will be of the main symptomatic outcomes alongside the data on
antibiotic use and side effects from antibiotics.Economic analysis
The type of economic analysis is informed by the likely directions of changes in both costs and beneﬁts are
summarised in Table 1. This shows that cost effectiveness may not be an issue, and if it is, only short term
cost differences will be captured in the trial. Long term cost effects of reduced antibiotic resistance can
only be estimated from the literature, and are likely to be highly uncertain.97
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TABLE 1 Likely changes in costs and health effects due to RADTs (or rule)
Cost effects Health effects
Short term Long term Short term Long term
RADTs (or rule) Up (cost of tests, +
medicalisation)
Up (medicalisation) Unchanged or improved Unchanged or improved
Antibiotic use Down Down (less costs due
to AB resistance)
Up (fewer side effects) Up (Less AB resistance)
Net ? ? Up Up
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98The table indicated that net cost effects are uncertain but beneﬁts likely to increase, modestly in short
term, perhaps more in longer run, but subject to uncertainty. If costs were reduced, then RADTs would be
dominant (beneﬁts up, costs down). Only if costs increase is cost effectiveness an issue.
Short term costs depend on whether RADTs or a rule is preferred, as the costs of the latter would be low.
If RADTs were preferred, their increased could lead to reduced cost per test over time (whether short or
longer term). Reduced antibiotic use would reduce costs immediately. Medicalisation in the short term
would increase costs. Net short term net costs could move up or down.
Longer term costs depend on the balance between the increased costs of medicalisation (long term) and
the possibly reduced costs due to reduced AB resistance. As neither of these are likely to be established
with any certainty in the trial (follow up 1 or 2 years?), various assumptions will have to be made and
tested in sensitivity analysis. As costs in the future would be reduced to net present values by discounting,
their timing would also be important. Overall, it seems possible that a rough balance may prevail on
long-term costs.
The economic analysis will provide:
1. a cost consequences analysis plus a simple cost effectiveness model to be used for sensitivity analysis
linking costs to each of the main outcomes in the trial; and
2. a review of the literature on costs and beneﬁts of reduced antibiotic prescribing which would be
included in the model if and as appropriate. Further work might then be deemed worthwhile or not,
an issue which would be discussed with NCCHTA and a case made for further resources if appropriate.
The cost of intervention and follow-up related service use, including the time taken to train staff, surgery
attendance, admissions and referrals, will be collected in the trial. The major increment in health service
costs associated with advice to use antibiotics and/or RADTs are likely to be due to the time taken in the
index consultation, and the effect on subsequent consultation behaviour.23,49 Resource use data will be
collected by notes review, GP and nurse documentation (e.g. of consultation time) and patient self-report.
Although our primary analysis will be from the health service perspective we are also interested in the
personal costs of managing sore throat. Thus during piloting and in qualitative work we will explore the
range of resource use – e.g. pharmacy use, transport to pharmacy and to surgery, time taken off work/
school etc. – to make sure we are not missing important costs. During this phase we will also explore
streamlined computerised methods of collecting NHS data on resource use from GP notes since most
practices are likely to be computerised. We will model the potential long-term economic costs and health
beneﬁts by extrapolating the trial’s results based on assumptions about behaviour change among GPs and
patients. The potential impact of any new generation rapid test will be included in post trial modelling.
Unit costs will be based on national rather than local unit costs wherever possible to aid generalisability of
the results. The ﬁrst phase of analysis will be to perform a cost-consequence analysis where the healthNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18060 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 6service costs and consequences of the different strategies are compared – symptom duration, symptom
severity, quality of life in the immediate episode, antibiotic use, side effects of antibiotics (diarrhoea, rash).
A simple model will be constructed to estimate incremental cost per moderately bad sore throat
prevented, per day with sore throat, with and without side effects. These data will be collected either as
part of Study 1.
The implications of reduced antibiotic use and changed antibiotic resistance will be derived from a
systematic review of relevant studies. While this element is difﬁcult to quantify, ignoring it would be to set
these key effects to zero.
These longer terms changes in costs and beneﬁts will be included in the model. Sensitivity analysis will
explore plausible scenarios and the scope for further more detailed work.Assessment of the potential effect on clinical behaviour
This sub-study will allow us to understand some of the key issues in applying the trial evidence in practice.
A Judgement Analysis (JA) study based on social judgement theory88 will be used at the end of Phase II to
estimate the impact on GP behaviour of the trial results (availability of RADT information and/or clinical
scores) in their assessment of patients. We will present the study results to both participating GPs and a
further sample of ‘naïve’ GPs. We will construct a series of vignettes89 presenting combinations of clinical
characteristics (cue proﬁles), including RADT results and/or clinical scores.
The Social Judgement Theory advocates a ‘representative design’,90 therefore vignettes should be
representative of patients that doctors deal with in their practice. To this effect, cue proﬁles will be
constructed from the patients participating in phase 1. Out of these, a certain number of cue proﬁles will
be randomly selected. The number will depend on the number of cues that we decide to include – as a
rule-of-thumb, 5–6 cues require a minimum of 30 cue proﬁles, but feasibility (stamina and patience of
GPs) argues for a limited number of cues and cue proﬁles. Vignettes will be presented to GPs who will be
asked to estimate the likelihood of each patient having streptococcus (on a 0–100 VAS), and to decide
whether they would prescribe antibiotics or not.
The judgement and treatment policies of each GP will then be modelled as separate regression equations.
These equations will show which cues each GP actually used in assessing likelihood of infection and
making treatment decisions (a cue is considered used if its regression co-efﬁcient is signiﬁcant). We
hypothesise that GPs who took part in the main trial are more likely to use the RADT results or the clinical
scores than ‘naïve’ GPs both to assess likelihood of streptococcus infection and to decide about
treatment.91 To assess consistency of cue use and judgments/decisions, the same vignettes will be
presented to the GPs a week later in a different order. Development and preparation of the vignettes will
commence during the last 9 months of the study, but the ﬁnal version of the vignettes can only be sent to
the GPs once we have the results of the trial. We will therefore analyse the JA study in the penultimate
month of the proposed study period allowing a month for write up.Risk and benefits for trial participants
Since the study will use existing widely practiced strategies (but used in an ad hoc manner) there should be
no risk to participants. All participants will be advised to return to the doctor if their symptoms are
worsening. Major complications are unlikely in this sample,23 and given structured advice to
patients – probably better information than is normally available in routine care – the standard of care
they receive is likely to be higher than routine practice. We have chosen the control group to be delayed
prescription which provides both a way of minimising antibiotic use, minimising the medicalisation of
illness, reducing return rates to the surgery, and a safety net for patients: it is not associated with any
higher risk of complications.46,4899
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100Independent supervision
We will nominate a Chairman and two independent members, one of whom will be a statistician, to form
a trial steering committee (TSC) which will meet early in the feasibility phase, and thereafter annually
unless there are problems in which case more frequent meetings will be arranged.Recruitment
The current research climate in primary care makes robust recruitment essential. To ensure recruitment we
will book nurse sessions in advance with adequate reimbursement (for both opportunistic referrals, and
the invited community sample), and very conservatively assume that 1 : 3–4 sessions will be receive a
referral, of these 1 : 3–4 parents agree, and that up to two full winters may be needed for Phase I, and
two for Phase II. Three centres are needed (Southampton; Birmingham and Oxford), and Oxford’s
experience of recruiting children for such studies will be invaluable. In recent years in the difﬁcult research
climate in primary care our three centres have shown that they can recruit both adults and children in the
numbers required for the successful completion of this study. We are keenly aware of the issue of
feasibility, and agree that for consultations for some GPs on some days there may not be time – which is
why we have assumed conservatively that recruitment may be as little as 1/2 of what we expect in one
winter, and have gone further to allow two winters for both phases. We will explore the issue of any
possible bias due to differential recruitment rate among GPs in analysis, but previous studies have
suggested little evidence of recruitment bias.33,47
The clinical proformas, and taking of the two double throat swabs, provides the main work for GPs/nurses.
The clinical proformas are very simple, and they have already been piloted, and so has the taking of throat
swabs. One of the arguments for the feasibility study is to be able to conﬁrm recruitment rates, potentially
overcome any issues of feasibility, and as necessary widen the net of GPs (and in the worst case scenario
of course stop the study, and thus minimise risk to the NCCHTA).
The GPs we are recruiting will all be part of local Networks. Our group has a wide experience of
recruitment and retention of GPs and patients to primary care trials. A number of strategies can be utilised
to maintain GP recruitment including recruitment holidays, electronic reminders, Network newsletters, and
incentives – so GPs will not be allowed to ‘forget’ the study, (also see trial management).
Will recruitment and logistic organisation for PRISM overlap with the MRC DESCARTE study? The
proposed study for this application (PRISM) is more intensive than the DESCARTE study – with clinical
sampling. Therefore PRISM requires more support than the very simple DESCARTE study. Our approach will
be to target research practices for PRISM, with local nurses and the RA in each centre providing support to
groups of practices, i.e. we will be targeting particular practices to perform PRISM. In reality it will not be
‘either’ PRISM ‘or’ DESCARTE: there will be no competition between the studies since we are using the
same baseline clinical proforma for both studies. Thus although the operation and data management of
the studies will be completely independent, the PRISM data can contribute data to the data set for
DESCARTE and the PRISM patient information leaﬂet will consent patients to the documentation of
adverse events (i.e. the main outcome in DESCARTE; we would have consented patients to this anyway
even if DESCARTE had not been funded).Trial management
The Trial management group will meet 2 monthly initially, then 6 monthly if progress is good, or more
often as needed. The study team will pay close attention to both recruitment retention and performance
of GPs/practices.
Some GPs will certainly stop recruiting; as with all our studies we will maintain recruitment of GPs
throughout the study period.33,47,49
Underperformance will be dealt with initially by letters from each regional co-ordinator to GPs, then visits
to GPs (from the local champions in each Network, the overall study co-ordinator, and applicants and PI asNIHR Journals Library www.journalslibrary.nihr.ac.uk
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proforma or how to document clinical features (which can be clariﬁed), how most efﬁciently to recruit
(examples of good practice can be provided from the other Networks) etc. If performance in one year is
poor and remains poor and cannot be improved in the last resort we will transfer the funds to the better
performing practices in addition to continuing to recruit practices.
The new UKPCRN arrangements will also hopefully help in managing Network performance.Project timetable
Oct 2006-Mar 2007: Recruit practices, and feasibility phase (pilot, train nurses; obtain ethics and RM+G
approval for all sites; perform qualitative work to explore patients perceptions);
Feb 2007-Dec 2007: Recruit patients for Phase I (1 winter);
Jun 2007-Aug 2007: Prepare for Phase II (including completing the economic modelling exercise and
pilot recruitment);
Aug 2007-Dec 2007: Phase II pilot recruitment;
Jan 2008-Apr 2010: Recruit patients;
Jan 2010-Jun 2010: Follow-up, notes searching and data cleaning, development of vignette study and
agreement from GPs to participate;
Jun – Sep 2010: Finalise data collection/analysis report writing, vignettes sent to GPs.Consumers
There is no national consumer group associated with the management of sore throat, but we will invite
2 lay members from one of our practices to join the trial management group (as we have done in a similar
validation study funded by the NCCHTA of urinary dipsticks). The perspective of consumers will also be
explored during the qualitative phase, and their perceptions incorporated into the trial materials and
procedures.Justification of Support. We need:l staff: 1 trial manager is needed for 4 years; the trial manager will have overall responsibility for day to
day running of the trial and will be supported by a part time secretary who will also manage the data
bases; the model of the trial manager also running one centre with secretarial support has worked in
our multicentre MRC ATEAM trial; an RA is needed in the Birmingham and Oxford for 3 years,
supported by P/t secretarial staff; lab technicians for 1 year are needed to perform the in vitro studies
and support microbiology; 12 months of higher level RAs for economic analysis, and 1 year of P/T RA
for the judgement analysis study are needed;
l microbiology (throat swabs and antibody titres);
l GP and nurse panel time: these costs may be negotiable as part of support for science;
l data management (web based randomisation service; data entry);
l support for recruitment (£40 per patient research costs to allow booking of time in advance): we may
be able to negotiate these costs as part of support for science;
l support for transcribing qualitative data;
l equipment (computers, tempadots);
l stationery for outcomes and also routine; also postage and telephone;
l travel to practices, for meetings;
l qualitative consultancy (Dr Leydon); statistical consultancy (Dr Mullee).101
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